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Abstract 
Pancreatic NETs occur with an annual incidence of around 5 per 1,000,000 population 
per year, with survival rates of between 30 – 97% at 5 years depending on the tumour 
subtype. The PPARs (peroxisomal proliferator-activated receptors) are members of the 
nuclear receptor superfamily that includes receptors for thyroid, steroid and retinoid 
hormones. PPARγ protein is also thought to be expressed in human pancreatic islet cells 
and has been shown to be a negative regulator of islet β cell mass both in vivo and in 
vitro. Its emerging function in controlling cell proliferation, differentiation and 
apoptosis, both in vivo and in vitro, has suggested a putative role as a tumour suppressor 
gene.  
 
I postulated that PPARγ is expressed in pancreatic neuroendocrine tumours and that 
agonism with a thiazolidinedione will cause an anti-proliferative effect. Three different 
types of tissue/cells were available to me: frozen human pancreatic neuroendocrine 
tumours following surgical resection, paraffin-embedded samples held in the 
histopathology archives, and human neuroendocrine tumour cell lines CM, BON and 
QGP1 (insulinoma, carcinoid and somatostatinoma respectively). 
 
PPARγ RNA was shown to be present in the majority of frozen surgical samples. 
Immunohistochemistry for PPARγ protein on the paraffin-embedded samples, however, 
revealed a lack of positive staining. These samples were then subjected to further 
immunohistochemistry for detection of other potentially important proteins involved 
with cellular proliferation including p27, phospho-p27, JAB1, PTEN and phospho-
AKT. In the tumour cell models, PPARγ RNA and protein was present in both BON 
and QGP1. Proliferation studies following treatment doses of PPARγ agonist 
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rosiglitazone show a significant anti-proliferative effect. Recovery of cells was shown 
following removal of treatment. However, inhibition of the effect was not achieved with 
the use of PPARγ antagonists raising the possibility that the anti-proliferative effects of 
thiazolidinediones may be independent of PPARγ. 
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INTRODUCTION 
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1.1 Tumours of the neuroendocrine system 
Neuroendocrine cells may either co-localise within glands (for example the pituitary, 
parathyroid, and adrenal medulla), or may be found scattered amongst other non-
endocrine cells throughout the body making up the diffuse neuroendocrine system. 
Initially thought to derive from a common origin within the neural crest, it appears that 
neuroendocrine cells have diverse embryological origins and acquire similar properties 
during cell differentiation (Duerr et al 2007, Andrews et al 1998). Tumours arising from 
neuroendocrine cells, neuroendocrine tumours (NETs) thus comprise a heterogeneous 
group of disorders that have defied easy classification. The majority of NETs associated 
with the diffuse neuroendocrine system arise from the gastro-enteropancreatic (GEP) 
system, although up to 30% may develop in the bronchopulmonary system, with 
occasional tumours arising within tissues including the urogenital system, thyroid and 
thymus (Modlin et al 2003, Rindi et al 1998). The annual incidence of these tumours is 
around 5 per 1,000,000 per year and is thought to have increased in recent years – 
probably reflecting both greater awareness and improved diagnostic modalities. 
Predicted frequencies from autopsy series suggest that they remain under-diagnosed 
(Gustaffson et al 2008).  
 
The term “carcinoid” has in the past been widely applied to NETs in general, but was 
first coined by Oberndorfer (Karzinoide Tumoren des Dünndarmes. Frankfurter 
Zeitschrift für Pathologie, 1907, 1: 426-429) to describe “cancer like” tumours with 
apparently low malignant potential identified in the small bowel (Modlin et al 2004). 
The classical symptoms of “carcinoid syndrome” include flushing, hypotension, 
wheezing and diarrhoea, and may be related, at least in part, to serotonin released from 
tumours derived from the EC (Kultchitsky) cells of the gastrointestinal tract or bronchi, 
although vasoative substances are also involved.  
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Early categorisation divided neuroendocrine tumours according to the embryological 
site of origin. Thus foregut tumours included those arising from the lung, stomach, 
duodenum and upper jejunum and pancreas, midgut tumours comprising lower jejunum, 
ileum, appendix and caecum, and hindgut tumours describing those found within the 
colon and rectum. However, this classification failed to take into account the diversity 
of neuroendocrine cell types from which these tumours arise, a distinction that is more 
relevant to the syndromes encountered clinically than the embryological site of tumour 
origin (reviewed by Kloppel 2004). To add further complexity, eponymous terms such 
as Zollinger-Ellison syndrome and Verner-Morrison syndrome are still frequently used 
in the context of NETs, as are descriptive terms such as Watery Diarrhoea 
Hypokalaemia Achlorhydra (WDHA) syndrome.  
 
A recent classification system introduced by the World Health Organisation has 
attempted to clarify the nomenclature applied to GEP-NETs, although it is not relevant 
to tumours arising elsewhere. The term carcinoid has been replaced (to a large extent) 
by the term neuroendocrine tumour. Such tumours are described histologically as either 
a well differentiated tumour (confined to mucosa/submucosa, non-angio-invasive), a 
well differentiated carcinoma, (with invasion of the lamina propria or identifiable 
metastases) or a poorly differentiated carcinoma with high malignant potential. There is 
also a mixed-exocrine-endocrine carcinoma. Tumours may then be further subclassified 
according to their anatomical site of origin and secretory profile (Kloppel 2007).  
 
Pancreatic NETs have survival rates of between 30 – 97% 5 year survival depending on 
the tumour subtype (Modlin et al 2003). 50–60% of pancreatic NETs are hormonally 
active, with the remainder being hormonally silent. The numbers of hormonally silent 
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pancreatic NETs diagnosed has risen over recent years, probably as a result of improved 
imaging rather than a true increase in incidence. Functioning tumours are associated 
with the secretion of a large variety of hormones including insulin (insulinoma), 
glucagon (glucagonoma), gastrin (gastrinoma), and vasoactive intestinal peptide 
(VIPoma). They may rarely secrete adrenocorticotropic hormone (ACTH), or growth 
hormone.  A single tumour may be associated with the secretion of more than one 
hormone (Belchetz et al 1973). Pancreatic NETs are usually solitary (but may be 
multiple in familial disease) and well-demarcated, measuring between 1 – 4 cm in 
diameter. Although insulinomas are usually histologically benign (the clinical 
consequences of uncontrolled insulin release may however be catastrophic), the 
remainder of the pancreatic NETs frequently show malignant features. Evidence of 
microangioinvasion, high mitotic rate and a size greater than 2 cm give cause for 
concern (Kloppel 2007). Interestingly, the organ of origin of NETs appears to play a 
part in the clinical progression of disease – for example pancreatic gastrinomas are in 
general more aggressive that those arising in the duodenum (Modlin et al 2005). 
 
1.2 Pancreatic development and cellular differentiation 
The pancreas is an organ containing two distinct populations of cells, the exocrine cells 
that secrete enzymes into the digestive tract and the endocrine cells that secrete 
hormones into the bloodstream. During early embyrogenesis (28 days in the human) the 
ventral and dorsal buds of the early pancreas develop as evaginations of the embryonal 
foregut. Arising opposite each other, the ventral bud moves round to form the posterior 
part of the pancreatic head and uncinate process while the remainder of the organ 
develops from the dorsal bud (reviewed Peters et al 2000). The longstanding hypothesis 
that pancreatic exocrine and endocrine cells are derived from different cell pools (gut 
endoderm and neural crest respectively) has been refuted with a number of cell lineage 
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experiments and molecular studies. Pancreatic NETs are likely to originate from cells of 
the primitive gut endoderm that ultimately give rise to all the cell types of the mature 
pancreas - the ductal cells, acinar cells and endocrine cells. 
 
The exocrine pancreas is a lobulated, branched, acinar gland. The acini are pyramidal in 
shape with basal nuclei, regular arrays of rough endoplasmic reticulum, a prominent 
golgi complex and numerous secretory granules containing the digestive enzymes, of 
which there are at least 22 including proteases, lipases, amylases and nucleases. Often, 
these are precursors which are activated within the gut following secretion. Control of 
secrtetion is by hormonal stimulation including secretin, cholecystokinin and gastrin. 
Neural stimulus is also involved.  
 
The endocrine cells are mainly grouped into Islets of Langerhans, which are compact 
spherical clusters of cells embedded within the exocrine pancreas. They form by 
aggregation of polyclonal endocrine cells. This seems to occur when they start to 
express cell adhesion molecules such as N-CAM and cadherins. There are four principal 
types of endocrine cell. The β cells secrete insulin and also Islet Amyloid Polypeptide 
(IAPP) or amylin. These are the most common cells in the islets. The α cells secrete 
glucagon, the δ cells secrete somatostatin and the PP cells secrete pancreatic 
polypeptide. A proportion of the adult islet cells make peptide YY in addition to their 
principal product. Ghrelin, an endogenous ligand of the growth hormone secretagogue 
receptor (GHS-R) is also thought to be expressed by the endocrine pancreas. Wierup et 
al. (2002) identified ghrelin secreting cells (upto 10% of all endocrine cells) in the fetus 
from mid gestation to post natally. In the adult the cells were few and seen at the 
periphery of the islets, exocrine tissue, ducts and ganglia. They were not co-expressed 
and therefore a new islet cell type was proposed. Controversy has surrounded this issue, 
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Volante et al (2002), again confirmed the presence of ghrelin in the islets but it was 
confined to the β cell population. Date et al (2002) on the other hand confirmed ghrelin 
to be present at the periphery of the islets in humans and rats but only co-expressed with 
glucagon suggesting localisation in the α cells. Furthermore, Prado et al (2004) 
identified that mice lacking Nkx2.2, a homeodomain protein known to be essential for β 
cell differentiation, have normal sized islets but the resulting cells produce ghrelin. They 
postulated that insulin and ghrelin cells share a common progenitor and that the lack of 
β cell stimulus leads to preferential ghrelin cell differentiation.  
 
In the developing pancreatic buds, the endocrine cells start to differentiate before the 
exocrine cells and co-expression of different hormones by the same cell is possible at 
early stages. In humans, the first identifiable endocrine cells develop at around the 7th 
week of gestation and are found scattered amongst ductal cells. These cells express 
somatostatin and pancreatic polypeptide (PP). This is followed by the development of 
glucagon-producing cells, then insulin-producing cells. The embryonal pancreas also 
appears able to express gastrin, gastrin inhibitory peptide, serotonin, catecholamines and 
prostaglandins, expression of which is lost in the adult pancreas. This pattern of 
hormone expression is different to that seen in mice, where the first hormone expressed 
is insulin, then somatostatin and PP. Interestingly, mouse studies have suggested that 
cells of the foregut, not destined to form the pancreas, are also able initially to express 
pancreatic hormones including insulin, glucagon, PP, and somatostatin in chronological 
order. It may be that this expression of endocrine hormones heralds the development of 
neuroendocrine cells of the bowel and confirms that they have the potential to express a 
variety of endocrine hormones (reviewed Peters et al 2000). 
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By the twelfth week of human embryogenesis, small groups of endocrine cells begin to 
bud out from pancreatic ducts and become vascularised. These are the precursors to 
islets recognised in the adult pancreas. They loose contact with the ducts by about 
weeks 17-20 at which point total islet cell tissue has increased to 8-13% of total 
pancreatic mass. The foetal pancreas also contains a large number of cell aggregates 
which decreases with gestation but can still be present in the adult pancreas and maybe 
associated with ductules. This accumulation is concomitant with the expression of 
certain transcription factors including the neural cell adhesion molecules (N-CAM) and 
cadherins. The majority of endocrine cells are contained within such islets, although a 
few β cells remain scattered amongst the ductal cells of the pancreas (reviewed by 
Peters et al 2000). In rodents there is segregation of cell types within the islets so that β 
cells lie in the centre and the other types at the periphery. In humans, this segregation 
does occur but it is less pronounced. All the types of islet cells also express a number of 
gene products characteristic of neuroendocrine cells such as neuron-specific enolase. 
 
It has been shown that in the developing pancreatic diverticula, exocrine and endocrine 
cells originate from epithelial cells with features of ductal cells (Pictet and Rutter, 
1972). This suggests that the ductal cells harbour the stem cell compartment from which 
acinar or islet cells originate. The phenotype of this pancreatic stem cell is yet to be 
fully defined but various studies have suggested possible markers such as tyrosine 
hydroxylase (Teitelman et al, 1993), glucose transporter (GLUT-2) (Pang et al, 1994), 
cytokeratins (Bouwens et al, 1994), and PDX-1 (Jonsson et al, 1994). Regarding 
endocrine differentiation, Upchurch et al. (1994) found cells of all 4 main endocrine cell 
types to co–express peptide YY at the early stages and thus suggested a common 
peptide YY producing progenitor cell for all the endocrine cell types. 
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The differentiation of islet cells from pluripotent ductal cells appears to be dependent 
upon the influence of mesenchymal factors that induce the expression of transcription 
factors such as pancreas duodenum homeobox 1 (PDX1) and islet1 (ISL1) within the 
embryonic pluripotent cell (Peters 2000). PDX1 also known as IPF-1 is a transcription 
factor important in regulating the expression of insulin and somatostatin that is initially 
expressed throughout the embryonic pancreas and duodenum. Mouse knock-out models 
suggest that PDX1 is important in the initial organ commitment of the pancreas while 
the differentiation of cells into pancreatic endocrine cells is reliant upon the subsequent 
expression of pax genes. Indeed, PDX1 probably has one of the most critical roles in 
early pancreatic development because when it is removed from mice by targeted 
mutagenesis, the embryos completely lack a pancreas (Jonsson et al 1994). In later life 
this gene is thought to be expressed only in the β cells and acts as a transcription factor 
for insulin. Other transcription factors expressed in the early pancreas, as well as in 
other parts of the body, are prox-1 (Oliver et al 1993), Tlx-1 (Raju et al 1993) and pax6 
(Turque et al 1994) which all belong to the homeobox gene group. The whole early 
rudiment of the pancreas also expresses the enzyme L-amino acid decarboxylase 
(AADC), which becomes confined to the islet cells postnatally (Teitelman et al 1987). 
 
Epithelial- mesenchyme interactions have been thought to be important for some time. 
In the absence of mesenchyme it is thought that isolated pancreatic epithelium is unable 
to differentiate into exocrine or endocrine tissue. This role was further defined by Kim 
et al, 1997, who reported that removing the notochord (representing early mesenchymal 
tissue) from the endoderm essentially stops pancreatic development, thus suggesting 
that signals from the mesenchyme are essential for the differentiation of the primitive 
gut endoderm into pancreatic cells. 
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ISL1 is also important in the initial organ commitment of the pancreas and the 
differentiation of islet cells (Peters et al 2000). ISL1 is expressed in all classes of islet 
cells in the adult. It is also expressed in the mesenchymal cells that surround the dorsal 
but not the ventral evagination of the gut endoderm. Ahlgren et al (1997) analysed 
acinar and islet cell differentiation in the developing pancreas in mice deficient in ISL1 
to define its role. They found that dorsal pancreatic mesochyme did not form in the 
ISL1 mutants and that there is an associated failure of exocrine cell differentiation in the 
dorsal but not the ventral pancreas. There was also a complete lack of differentiated islet 
cells. In vitro, the provision of mesochyme derived from the wild type resulted in 
exocrine but not endocrine cell differentiation. They argued that ISL1 by virtue of its 
requirement for dorsal mesenchyme formation is necessary for the formation of the 
dorsal exocrine pancreas. ISL1 expression in pancreatic epithelial cells was also shown 
to be required for the differentiation of islet cells. It would appear that the development 
of the pancreas is controlled by sequential activities of distinct classes of transcription 
factors. PDX1 specifies the early pancreatic epithelium, permitting its proliferation and 
differentiation. Other factors, such as neuroD/BETA2 which are expressed in pancreatic 
endocrine cells, may also act upstream of ISL1 in the islet cell differentiation sequence. 
 
Growth factors are important in the induction of endocrine cell growth and functional 
differentiation. Insulin-like growth factor (IGF-1 and IGF-2) may exert diverse effects 
including mitogenic effects, insulin like action, stmulation of chemotaxis and induction 
of cell differentiation. IGF-1 binds to the IGF receptor, a tyrosine kinase which has 
considerable similarity to the insulin receptor (Ullrich et al, 1990). IGF-1 and -2 plus 
IGF binding proteins have been shown to be present and have developmental patterns 
which vary during early pancreatic life (Hogg et al, 1994).  
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Transforming Growth Factor (TGF) α exerts its effects through binding to the 
Epidermal Growth Factor (EGF) receptor. It has been identified that when the 
pancreatic duct is ligated, TGF-α protein levels in the cells of tubular complexes and 
ducts is elevated as remodelling of the pancreatic parenchyma occurs. As its expression 
co-incides with increased duct cell proliferation and the formation of new β-cells, it has 
been postulated that it is involved in islet cell neogenesis (Wang et al, 
1997).Transforming Growth Factor (TGF) β1-3 has been shown to be present in islet, 
acinar and ductal cells in the human pancreas (Hogan et al, 1994). Transgenic mice 
which are TGF-β type 2 receptor negative have aberrant ducts and ductal cells 
suggesting TGF-β has an inhibitory growth effect on these cells (Bottinger et al, 1997). 
TGF-β may also induce the regression of the acinar compartment of the developing 
pancreas and promote endocrine tissue development (Sanvito et al, 1994).  
 
Other growth factors that have been implicated include Hepatocyte Growth Factor 
(HGF), levels of which increase during proliferation induced by partial pancreatectomy 
(Bonner-Weir et al, 1997), Nerve Growth Factor (NGF), whose high affinity receptor 
Trk-A is seen in islet cells and ductal cells during late fetal life of the rat but only β-islet 
cells in the adult (Kanaka Gantenbein et al, 1995), Betacellulin, an EGF family member 
which converts pancreatic acinar cells into insulin secreting cells (Mashima et al, 1996), 
Vascular Endothelial Growth Factor (VEGF) which stimulates the proliferation of 
ductal but not endocrine cells in vitro (Rooman et al, 1997) and Gastrin which is 
expressed at the mRNA and protein level during the period of cellular differentiation 
into ductal, acinar or endocrine cells but which disappears rapidly from the pancreas in 
the post natal period (Pictet et al, 1972). 
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1.3 Diagnosis of GEP neuroendocrine tumours  
NETs may cause symptoms simply by virtue of their physical presence, for example 
luminal obstruction, or as a consequence of hormones released from the tumour cells. 
Tumours not associated with hormone release are termed “silent” or “non-functioning” 
while the early symptoms associated with hormonally-active NETs are often non-
specific and frequently defy early recognition.  
 
1.3.1 Serum and immunohistochemical markers 
Secretory tumours may be detected through a combination of clinical symptoms and 
specific hormone measurements. NETs of the pancreas may be associated with the 
secretion of a variety of biologically active hormones including pancreatic polypeptide, 
insulin, glucagon, gastrin, vasoactive intestinal peptide (VIP) and rarely ACTH or 
growth hormone. Some tumours may be associated with the secretion of more than one 
hormone. The predominant hormone produced, for example insulin (insulinoma), 
glucagon (glucagonoma) or VIP (VIPoma) characterises the tumour. The most 
frequently encountered secretory NET is the insulinoma, perhaps reflecting the distinct 
clinical consequences of fasting hypoglycaemia that can quickly impact on quality of 
life. Diagnosis relies upon the demonstration of confirmed hypoglycaemia in 
conjunction with inappropriately raised insulin (and C-peptide) levels and the exclusion 
of exogenous drug ingestion. Such tumours tend to be benign, but may be multiple 
when occurring in the context of familial disease such as MEN1 (see below). Raised 
fasting peptide levels specific to the other tumour types can aid diagnosis, although such 
tests, in particular fasting gastrin levels, may be complicated by concomitant disease or 
medications reducing its sensitivity (in particular proton pump inhibitors). Fluctuating 
hormone secretion and unusual symptoms may also complicate diagnosis. Tumours may 
be multifunctional, secreting more than one hormone (frequently PP in addition to 
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another hormone), although not all will be associated with clinical consequences. Non 
insulinoma NETs of the pancreas often show malignant behaviour and have frequently 
metastasised at the time of diagnosis (Modlin et al 2008, Kloppel et al 2007).   
 
Serum chromogranin A levels are raised in 60-80% NETS and may be used as a general 
marker of both functioning and non-functioning neuroendocrine tumours (reviewed by 
Modlin et al 2008). However, they are non-specific markers, being positive tumour 
markers in other malignancies, and levels may also be raised in renal failure, or with 
enterochromaffin-like (ECL) cell hyperplasia seen in atrophic gastritis and with proton 
pump inhibitor therapy (Modlin et al 2008, Gustaffson et al 2008). Chromogranin B is 
more specific to insulinomas (Kaltsas et al 2004). Other general markers of NETs 
include neuron specific enolase (NSE) which may be raised in other pancreatic 
malignancies, chorionic gonadotrophin and pancreatic polypeptide, which is raised in 
up to 80% pancreatic NETs (Modlin et al 2008, Kloppel 2007). None, however, can 
reliably diagnose all pancreatic NETs and are thus suboptimal as tumour markers.  
 
Some immunohistochemical markers can be used to aid tissue diagnosis of presumed 
NETs. Cells of the diffuse neuroendocrine system may be identified by the expression 
of both endocrine and neuronal features. Production of neurotransmitter, 
neuromodulators or neuropeptides from small clear vesicles (40-80nm diameter), the 
presence of dense core secretory granules that release hormones by exocytosis (>80nm 
diameter), and the absence of axons, identify such cells histologically. In addition, the 
expression of molecular markers including chromogranin A (large granule associated), 
synaptophysin (small granule associated) and NSE can be used to confirm 
neuroendocrine cell origin. The majority of NETs express somatostatin receptors, and 
confirmation of this can also aid diagnosis of such tumours (Modlin et al 2008). 
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Although a high mitotic rate, nuclear atypia and few secretory granules may identify 
poorly differentiated, highly malignant neuroendocrine tumours, there are few 
histological clues as to predicting malignant behaviour in well-differentiated tumours 
(Kloppel 2004, 2007). The proliferation marker Ki-67 may be used to assess the rate of 
cell proliferation and thus suggest malignant potential (Modlin et al 2008), but an 
improved understanding of the biology of these tumours is required to aid diagnosis and 
prognostic predictions.   
 
1.3.2 Imaging 
Several imaging modalities are employed in localising pancreatic NETs and associated 
metastases, although the primary tumour may never be found. Imaging techniques may 
identify tumours by physical presence alone or by functionality. Imaging is important 
not only in initial tumour localisation and staging, but also in treatment planning and 
assessing response to therapy.  
 
Standard transabdominal ultrasound alone offers limited value in the management of 
pancreatic NETs, although endoscopic ultrasound and intraoperative ultrasound 
techniques have proven valuable in the assessment of disease – particularly in cases 
such as MEN1 where pancreatic lesions may be small and multiple. Endoscopic 
ultrasound has been developing over the past decade as an alternate form of imaging for 
diagnosis and localisation of tumours, with the added benefit of guided biopsies. It has 
been seen to be sensitive in up to 93% of proven pancreatic neuroendocrine tumours 
(Anderson et al. 2000), but is heavily operator-dependent. Multidetector CT scanning 
and MRI offer complementary aspects to the identification of mass lesions, the presence 
of metastases and subsequent response to treatment. MRI provides a good assessment of 
liver metastases but may also localise lesions not found on CT images (Rockall et al 
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2007). A review of MRI in the detection of pancreatic neuroendocrine tumours 
identified the fat saturated T1 weighted spin echo sequence as the most useful in the 
detection of these tumours (Owen et al 2001). Newer CT scanning techniques allow the 
detection of smaller pancreatic NETs, and sensitivities of up to 100% may be achieved 
when this imaging technique is used in conjunction with other modalities such as MRI 
and endoscopic ultrasound of the pancreas. 
 
Functional imaging of NETs provides a further means by which the physical presence 
of disease may be detected, but may also identify suitable candidates for targeted 
treatment in the form of labelled radionuclide therapy. Neuroendocrine cells are 
characterised by their ability to take up and concentrate amine precursors and to 
produce amines or peptides; they may also express peptide hormone receptors on the 
cell surface which together make functional imaging of these tumours possible. 
Somatostatin receptors (types 1-5) are widely expressed on neuroendocrine cells. This 
may be targeted in pancreatic NETs using radiolabelled somatostatin analogues, 
typically indium-labelled octreotide. The sensitivity of this technique in localising 
lesions may be further improved by its combination with CT.  MIBG, a catecholamine 
analogue, may be useful in the detection of some carcinoid tumours, which have been 
reported to take up and concentrate MIBG, in addition to paragangliomas and 
phaeochromocytomas. Its use is, however, limited in pancreatic NETs (Kaltsas et al 
2004). Positron Emission Tomography (PET) scanning again utilises the ability of NET 
cells to take up and concentrate substances that may then be identified if they have been 
labelled, in this case by positron emitting radionuclides. Uptake of fluorodeoxyglucose 
(FDG, a glucose analogue), L-hydroxyphenylalanine (L-DOPA) and 5 hydroxy-L-
tryptophan (5HTP) have all been used in imaging NETs with variable success. FDG-
PET uptake is not specific to NETs but is used widely in the diagnosis of oncological 
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disease processes. It is mainly helpful in detecting poorly differentiated lesions with a 
high proliferative rate. L-DOPA-PET has proven successful in detecting carcinoid type 
tumours, phaeochromocytomas and possibly medullary carcinoma of the thyroid, but 
has limited value in other subtypes of NET. Initial results using HTP-PET are promising 
but require further evaluation (Sundin 2007), and both of these require a cyclotron 
nearby as the isotopes have very short half-lives. As an alternative, more invasive 
procedures may be of value in difficult cases, for example, the direct injection of 
calcium gluconate into the arteries supplying the pancreas can stimulate insulin release 
and aid the diagnosis of insulinomas (Kaltsas et al 2004).  
1.4 Treatment 
1.4.1 Surgery 
Surgical management of pancreatic NETs depends on the primary diagnosis. 
Insulinomas are usually small and rarely metastatic. Thus, they may be surgically 
enucleated with good results. The exceptions are those associated with MEN1 that may 
be multiple and where identification of the principle secretory lesion should be 
attempted preoperatively. Insulinomas are frequently palpable at the time of surgery but 
the use of intraoperative ultrasound can complement this in identifying lesions. 
Malignant insulinomas are associated with multiple distal metastases and poor 
prognosis. The management of the other pancreatic NETs includes surgical resection 
and lymph node clearance, since the malignant potential of these tumours is high. 
Limited resection of hepatic metastases may also be attempted (Ackerstrom et al 2007). 
 
1.4.2 Hepatic embolisation 
Hepatic metastases may be managed with surgical resection where disease is limited. 
Localised hepatic embolisation either with or without additional chemotherapeutic 
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agents provides an alternative method. Since hepatic metastases receive most of their 
blood supply via the hepatic artery, while the liver itself receives part of its blood 
supply from the portal vein, occlusion of the branch of the hepatic artery feeding the 
tumour is a viable therapeutic option. Cells are thought to be more sensitive to 
chemotherapeutic agents when ischaemic, thus a local injection of chemotherapy may 
be used in addition (Toumpanakis et al 2007).   
 
1.4.3 Somatostatin analogues 
The majority of neuroendocrine tumours express somatostatin receptors and this can be 
used therapeutically. Somatostatin reduces hormone secretion from the anterior 
pituitary, gastrointestinal tract and pancreas. In general, NETs express a high density of 
such receptors, but the receptor subtype expressed can vary between tumours and within 
the same tumour. Somatostatin analogues including both short-acting and the long-
acting formulations have been successful in reducing the clinical burden associated with 
tumour hypersecretion syndromes, although tumour regression has not been a common 
result of therapy. Although somatostatin therapies could be used for all tumour 
subtypes, in general better symptom control is achieved in gastrinomas with proton 
pump inhibitors, and using diazoxide to manage insulinomas. Some stabilisation of 
tumour progression may be achieved using somatostatin analogues, but ultimately the 
effect of therapy wanes over time with tachyphylaxis. Interferon therapy may be 
associated with a reduction in tumour growth, but the side effect profile is more 
significant than that seen with somatostatin analogues (Plockinger et al 2007).   
 
1.4.4 Radiolabelled somatostatin analogues 
Tumour expression of somatostatin receptors has been exploited for the delivery of 
radiolabelled somatostatin analogues directly to the tumour bulk. Indium, yttrium, and 
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lutetium are the main radionuclides available for such therapy, and their effects vary 
according to the emitted particles that vary in terms of tissue penetration. Yttrium, a β-
emitter, has the most far reaching range which has benefits in terms of tumour 
management, but increases the risk of damage to other organs such as the kidneys 
(Forrer et al 2007).  
 
1.4.5 Chemotherapy 
The use of systemic chemotherapy on the management of NETs remains under 
evaluation. As slow growing malignancies they tend to respond poorly to such regimes. 
Streptozocin-based chemotherapy including either fluoruoracil or doxorubicin has been 
used in metastatic pancreatic NETs, although the optimal time to offer such therapies 
remains unclear. A combination of cisplatin and etoposide can be used in poorly 
differentiated NETs (Toumpanakis 2007). 
 
1.5 Models of tumour formation 
Disruption of the process of cell differentiation may result in malignant transformation 
of a cell. Abnormal cell cycle progression and tumour formation can be consequent on 
inappropriate gene expression (oncogenes) or a failure of tumour suppresser gene 
activity that would normally prevent uncontrolled progression through the cell cycle. 
Mutation of a single dominant oncogene can result in uncontrolled cell growth; 
however, recessive oncogenes are also recognised, where functional deletion of two 
copies of the same gene is required for tumour formation. Spontaneous mutations 
affecting both genes in the somatic cell would be relatively unusual, and thus sporadic 
forms of such tumours are rare. However, if a single autosomal recessive mutation in an 
oncogene is inherited at the germ cell level and a second gene deletion or mutation 
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occurs within the somatic daughter cell, tumour formation will result. This is the basis 
for Knudson’s “two-hit hypothesis” where a silent genetic fault is unveiled by a second 
deletion. Thus a recessive genotype becomes a dominant phenotype, where the second 
genetic “hit” is inevitable given the vast number of cells expressed in the target tissue. 
Such genetic abnormalities can be identified using loss of heterozygosity studies that 
confirm heterozygosity for a certain gene in non-tumour tissue (typically leucocytes) 
that is lost in tumour tissue (LOH). Genetic gain or loss may also be detected by 
comparative genomic hybridization (CGH) a technique that may be used to complement 
LOH studies or other more recent developments such as multiplex ligation-dependent 
probe amplification (MLPA) or single nucleotide polymorphisms (SNP) analysis. 
 
Genes may also be silenced through epigentic phenomena such as abnormal methylation 
patterns that would not be detected by LOH or CGH methods. DNA methylation, 
important in X chromosome inactivation and parental gene imprinting, is the transfer of 
a methyl group to the cytosine of a cytosine-guanine (CpG) nucleotide. CpG nucleotides 
tend to cluster as “islands” particularly at gene promoter regions, reflecting their role in 
control of gene expression. 
 
The process by which cells replicate DNA and divide is a tightly regulated cycle 
requiring input and facilitation from a variety of mitogens and growth factors. 
Activation mutations of oncogenes or loss of tumour suppressor genes may be 
implicated in many models of tumorigenesis, but so far none appear to be sufficient in 
explaining pancreatic NET formation. Studying inherited conditions in which NETs 
commonly occur has facilitated analysis of important molecular events in the 
differentiation of neuroendocrine cells. Familial diseases such as multiple endocrine 
neoplasia 1 (MEN1) and Von Hippel-Lindau disease (VHL) are typified by the 
 34 
occurrence of neuroendocrine tumours within the context of complex disease that may 
also include the presence of other non-endocrine malignancies.  
 
MEN1 is an autosomal dominant disorder typified by the formation of multiple 
endocrine tumours affecting the parathyroids, anterior pituitary, and endocrine pancreas. 
The MEN1 gene is located on chromosome 11q13 and its gene product menin probably 
has functions in both genome stability and transcriptional control. Up to 600 mutations 
have been identified in the MEN1 gene, including nonsense mutations, deletions or 
insertions, and splice variants. Although only 20% of sporadic foregut NETs (including 
pancreatic NETs) harbour an identifiable mutation in the MEN1 gene, up to 60% of 
sporadic pancreatic NETs exhibit LOH at chromosome 11, suggesting the presence of 
alternative genetic mutations at that locus (reviewed by Leotlela 2003, Duerr 2007). 
 
VHL disease is associated with pancreatic NETs occurring in conjunction with renal 
cell carcinomas, retinal/cerebellar haemangioblastomas and phaeochromocytomas. The 
VHL gene, located on chromosome 3p25-26 encodes a tumour suppresser gene 
important in hypoxia-induced cell proliferation and angiogenesis. Although the majority 
of VHL-associated pancreatic NETs exhibit LOH in the VHL gene, studies including 
both sporadic and VHL-associated pancreatic NETs suggest that a critical genetic defect 
may lie proximal to the VHL gene locus on chromosome 3, independently contributing 
to the development of such tumours (Lott 2002). Indeed, up to 30% of sporadic 
pancreatic NETs show LOH on chromosome 3p, an area that encodes many important 
genes including VHL, Retinoic acid receptor b (RARb), peroxisomal proliferator-
activated receptor (PPAR), RASSF1A (see below) and p51 (a member of the p53 
tumour suppresser family).  Interestingly, no mutations in the VHL gene were identified 
 35 
within this group of tumours, suggesting that its role is limited in explaining the 
pathogenesis of pancreatic NETs (Chung 1997, Zicusoka 2005).  
 
Pancreatic NETs are frequently associated with chromosomal changes, and these seem 
distinct from those identified as important in gastrointestinal NETs. Different 
chromosomal losses or gains may themselves be identified at distinct stages of disease, 
and may also predict tumour behaviour. Genetic aberrations may have a cumulative 
effect, some being important in early cell hyperplasia and dysplasia, others playing a 
role in the loss of cell differentiation and metastases (Baracat et al 2004). Pancreatic 
NETs may be either oligoclonal or monoclonal in origin, suggesting that more than one 
mechanism may result in tumour formation in a single individual (Katona et al 2006). 
Genomic gains have been identified on 4p, 4q, 7p, 7q, 9q, 12q, 14q, 17pq, 18q and 20q, 
while genomic losses have been identified on 1p, 3p, 6q, 10p, 11p, 11q, X and Yq. 
Efforts to identify specific genetic aberrations predictive of tumour behaviour have 
failed, although loss of 11q and gain of 7q appear most consistently to associate with 
pancreatic NETs, while malignancy may be predicted by gains on chromosomes 4, 7, 14 
and X or losses on 3, 21 and 6 (Zicusoka et al 2005).  
 
Non-functioning pancreatic NETs are associated with more genomic alterations, as 
compared to functioning tumours, in particular losses of 3p and MEN1 (reviewed Duerr 
2007). The pattern of allelic loss may also predict the type of pancreatic NET, 
functioning tumours associating with LOH of chromosomes 3, 11, 16 and 22, while 
non-functioning pancreatic NETs associate with LOH of 6 and 11 (reviewed by Rigaud 
et al 2001). LOH of chromosome 1 has been identified in one third of pancreatic NETs 
and appears to predict hepatic metastases (Ebrahimi et al 1999). Similarly, LOH studies 
have shown that chromosome 3q may play a critical role in the development of a more 
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malignant pancreatic NET phenotype (Guo et al 2002). CGH studies have identified 
loss of chromosome 6q in 100% of malignant insulinomas, possibly reflecting genetic 
influences specific to β-cell neoplasia. High expression of neuroendocrine secretory 
pepetide 55 (NESP55), a chromogranin gene product of chromosome 20, may be used 
to distinguish pancreatic NETS from gastric carcinoid tumours, a potentially useful tool 
in the evolution of metastatic disease of unknown origin (reviewed by Zicusoka 2005).  
 
1.6 Pancreatic neuroendocrine tumours and the cell cycle 
Several cell cycle regulators have been studied in the context of pancreatic NETs. The 
cyclin D proteins are critical in permitting a cell to advance through the cycle of DNA 
replication and division, and are of interest in many tumour models. Cyclin D1 allows 
progression through G1 and into the S phase of DNA synthesis by activating cyclin 
dependent kinases (CDK). These phosphorylate retinoblastoma protein (Rb - see 
below), thereby reducing its anti-proliferative effect (reviewed Musat et al 2004). The 
cyclin D1 gene (CCND1) is one of the most frequently amplified genes in human 
tumours and is associated with increased cyclin D1 protein expression (reviewed 
Hibberts et al 1999).  Increased nuclear expression of cyclin D1 has been shown in 50% 
pancreatic NETs as compared to non-neoplastic islet cell tissue, and is found regardless 
of tumour type or malignancy. This would suggest that it is an important factor early in 
development of the disease, and relevant to all tumours irrespective of the cell of origin 
(Chung et al 2000). 
 
Activation of the p53/MAPK and Akt/protein kinase B pathways have also been 
identified in pancreatic NETS, and may also influence progression through the cell 
cycle through increased cyclin D levels (reviewed Zicusoka et al 2006). Frequent 
activation of the p38/MAPK and Akt pathways but down regulation of the ERK 
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pathway in cyclin D1 over-expressing pancreatic neuroendocrine tumours has been 
reported (Guo et al, 2003). Hypermethylation of RASSF1A, a tumour suppresser that 
induces cell cycle arrest by interaction with cyclin D, has been identified in a subset of 
pancreatic NETs (Duerr 2007). 
 
Rb is a tumour suppressor gene that prevents progression of the cell cycle from G1 
through to the S phase of DNA replication. Phosphorylation of Rb by cyclin D1 and its 
associated kinases (CDKs) reduces the ability of Rb to prevent progression through the 
cell cycle. Although p53 and Rb deficient mouse models show a propensity towards 
developing neuroendocrine tumours, including pancreatic malignancies (Harvey 1995), 
there has not been conclusive evidence to implicate Rb in the pathogenesis of human 
pancreatic NETs to a date (Chung 1997).  
 
The cell cycle is regulated at various stages by the combined actions of cyclins, CDKs, 
and cyclin dependent kinase inhibitors (CDKIs). There are two main groups of CDKIs, 
the INK4 group comprising p15INK4B, p16INK4A, p18INK4C, p19INK4D, and the CIP/KIP 
group comprising p21CIP1, p27KIP1 and p57KIP2. The CDKI p27 maintains cells in a 
quiescent state by binding to and inactivating cyclin/CDK complexes to prevent entry 
into S phase (reviewed Musat et al 2004) and is negatively correlated to Ki-67 in 
pancreatic NETs, suggesting that it may reduce the proliferative rate in such tumours 
(reviewed Zicusoka et al 2006). Down regulation of p27 has also been identified in 
MEN1 knock-out mice that develop β cell hyperplasia within a phenotype that 
resembles MEN1 (reviewed by Duerr 2007). In mice lacking p27, created by gene 
targeting in embryonic stem cells, an increase in body size is noted with substantial 
increases in thymus, pituitary, adrenal and gonadal organ size, suggesting an important 
role for p27 in a variety of endocrine tissues (Nakayama et al, 1996). Reduced 
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expression of p27 has been associated with poor prognosis in most human cancers, 
including pancreatic adenocarcinoma (Lu et al 1999).  
 
Regulation of p27 within the cell is thought to occur at two levels, the rate of protein 
synthesis and, probably more importantly, the rate of protein degradation, in particular 
by the ubiquitin/proteasome pathway. Several studies have indicated that that 
phosphorylation of p27 is an important primary trigger for p27 degradation and is cell 
cycle-dependent, peaking in late G1 phase (Sheaff et al 1997, Vlach et al 1997, 
Montagnoli et al 1999). It appears that phosphorylation-mediated p27 degradation 
facilitates transition from G1 into S phase and thus enhanced phosphorylation has been 
implicated in over-proliferation of cells and many cancers. 
 
Jun activation domain-binding protein 1 (JAB1), an activator protein (AP-1) coactivator 
implicated in p27 degradation and transportation, is over-expressed in various tumours 
and correlates with low p27 expression. JAB1 interacts with p27 shuttling it from the 
nucleus to the cytoplasm; it has been shown that JAB1 binds directly to the C-terminal 
part of p27 in the nucleus and over-expression of JAB1 causes translocation of p27 into 
the cytoplasm (Tomoda et al, 1999). An inverse relationship in expression levels of p27 
and JAB1 has been reported in various cancer tissues, including ovarian (Sui et al, 
2001), invasive breast carcinoma and their adjacent normal breast tissue (Kouvaraki et 
al, 2003) and anaplastic large cell lymphoma (Rassidakis et al, 2003). High expression 
of JAB1 has also been shown in medullary cell carcinomas with a concomitant 
reduction in p27 expression (Ito et al 2005). Increased JAB1 expression was seen in 
pancreatic carcinoma samples and forced expression of JAB1 in pancreatic cell lines 
was associated with decreased p27 expression (Kouvaraki et al, 2006).  
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The protein Ki-67 was originally defined by the prototype monoclonal antibody Ki-67 
generated by immunising mice with nuclei of a Hodgkin lymphoma cell line (Gerdes et 
al 1983). The name is derived from the city of origin (Kiel) and the number of the 
original clone in the 96-well plate. When the antigen was found to be a protein, it was 
found that there was no homology to any known polypeptide. The function therefore 
remained indistinct and the name was kept. It has been well documented over the years 
that Ki-67 is associated with cell proliferation, being present during all active phases of 
the cell cycle but being absent in quiescent or resting cells in G0 (Gerdes et al, 1984).  
Ki-67 labelling index in neuroendocrine tumours of the pancreas have been shown to be 
independent predictors of survival in two separate studies showing reduced survival 
with values of >4% (Perret et al, 1998) and >5% (Pelosi et al, 1996). 
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Figure 1.1 Diagram showing the mechanism of p27 degradation within the cytoplasm 
following phosphorylation and nuclear export by JAB 
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Figure 1.2 Diagram showing some of the pathways that influence p27 synthesis and degradation
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1.7 The peroxisomal proliferator-activated receptor 
The PPARs (peroxisomal proliferator-activated receptors) are members of the nuclear 
receptor superfamily that includes receptors for thyroid, steroid and retinoid hormones. 
They were first identified in rodents following the observation that certain chemicals 
(peroxisome proliferators) could augment the size and number of hepatic and renal cell 
peroxisomes, thereby increasing their capacity for fatty acid metabolism (reviewed in 
Kliewer 1994). Natural ligands include long-chain polyunsaturated fatty acids, 
metabolites of the arachidonic and lipoxygenase pathways, oxidised low-density 
lipoproteins and prostaglandins. The major synthetic ligands of PPARs are the anti-
diabetic agents, thiazolidinediones, and non-steroidal anti-inflammatory agents 
including indomethacin and ibuprofen (reviewed in Wang et al 2006).  
 
Consistent with other members of the nuclear hormone receptors the PPARs comprise 
an N-terminal ligand-independent transcriptional activation domain (AF1), a central 
DNA-binding domain, and a C-terminal ligand binding and ligand dependent 
transcriptional activation domain (AF2).  Ligand binding results in a conformational 
change, releasing corepressors and recruiting coactivators to allow gene transcription 
(reviewed Knouff et al 2004). The PPARs form heterodimers with members of the 
retinoid X receptor (RXR) superfamily to initiate transcription of target genes 
(Thompson 2007). Preformed PPAR/RXR heterodimers interact with corepressor 
proteins such as retinoblastoma (Rb) in the basal state, which may then be released 
following ligand binding and consequent conformational change (reviewed Knouff et al 
2004). PPARs may also influence gene transcription independently of ligand binding, 
probably through phosphorylation of the AF1 domain by kinases; for example 
alterations in PPARγ phosphorylation by ERK- and JNK- MAPK can affect both ligand 
dependent and ligand independent effects on gene transcription (Burns et al 2007). 
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Three main isoforms have been identified, PPARα, PPARγ and PPARβ/δ. All have a 
similar structure but are coded for by different genes, on chromosomes 22, 3 and 6 
respectively (reviewed in Theocaris 2004). The PPARs are widely expressed throughout 
many tissues. PPARα, the first PPAR to be identified, is expressed in tissues with high 
oxidative capacity including cardiomyocytes, hepatocytes, enterocytes and the renal 
proximal tubule. PPARβ/δ, the least studied of the PPAR family, is expressed almost 
ubiquitously (Burns et al 2007). PPARγ, intensively investigated for its role in lipid 
metabolism, is expressed in adipose tissue as well as intestine, liver, prostate, colon, 
pneumocytes and cells of the immune system including T and B cells, natural killer 
cells, dendritic cells and macrophages (Theocaris et al 2004, Wang et al 2006). PPARγ 
protein is also highly expressed in human pancreatic islet cells including the α, β and δ 
cell subtypes (Dubois 2000) and has been shown to be a negative regulator of islet β cell 
mass both in vivo and in vitro (Rosen 2003). Four isoforms of PPARγ (PPARγ1-4) have 
been identified thus far and are generated by alternate splicing of a single gene, located 
on chromosome 3, band 3p25 (Beamer et al 1997, Wang et al 2006). The majority of 
biological actions of PPARγ are mediated by the widely expressed PPARγ1. PPARγ2 
expression is limited to adipose tissue; the protein product comprises 30 additional 
amino-acids in comparison to PPARγ1, with a consequent increase in ligand-
independent activation. PPARγ3 and 4 are identical in terms of protein product to 
PPARγ1, but PPARγ3 expression is restricted to macrophages, adipose tissue and colon, 
while the tissue distribution of PPARγ4 remains unclear (reviewed Knouff et al 2004).  
 
PPARγ has been implicated not only in adipocyte differentiation and insulin sensitivity, 
but also in atherosclerosis and inflammation. Its emerging function in controlling cell 
proliferation, differentiation and apoptosis, both in vivo and in vitro, has suggested a 
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putative role as a tumour suppresser gene, although an anti-tumour effect is not 
universal (Muellar et al 2000, Yang et al 2005, Wang et al 2006). In particular, there 
have been concerns that the TZD agents may predispose to colonic neoplasia in an in 
vivo mouse model (Yang et al 2005). PPARγ is highly expressed in a variety of solid 
malignancies including prostate, breast, colon and gastric carcinoma, and may be 
associated with pancreatic adenocarcinoma, with a possible prognostic value in 
identifying the more malignant cases (Kristiansen 2006). PPARγ has been shown to 
induce terminal differentiation in a variety of cancer models, including the upregulation 
of markers of cell differentiation carcinoembryonic antigen, E-cadherin and alkaline 
phosphatase in pancreatic cell lines (reviewed Wang et al 2006). One study has shown 
differential anti-tumour effects of TZDs in breast cancer cell lines, rosiglitazone being 
associated with reduced cell proliferation and promotion of cell differentiation while the 
agent KR-62980 only induced a reduction in cell proliferation. Thus, the effects of each 
single TZD should not be regarded as indicative of the potential action of the whole 
group (Kim et al 2006).  
 
Interestingly, LOH studies of human pancreatic neuroendocrine tumours have indicated 
allelic loss at the chromosomal site corresponding to 3p25 in up to 30% patients, also 
with a possible predictive role of outcome in advanced disease (Chung et al 1997). 
Despite this, no mutation affecting the PPARγ gene was identified in a series of 23 
pancreatic neuroendocrine tumours (including insulinomas, gastrinomas, glucagonomas 
and non-functioning tumours). This may suggest that either epigentic phenomena occur 
to affect gene function (for example hypermethylation) or that an alternative candidate 
gene exists at the chromosomal locus (Costa-Guda 2005).  
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PPARγ agonists have been associated with an up-regulation of CDKIs including p18, 
p21 and p27. These inhibitors are critical in preventing phosphorylation and inactivation 
of Rb. Rb in the unphosphorylated form exists as a “gatekeeper” preventing 
uncontrolled progression through the cell cycle from G1 to S. Upregulation of p21 and 
p27 with associated cell cycle arrest in G1 has been described in pancreatic tumour cell 
lines following treatment with glitazones (Motamura et al 2000, Kawa 2002). PPARγ 
agonists have also been shown to reduce activation of CDKs in a variety of tumour cell 
lines including the pancreas by reducing the expression of cyclin D1, an important 
activator of CDKs (Toyota et al 2002).  
 
PPARγ agonists have also been implicated in attenuating Ras (a commonly altered 
oncogene in human malignancy)-dependent phosphatidylinositol 3-kinase (PI3K) 
activity (Bos et al 1989). Growth factor signalling via tyrosine kinase receptors leads to 
up-regulation of Akt via phosphorylation and activation of PI3K. PPARγ has been 
associated with up-regulation of the PI3K inhibitor Phophatase and tensin homologue 
(PTEN), a lipid phosphatase that is critical in controlling cell cycle arrest and apoptosis.  
 
PTEN is a tumour suppressor gene which encodes a multifunctional phosphatase which 
is expressed almost ubiquitously and regulates the cell cycle, apoptosis and possibly cell 
adhesion. It is linked to cell cycle control through the retinoblastoma gene (Paramio et 
al, 1999) and promotes cell death. Deletions and mutations to PTEN occur in a range of 
cancers including breast (Perren et al, 1999), endometrial (Mutter et al, 2000), brain and 
prostate (Li et al, 1997). PTEN is thought to negatively control the PI3K-Akt pathway 
by dephosphorylating the 3 position of phosphoinositide. A mutation in the PTEN gene 
on arm 10q that causes loss of the protein's function result in excessive proliferation of 
cells, resulting in hamartomatous growths in a syndrome called Cowdens disease. 
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Loss of PTEN has been implicated in the development of metaplasia in pancreatic 
ductal cells, which may herald the early genesis of pancreatic adenocarcinoma (Stanger 
et al 2006). Akt over expression has been shown in pancreatic adenocarcinoma cells, 
with associated loss of PTEN expression (Schleiman 2003, Altomare 2002). Putative 
PPARγ response elements have been identified within the promoter region of the PTEN 
gene, and a dose-dependent upregulation of PTEN protein expression has been 
confirmed following treatment of macrophages with rosiglitazone. This increase in 
PTEN was associated with a down regulation of PI3K activity (Patel et al 2001). PTEN 
expression has been shown to be raised in pancreatic cancer cells following treatment 
with the TZD rosiglitazone. Levels of phosphorylated Akt decreased as PTEN levels 
increased, indicating inhibition of PI3K. Antagonism of rosiglitazone by GW966 
abolished these effects (Farrow et al, 2003). 
 
Malignant progression of cancers relies upon breakdown of the extracellular matrix by 
proteinases allowing access of cells to lymphatics, the blood stream and invasion of 
local tissues. This process depends upon proteases such as the serine proteinase 
urokinase type plasminogen activator (uPA) and its receptor, which may be upregulated 
in a variety of malignancies including pancreatic cancer. Glitazones are known to 
reduce uPA activity and to increase levels of plasminogen activator inhibitor (PAI) in 
pancreatic cell lines (Sawai 2006). 
 
Altered function of PPARγ may be associated with tumorigenesis. Sporadic loss of 
function mutations of PPARγ have been identified in human colonic cancer (Sarraf et al 
1999), as have dominant negative splice variants of the gene product (Sabatino et al 
2005). A dominant negative fusion protein combining the thyroid transcription factor 
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PAX-8 and PPARγ has also been identified in a subset of thyroid follicular carcinomas 
(Kroll et al 2000). However, screening of 159 samples of various human tumours 
including breast, colon, lung, prostate and haematological malignancies failed to 
identify mutations of PPARγ suggesting that these are rare events in malignancy (Ikezoe 
2001).  
 
An increased understanding of the molecular basis of pancreatic NETs is critical to 
explaining the diverse biological behaviour of this group of tumours. At present, 
diagnosis can be complicated and prediction of malignancy impossible making 
therapeutic decisions and monitoring of disease progress difficult. Modulation of cancer 
outcomes using nuclear hormone receptors has also gained interest recently through the 
use of retinoic acid in the treatment of a variety of malignancies including leukaemia, 
melanoma and cervical cancer (reviewed by Wang 2006). 
 
1.8 Human Pancreatic Neuroendocrine Cell Lines 
There are a large number of human pancreatic adenocarcinoma cell lines available 
commercially e.g., AsPC-1, BxPC-3, CAPAN-1, CAPAN-2, FA6, MIA PaCa-2, JF305 
and PANC-1, amongst others. These have allowed a significant amount of research 
work to be performed on pancreatic adenocarcinoma, the processes involved and 
potential treatment models. Pancreatic endocrine cell lines are less common. Animal 
insulinoma cell lines such as Ins-1, RINm5F and HIT have been available for some time 
and have been used extensively to study the physiology and pathophysiology of the 
mechanisms involved in glucose homeostasis.  
 
Human pancreatic neuroendocrine tumour cell lines are rare, and at the time of study the 
cell lines CM, BON and QGP1 represented the only tumour cell lines held in culture 
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and described in the literature. The CM cell line is a human pancreatic insulinoma cell 
line that was established from peritoneal ascites of a patient affected by a primary 
pancreatic insulinoma (Gueli, et al 1987). It grows spontaneously in vitro as an adherent 
semiconfluent monolayer. The CM line has been studied mainly for its antigenic 
properties with the purpose of establishing an in vitro model to investigate the immune 
mechanisms leading to β-cell destruction in IDDM (Cavallo et al. 1996). Studies on 
early-passaged cells provided evidence that insulin and C peptide were detectable in the 
supernatants of CM cell culture (Cavallo et al. 1992). Baroni et al (1999) showed that 
CM cells from an early passage express specific β-cell genes in response to glucose 
stimulation. In particular the insulin and glucose transporter (GLUT 1 And GLUT 2) 
genes are expressed. In insulin dependent diabetes, it has been postulated that β cells are 
subject to cytokine mediated cytotoxicty. Cavallo et al. (1996) showed that CM cells are 
subject to TNF-α mediated toxicity and that glutathione has a dose dependent protective 
effect. CM remains one of the very few human β-cell lines in existence due to the 
difficulties in obtaining and culturing them for long periods.   
 
 
The BON cell line was established from a lymph node metastasis of a human pancreatic 
carcinoid tumour and was first described by Parekh et al (1994). The operative 
specimen of a peripancreatic lymph node was obtained in 1986 from a 28 year old man 
who presented with obstructive jaundice and diarrhoea from a metastatic carcinoid 
tumour of the pancreas. The node was washed and minced and tumour fragments were 
placed in cell medium. All fibroblasts were removed and the resulting cells frozen at 
passage 5. Evers et al. (1994) showed that BON cells contain serotonin, chromogranin 
A, neurotensin and pancreastatin and have a predictable pattern of growth. They possess 
receptors for gastrin, somatostatin and acetylcholine. They also showed that BON 
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tumours could be sensitive to a somatostatin analogue and INF-α. Both BON and CM 
cell lines were used in an investigation of the effects of gefitinib, an inhibitor of 
epidermal growth factor receptor-sensitive tyrosine kinase (Hopfner et al, 2003), which 
showed significant growth inhibition, increased apoptosis and cell cycle arrest.  
 
The cell line QGP1 represents a human pancreatic somatostatinoma that was isolated 
and cultured by Kaku et al in 1980. QGP1 cells grow as a confluent monolayer of 
epithelioid cells. They express carcinoembryonic antigen (CEA). Iguchi et al, (1990) 
showed that they secrete somatostatin in keeping with a somatostatinoma. Implanting 
QGP1 cells into nude mice caused a tumour consisting of islet cells which secreted CEA 
and somatostatin. Doihara et al. (2009) showed that QGP1 cells expressed 
enterochromaffin cell markers such as tryptophan hydroxylase, chromogranin A, 
synaptophysin, ATP-dependent vesicular mono-amine transporter 1 (VMAT1), 
metabotrophic glutamate receptor 4 (mGluR4), β adrenergic receptor, muscarinic 4 
acetylcholine receptor (ACM4), substance P, serotonin transporter (SERT) and 
guanylin. They also identified expression of transient receptor potential ankyrin1 
channel (TRPA1) and showed that agonists of these channels increase intracellular 
calcium and release of 5-HT. Both BON and QGP1 cell lines were used in a study 
looking at the potential anti-proliferative effect of interferon alpha (Detjen et al, 2000). 
It found that interferon alpha directly inhibited growth by delaying progression through 
the S phase and into G2/M. More recently QGP1 and BON cell lines have been used to 
investigate the role of the PI3K/AKT/mTOR pathway during cell adhesion. Src kinase 
inhibitors reduced the activation of the mTOR pathway during QGP1 cell adhesion (Di 
Florio et al. 2008) 
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1.9 Aims 
 
The aim of this project was identify the expression characteristics of PPARγ in human 
pancreatic neuroendocrine tumours in three different types of samples: resected freshly 
frozen specimens, archived paraffin-embedded specimens and cell cultures. Secondly, if 
PPARγ is present, I aim to explore whether proliferation is altered by the administration 
of an agonist at this receptor. 
 
Additional aims include: 
 
An examination of p27 and phospho-p27 expression  
An examination of JAB1, p-Akt, and PTEN proteins implicated in p27 function 
An examination of somatostatin receptor expression in cell cultures. 
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CHAPTER 2  
 
MATERIALS AND METHODS 
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2.1 Laboratory consumables 
Pipette tips, plastic and glassware were purchased and used as according to normal 
laboratory protocol. Solutions were autoclaved where appropriate. Heat labile solutions 
(e.g. foetal calf serum, FCS) were filtered through 0.22µm syringe filters prior to use. 
Standard tissue culture techniques were followed to maintain sterility.  
 
2.2 Human tissue samples 
2.2.1 Homogenization 
Frozen tissue samples held at -800C were retrieved and placed in liquid nitrogen whilst 
waiting cutting to give a sample size of up to 30mg. Homogenization was performed 
mechanically using a mounted Sigma-Aldrich Ultra Turrax 8 devise. Care was taken to 
decontaminate and clean the blades, including immersion in hydrogen peroxide for 30 
minutes prior to usage and thorough washings between samples with 1 x 100% ethanol 
and 2 x RNase free water. 
 
2.2.2 RNA extraction 
Promega SV Total RNA Isolation System 
RNA isolation requires four essential steps: effective disruption of cells of tissue, 
denaturisation of nucleoprotein complexes, inactivation of endogenous ribonuclease 
(RNase) activity and removal of contaminating DNA and proteins. The technique 
allows the homogenisation of tissue within a buffered solution containing guanidine 
thiocyanate and β-mercaptoethanol to inactivate the ribonucleases present in cell 
extracts. Addition of dilution buffer and heating to 700C allows selective precipitation 
of cellular proteins to occur whilst the RNA remains in solution. The debris was 
removed with centrifugation and the RNA is precipitated out of solution by ethanol and 
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bound to silica glass fibres found in a manufactured ‘spin basket’. Contaminating DNA 
is then digested by the direct application of RNase-free DNase. Further washing steps 
help to improve the purity of the RNA. The RNA product is then eluted from the basket 
by the addition of nuclease free water. 
 
2.2.3 Spectrophotometry 
Quality and concentration of RNA can be estimated by the measurement of absorbance 
of light at wavelengths of 260nm and 280nm.  
 
Following adequate calibration of the spectrophotometer, 5µl of prepared RNA solution 
is added to 495µl of TE (TRIS-EDTA buffer) and the absorbance at 260nm and 280nm 
were documented. Care was taken to prevent contamination between samples. 
 
The yield of total RNA obtained is determined by the absorbance at 260nm where 1 
absorbance unit equals 40µg of single stranded RNA/ml. The quality or purity can be 
estimated by the ratio of absorbance 260nm/280nm where pure RNA will exhibit a ratio 
of 2.0. Acceptable ratios are between 1.8 and 2.1. 
 
2.2.4 RNA gel 
Integrity of purified RNA can be estimated by agarose gel electrophoresis. The ratio of 
28S to 18S eukaryotic ribosomal RNAs should be approximately 2:1 by ethidium 
bromide staining, indicating that no gross degradation of RNA has occurred. With 
degradation the ratio is reversed as 28S characteristically degrades into an 18S-like 
species. 
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2.2.5 Preparation of Agarose Gel for RNA electrophoresis 
Stock TAE (x50) 
242 g Tris base dissolved in approximately 750 ml deionized water. 
Add 57.1 ml glacial acid and 100 ml of 0.5 M EDTA (pH 8.0). 
Adjust the solution to a final volume of 1l 
 
Working Solution of TAE (x1)  
The working solution of 1x TAE buffer is made by simply diluting the stock solution by 
50x in deionized water.  
Final solute concentrations are 40 mM Tris acetate and 1 mM EDTA.  
 
Gel 
1% Agarose gel for RNA 
0.5g agarose added to 50 ml 1x TAE (Tris-acetate-EDTA) buffer and heated in 
microwave for 2 minutes. 
Add 1µl ethidium bromide (carcinogen) 
Place combs and allow gel to set prior to transfer to running chamber and loading of 
sample. 
Load 2µl RNA solution plus 8µl water plus 2µl loading dye and run at 150 Volts for 30 
minutes. 
 
Visualizing the RNA 
The gel is placed on the transilluminator (UV light of wavelength 254 nm). Ethidium 
bromide is a fluorescent dye that intercalates between the bases of DNA and RNA. 
Photos taken as required. 
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Example of RNA gel showing 18S and 28S bands 
 
 
2.2.6 Reverse Transcription and production of cDNA 
Applied Biosystems (ABI) TaqMan standard protocols. This produces 50µl of cDNA 
from 1µl of  totalRNA. 
 
Following calculation of the concentration of RNA by spectrophotometry, the volume 
for 1µg of RNA is pipetted and made upto 19.25µl in TE in a 0.2ml microtube. 
A mastermix was prepared with the following constituents: 
 5µl 10x RT Buffer 
 11µl 25mM MgCl2 
 10µl deoxyNTPs (10nM) 
 2.5µl Random Hexamers 50µM 
 1µl Rnase Inhibitor (20U/µl) 
 1.25µl Multiscribe RT enzyme (50U/µl) 
Total 30.75µl  
 
The 30.75µl is added to the RNA solution to make a total solution of 50µl which was 
gently mixed. The mixed solution was then placed in the GeneAmp 970 thermal cycler 
programmed with the settings below. 
← 28S 
← 18S 
 56 
 
 25oC  10mins 1cycle 
 48oC  30mins 1cycle 
 95oC  5mins  1 cycle 
 
Subsequent cDNA was frozen immediately at -20oC. 
 
2.2.7 Polymerase Chain Reaction (PCR) for GAPDH 
The standard Polymerase Chain Reaction (PCR) amplifies genes of interest, determined 
by the choice of primers introduced to the PCR mixture. Following a DNA denaturing 
step, these primer sequences bind to the template DNA allowing amplification of the 
subsequent DNA sequence with a DNA polymerase in the presence of excess dNTPs. 
 
Primers used were standard laboratory primers. 
 
GAPDH Genebank M33197 
Primers 
 
SHORT 
 GAPDH F  5' CCATGGAGAAGGCTGGGG 
 GAPDH R  5' CAAAGTTGTCATGGATGACC 
 
LONG 
 GAPDH Long F 5' GAGTCAACGGATTTGGTCGT 
 GAPDH Long R 5' GGTGCTCCAGGGGTCTTACT 
Product =486bp 
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Promega PCR protocol 
Primers, dNTP and DNA polymerase were kept on ice during working time. A 
‘mastermix’ of the components below was made up and added to 2.5µl of cDNA 
 
H2O   16.875µl 
x10 Taq buffer 2.5µl 
25mM MgCl2  1.5µl 
20mM dNTP  0.25µl 
0.5 µmol S primer 0.625µl 
0.5 µmol AS primer 0.625µl 
Taq enzyme  0.125µl 
Total   22.5µl 
 
Samples were mixed thoroughly and 3 drops of mineral oil were added to the surface. 
Samples were then placed in the thermal cycler and run with the program below: 
 
Stage 1  95oC  5mins  1 cycle  Denaturing 
Stage 2  94oC  1mins  
   55oC  1mins  26 cycles Annealing 
   72oC  1mins    Extension 
Stage 3  72oC  10mins 1 cycle  Poly A tail 
2.2.8 DNA gel 
To assess the adequacy of the PCR products, samples were run on a 2% agarose gel 
with ethidium bromide, as described for the RNA gel above. 10µl of PCR product was 
mixed with 2µl loading dye. PhiX 174 HinF I digest (Promega G1751) molecular size 
markers were run alongside PCR products in each gel. Positive and negative controls 
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were used as appropriate. Electrophoresis was performed for 30-45 minutes at 150V 
depending on the size of gel. Bands were visualised by ethidium bromide fluorescence 
using a UV transilluminator and photographs taken. 
 
2.2.9 PPARγ PCR 
Tissue samples were assessed to identify the presence of PPARγ by standard Quiagen 
PCR protocols with conditions optimised within the laboratory by previous 
experimental work (Dr C Merulli). 
 
Primers (Sigma-Genosys) 
PPARγ sense   5’ TCTCTCCGTAATGGAAGACC 
PPARγ antisense  5’ GCATTATGAGACATCCCCAC 
Product = 474bp 
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A mastermix of the following components was made up and added to 2.5µl of cDNA. 
H20     13.5µl 
Qiagen x10 buffer   2.5µl 
Q solution    5µl 
dNTP     0.25µl 
0.4 µmol PPARgamma S  0.5µl 
0.4 µmol PPARgamma AS  0.5µl 
Q hotstart Taq    0.25µl  
Total     22.5µl  
 
Samples were mixed thoroughly and 3 drops of mineral oil were added to the surface. 
Samples were then placed in the thermal cycler and run with the program below: 
 
Stage 1  95oC  15mins 1 cycle   
Stage 2  94oC  1mins  
    55oC  1mins  40 cycles  
    72oC  1mins     
Stage 3  72oC  10mins 1 cycle  
 
DNA gels were run on ethidium bromide agarose gels as previously described and 
visualised by UV transillumination. 
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2.3 Immunohistochemistry 
 
2.3.1 Immunohistochemistry Objectives 
Two objectives were set for this work. Firstly, the location and quantification of the 
strength of staining in each tissue type (insulinoma, gastrinoma, islet and exocrine 
pancreas). Secondly, a comparison of the tissues against each other, using total positive 
counts for both nuclear and cytoplasmic compartments, was determined.  
 
In particular, interest was focused on differences between insulinoma and normal islets, 
which were considered its control. Although the number of gastrinomas was small (n=3) 
it was felt worthwhile to see if there were any significant differences between these and 
the insulinomas. Exocrine pancreas was included to highlight differences between the 
endocrine and exocrine pancreas. 
 
2.3.2 Case selection 
A trust wide search for pancreatic neuroendocrine tumours through histopathology 
records, endocrine department records and surgeons logbooks was performed. All 
paraffin embedded sections available were retrieved and closely inspected for suitability 
of usage.  
 
Representative slides of each case were stained with haematoxylin and eosin and all 
were reviewed for suitability of study with consultant histopathologist Dr Diaz-Cano. 
Where possible, tumour, normal exocrine pancreatic tissue and islets were identified on 
each slide and marked to allow standardisation of slide assessment. The first and last 
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slides prepared from each block were checked to ensure that all contained the same 
components. 
 
When multiple samples were present for a case, all underwent immunohistochemistry 
and were counted individually. The resulting counts were then combined to give an 
average result for that case. 
 
2.3.3 Optimisation of Antibodies 
With the exception of Ki-67, which has previously been widely used within the 
laboratory, all antibodies underwent optimisation studies. Starting points were guided 
by manufacturer advice and standard laboratory protocols with help from consultant 
histopathologist Dr S Diaz-Cano. Variations in antibody dilution and incubation times, 
blocking times, and staining times for DAB and Gills Haematoxylin were explored to 
identify optimal conditions of all antibodies. 
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2.3.4 Summary of antibodies 
       DILUTION 
PPARγ (E-8): c-7273     1:50 
Santa Cruz Biotechnology 
 
p27 (SX53G8)      1:300 
 Gift from Dr X Lu, 
 (Ludwig Institute for Cancer Research, St Marys Hospital, London.) 
 
Phospho-p27 (71-7700)    1:250 
Zymed laboratories Inc. 
 
JAB 1 (37-1400)     1:250 
Zymed laboratories Inc.  
 
Phospho-Akt (Ser473)     1:100 
Cell Signaling Technology.  
 
PTEN  (NCL-PTEN)     1:100 
Novocastra Laboratories Ltd. 
 
Ki-67 (NCL-Ki67-MM1)    1:200 
Novocastra  Laboratories Ltd 
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2.3.5 Control Samples 
For all immunohistochemistry experiments positive and negative controls were run 
simultaneously. Tonsil sections were used as positive controls for all antibodies with the 
exception of PPARγ, where skin samples containing sebaceous glands were found to be 
effective. Photographic examples of positive controls for each antibody are shown in the 
results section. Negative controls were constantly included where the primary antibody 
was excluded. 
 
2.3.6 Supervision of Counting 
Counting cells can be open to variability due to the subjective nature of interpretation of 
staining. We hoped that by separating the strength of staining out into strong, medium 
and weak would help highlight those which may be may difficult to classify. With little 
previous personal experience, it was felt imperative that expert instruction with the 
techniques of immunohistochemistry, cell counting and interpretation of results was 
gained. This was kindly provided by Dr S Diaz-Cano (Royal London Hospital). 
Subsequent review of all the slides and an estimation of Ki-67 index were performed by 
Dr E Carlson (St Bartholomew’s Hospital). External quality control was therefore 
gained by 2 separate sources but it is accepted that no internal control studies were 
performed to confirm reliability and repeatability of my own counting on different days. 
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2.3.7 Vectastain Universal Elite ABC (kit code pk-6200) 
All immunohistochemistry methods were based on the standard ABC method, the 
standard laboratory protocol being highlighted below. 
 
Procedure 
1. The following controls should be used. 
2. Positive control section for each primary antibody used. 
3. Negative control section [omitting primary antibody] 
4. Dewax sections in xylene. 
5. Dehydrate sections in alcohol. 
6. Place sections in endogenous peroxidase block for 15 minutes. 
7. Wash sections in tap water for 2 minutes. 
8. If antigen retrieval is required, go to the appropriate procedure. 
9. Transfer to tap water and wash for 2 minutes. 
10. Soak sections in a trough of TBS for 3 minutes. 
11. Wipe around the sections and apply the PAP pen. 
12. Apply normal horse Serum for 3 minutes. 
13. (Add 1 drop (50µl) of yellow labelled bottle to 5ml of antibody dilutant) 
14. Tip off the horse serum. 
15. Apply primary antibody at the appropriate dilution in antibody dilutant for 40 
minutes. 
16. Apply only antibody dilutant to the negative control section. 
17. Wash off the antibody with TBS x 2 and flick slide to remove excess. 
 
18. Apply the universal biotinylated secondary antibody (from the kit) for 20 
minutes. 
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19. (Add 2 drops (100µl) of normal horse serum (yellow label) to 5ml of TBS, then 
add 2 drops (100µl) of biotinylated secondary antibody (blue labelled bottle). 
Vortex solution.) 
20. Make up the Avidin Complex Solution. This must stand for 30 minutes before 
use. 
21. (Add 2 drops (100µl) of Reagent A (grey label A) to 5ml of TBS, then add 2 
drops (100µl) of Reagent B (grey label B). Vortex solution. Leave to stand. 
22. Wash off the antibody with TBS x 2 and flick slide to remove excess. 
23. Apply the avidin complex solution for 20 minutes. 
24. Wash off with TBS x 2 and flick slide to remove excess. 
25. Apply DAB solution for 3 – 5 minutes. 
26. Wash in running tap water for 5 minutes. 
27. Counterstain in Gills Haematoxylin for 60 seconds. 
28. Wash in water bath for 2 mins (Blue) 
29. Dip in acid-alcohol x 2  (Differentiate) 
30. Wash in water again (Blue) 
31. Dehydrate and clear (2 mins each in alcohol, alcohol, xylene, xylene)  
32. Mount. 
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2.3.8 Antigen Retrieval 
Antigen retrieval was performed using a microwave technique. Slides were placed in 
citrate buffer during treatment before continuing with step 7 above. 
 
Microwave Buffers 
Citrate buffer stock 
  Citric acid  7.56g 
  Trisodium citrate 47.56g 
  Distilled water 2000ml 
  Stored at 4°C 
 
Citrate buffer working solution 
  Citrate buffer stock 100ml 
  Distilled water   900ml 
  1M Sodium hydroxide  to bring pH to 6.0 
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2.3.9 Preparation of Immunohistochemistry Reagents 
Antibody Dilutant 
  Sodium chloride   4.1g 
Tris     0.3g 
  Bovine albumin   0.2g 
  Sodium azide    0.2g 
  1M Hydrochloric acid   2ml 
  Casein     50µl 
  Distilled water   500ml 
0.1M Sodium hydroxide  to bring pH to 7.6 
  Stored at 4ºC 
  
Endogenous Peroxidase Block 
  100 vol. Hydrogen peroxide 3ml 
  Methanol 97ml 
 
0·05M Tris Buffered Saline (TBS)     pH7·6 
  Sodium Chloride   8.76g 
  Tris     6.06g 
  1M Hydrochloric acid   36ml 
  Distilled water   800ml 
  1M HCl    to bring pH to 7.6 
  Made up to 1 litre with distilled water 
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2.3.10 Cell counting 
Counting was performed using a grid overlying a 40x powered magnified field of view 
and reviewed on a computer screen. For each case and antibody, approximately 500 
cells (approx 100 cells per high power field x 5) were counted for insulinoma, 
gastrinoma, islet and exocrine pancreas. Each was assessed for both nuclear and 
cytoplasmic staining. Staining was described as strong, moderate, weak or negative.  
 
The total number of cells counted in each group (insulinoma, gastrinoma, islet or 
exocrine) was tabulated in Microsoft excel spreadsheets and calculation of a percentage 
and standard error of the mean for each strength of staining was performed. To allow for 
easier comparison between groups, it was felt that a single value for positive staining 
would be helpful.  Due to the nature of counting in immunohistochemistry it was 
debated whether the positive count should be calculated by adding all stained cells 
(strong, moderate and weak) together or by adding the strong and moderately stained 
cells together, excluding the weakly stained cells as inconclusive. Both methods were 
used for all data: I found that the outcome was similar in nearly every case. For all 
results, the data shown uses positive count equal to strong + moderate + weak staining.  
 
On occasion and where appropriate, data using positive count equal to strong plus 
moderate staining has been additionally used to illustrate patterns. This is highlighted in 
the text. 
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 2.4 Cell culture work 
2.4.1 Cell lines 
All 3 cell lines were generously donated by Professor Nicolas Lemoine (Institute of 
Cancer, Barts and The London, Queen Mary's School of Medicine and Dentistry). 
CM  - Human insulinoma cell line isolated from ascites 
QGP1  - Human pancreatic somatostatinoma 
BON  - Human pancreatic carcinoid 
 
2.4.2 Culture media and conditions 
CM  - RPMI 1640 with L-glutamine (Gibco 21875) 
QGP1  - RPMI 1640 with L-glutamine (Gibco 21875) 
BON  - DMEM high glucose (Gibco41966) 
 
To all media, 10% foetal bovine serum (Gibco 10106) was added along with 
penicillin/streptomycin antibiotics (Gibco 15140) and fungizone (Gibco 15290). Cells 
were incubated in T-75 flasks with culture medium at 37ºC with 95% air, 5% CO2. 
Media was freshened every two to three days by discarding old media and adding 10-
15mls new culture medium, warmed to 37ºC. Cells were passaged once they reached 
60-80% confluence. Medium was removed and the cells washed with 5ml warm (37ºC) 
PBS. 1ml trypsin/EDTA was added per flask and the cells incubated for approximately 
5 minutes until all had detached from the flask. Trypsin activity was terminated by the 
addition of 5ml culture medium and the suspension mixed by gentle trituration.  
 
Cells were counted using a Trypan Blue method, whereby dead cells stain deep blue 
while live cells remain translucent, since viable cells do not take up dye. 25µl of 0.4% 
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trypan blue (Sigma) was added to 75µl PBS. The addition of 100µl cell suspension gave 
a final concentration of 0.05% trypan blue. The suspension was mixed by gentle 
pipetting and 100µcl transferred to a haemocytometer. Cells falling within the 
boundaries of two squares were counted and the mean total for one square (volume 
0.1mm3) was used to calculate the concentration of cells per ml of original suspension: 
 
Cells/ml = average cell count x 2 (dilution factor) x 10000 
 
Approximately 2 million cells were plated per fresh T-75 flask and 10-15ml culture 
medium added. Flasks were returned to the incubator.  
 
2.4.3 Cell freezing 
Medium was removed and the cells washed with 5ml warm (37ºC) PBS. 1ml 
trypsin/EDTA was added per flask and the cells incubated for approximately 5 minutes 
until all had detached from the flask. Trypsin activity was terminated by the addition of 
5ml culture medium followed by gentle titration. Cells were centrifuged at 1000 rpm for 
5 minutes then medium discarded. Cells were washed in PBS, centrifuged as before, and 
the pellet resuspended in cell freezing medium (90% fetal calf serum, 10% DMSO).  
 
Cells were transferred to a cryotube and placed on ice for 20 minutes, then at -20ºC for 
approximately 2 hours, transferred to -70ºC for a further 2 hours prior to storage in 
liquid nitrogen.  
 
2.4.4 RNA extraction 
Cells were trypsinised, harvested, washed and counted prior to RNA extraction. 
Extraction was performed using standard Promega SV Total RNA Isolation System 
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protocols for lysis of cultured cells. A maximum of 5 x 106 cells were washed and 
centrifuged prior to addition of lysis buffer. Vigorous vortexing and passage through a 
20 gauge needle aided DNA shearing prior to the addition of dilution buffer and 
preparation for RNA purification by centrifugation. 
 
2.4.5 RNA spectrophotometry and electrophoresis 
Quality of RNA was assessed by spectrophotometry and agarose gel electrophoresis as 
previously described for every RNA extraction. 
 
2.4.6 Reverse transcription  
Extracted RNA from cell lines were subject to reverse transcription using ABI standard 
protocols as described previously. 
 
PCR for GAPDH 
cDNA recovered following reverse transcription, underwent conventional PCR for 
GAPDH using Promega standard protocols as described previously. Electrophoresis on 
ethidium bromide agarose gel was performed for identification of products 
 
2.4.7 Expression of PPARγ 
Expression of PPARγ in each of the cell lines was assessed by conventional PCR using 
Quiagen kit and protocols as described previously. Products were run on ethidium 
bromide agarose gel for identification. 
 
Primers (Sigma-Genosys)  Product = 474bp 
PPARγ sense   5’ TCTCTCCGTAATGGAAGACC 
PPARγ antisense  5’ GCATTATGAGACATCCCCAC 
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2.4.8 Expression of Somatostatin Receptors (SSTR1-5)  
Widespread expression of somatostatin receptors in endocrine tissues and tumours led 
us to investigate the expression of SSTR’s 1-5 in our cell lines. Previously extracted 
samples from all three cell lines were subject to conventional PCR using Promega 
materials and protocols as described earlier. 
Thermal cycling conditions were: 
 
Stage 1  95oC   5 minutes 
Stage 2  94oC   1 minute 
   60oC   1 minute  35 cycles 
   72oC   1 minute 
Stage 3  72oC   10 minutes 
 
SSTR Primers 
SSTR1: 5’-GCTACGTGCTCATCATTGCTA-3’ 
5’-GGACTCCAGGTTCTCAGGTTG-3’  product 401 bp 
SSTR2:  5’-TTGGTACACAGGGTTCATCAT-3’ 
5’-GTCTCCGTGGTCTCATTCAGC-3’   product 459 bp 
SSTR3:  5’-CTGGGTAACTCGCTGGTCAT-3’ 
5’-CAGGCAGAATATGCTGGTGC-3’,  product 225 bp 
SSTR4: 5'-AACGGAGGCGCTCAGAGAAGAAGA-3'  
  5’-AGGCGAGGTGAGGGAGGGTAAAAT-3’ product 451 bp 
SSTR5:  5’-TCATCTGCCTGTGCTACCTG-3’  
5’-GGAGAGGATGACCACGAAGA-3’  product 233 bp 
 
Products were subject to ethidium bromide agarose gel electrophoresis for identification 
of products.  Photographs are shown in the Results section. 
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2.4.9 PPARγ Protein Expression 
Untreated cells from all cell line cultures were subjected to protein extraction, 
performed using cytobuster reagent (Novagen 71009). Cytobuster is a formulation of 
detergents optimised for extraction of soluble proteins from mammalian cells. All 
protein extraction procedures were performed under strict laboratory protocols within 
the cell culture hood 
 
Procedure 
The below reagents were added together 
•  3ml Cytobuster Protein Extraction Reagent  
•  30µl Phosphatase Inhibitor 1 (Sigma P-2850)  
•  30µl Phosphatase Inhibitor 2 (Sigma P-5726)  
 
Spent media was removed from the cell wells and cells were washed briefly with ice 
cold PBS. PBS was removed. Then, 250µl of the above solution was added to each cell 
well to coat the wells and left in place for 5 minutes. After 5 minutes the wells were 
scraped and the resulting suspension was pipetted into a separate eppendorf tube.  The 
suspension was then centrifuged at 13000 rpm for 5 minutes at 4oC and the supernatant 
removed to a separate tube prior to protein assay or freezing. 
 74 
2.4.10 Protein Assay Protocol 
Initial assays were performed with Bradford reagents which is in general use in the 
laboratory. However, it became apparent that cytobuster is not compatible with 
Bradford reagents, and a different method of protein assay was applied – BCA Protein 
Assay Kit (Pierce 23225). 
 
The BCA assay relies upon the formation of a copper (II) – protein complex under 
alkaline conditions, followed by reduction of the copper (II) to copper (I) which is 
associated with a colour change that can be measured. The amount of reduction is 
proportional to the amount of protein present. Generation of a BSA (Bovine serum 
albumin) standard curve allows for quantification of protein samples. 
 
To allow direct comparison with the protein samples, BSA was diluted in Cytobuster. A 
known concentration of BSA, 1mg/ml, was made by dilution of 0.01g BSA in 10ml 
total volume made up of 8mls sterile water and 2mls Cytobuster. From this 1mg/ml 
solution further dilutions achieved concentrations of BSA ranging between 0 – 1mg/ml 
for generation of a standard curve. 25µl of each known BSA dilution or diluted sample 
was placed in triplicate into wells of a 96 well plate. 200µl of BCA/Copper mix was 
added to each well. Samples were left at 37˚C for 30 minutes and the colour change 
read on a Wallac “Victor” 1420 Multilabel Counter. An example standard BSA curve is 
shown in figure 2.1. The regression co-efficient was calculated to assess the suitability 
of the standard curve generated. 
 
From this standard curve, concentrations of each protein sample can be estimated from 
their measured absorption at 595nm. Samples were then normalised for protein content, 
to the sample with the least amount of protein, prior to loading into SDS-PAGE gel. 
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Figure 2.1 Example of a protein standard curve using BCA reagents. 
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2.5 Western Blotting Protocol 
 
2.5.1 Materials Required 
• Tris base (Tris hydroxymethyl methylamine) (VWR; 103156X) 
• Tris acid (Tris hydroxymethyl aminoethane hydrochloride) (Sigma T-3253) 
• Glycine (Sigma; G7126) 
• SDS (sodium dodecyl sulfate) (Sigma; L-4509) 
• Methanol (VWR; 101586B) 
• Sodium chloride (NaCl) (Sigma) 
• Hydrochloric acid (HCl) (Sigma) 
• Tween-20 (polyoxyethylene (20) sorbitan monolaurate) (VWR; 66368-B) 
• 2-mercaptoethanol (Sigma M-3148) 
• Skimmed (no fat) milk powder; Tesco 
• SDS-PAGE Ready Gels 10% Tris/HCl 10 wells (Bio-
Rad; 161-1155) 
• Kaleidoscope Protein Marker (Bio-Rad; 161-0324)   
• Electrophoresis Tank (Bio-Rad; 165-3126) 
• Transfer Kit (Bio-Rad) 
2 pieces of sponge cut to size of gel 
4 pieces of blotting paper (Biorad; 170-3932) 
Transfer cassette and tank (Bio-Rad; 170-390) 
 
• Detection Reagent ECL Plus Western Blotting System (Amersham; RPN2132) 
• PVDF (polyvinylidene difluoride) Membrane (Amersham; RPN303F) 
210 
135 
 
82 
 
38.7 
 
31.9 
 
18.1 
7.4 
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• Kodak Scientific Imaging Film X-OMAT (VWR no. 165-1579) 
• Antibodies: primary and secondary 
• Saran Wrap (VWR) 
• Aluchef foil (VWR; 236401001) 
 
2.5.2 Buffers and Reagents 
SDS Loading Buffer 
1.514g Tris base (125mM), 4g SDS (4% w/v), 16 ml Glycerol (20% w/v), 0.02g 
Bromophenol Blue (0.002% w/v) 
 
Dissolve Tris base in 100 ml of ddH2O and adjust pH to 6.8. Then add the remaining 
reagents and store at 40C.  
 
Running Buffer 
30.25g Tris base, 144.13g Glycine, 10g SDS. 
Make up to 1 litre with ddH20, gives 10X Tris/Glycine/SDS 
Use 1 in 10 (i.e. 100 ml in 1000 ml ddH2O) 
 
Transfer Buffer 
3.04g Tris base, 14.14g Glycine, 800 ml ddH2O, 200 ml Methanol 
 
Dissolve Tris and glycine in H2O. Add methanol, total 1000 ml. Stir well with magnetic 
stirrer. Store at 40C. 
 
Washing Buffer 1X TBS-Tween 
10X TBS (Tris-buffered saline): 
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To prepare 1 litre of 10X TBS: 24.2g Tris base, 80g NaCl, Adjust pH to 7.6 with HCl 
(use at 1X). 
 
To make 1XTBS-Tween (wash buffer): 1X TBS, 0.1% Tween (i.e. 500 µl Tween to 500 
ml 1X TBS). 
 
Blocking Buffer 
2.5g Skimmed (no fat) milk, 50 ml 1X TBS-Tween 
Gives 5% milk solution. 
 
Stripping Buffer 
0.985g Tris hydrochloride, 2g SDS, 781 µl 2-mercaptoethanol 
 
Add 100 ml ddH20 to SDS and Tris, then add 2-mercaptoethanol. 
 
2.5.3 Antibodies 
Anti-PPARγ (E-8): c-7273 Santa Cruz Biotechnology 
A mouse monoclonal IgG antibody raised against a peptide mapping to the carboxy 
terminus of PPARγ of human origin. Used at a dilution of 1:50 at 4oC overnight 
Secondary antibody: Goat anti-mouse 1:10000 
 
Anti-PPARγ (Calbiochem 516555) 
A rabbit polyclonal antibody raised to a peptide found in mouse PPARγ2. Used at a 
dilution of 1:2000 for 90 minutes at room temperature 
Secondary antibody: Goat anti-rabbit 1:10000 
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β-actin (Cell Signalling Technology) 
Affinity purified rabbit polyclonal antibody raised against a synthetic peptide 
corresponding to the amino terminal of human β actin. Used at a dilution of 1:5000 at 
4oC overnight 
Secondary antibody: Goat anti-mouse 1:10000 
 
2.5.4 Method 
Protein samples were normalised to the samples with the lowest protein concentration. 
The volumes required for each sample were calculated and aliquoted into 0.5ml tubes. 
Kaleidoscopic marker was also pipetted at this time. Equal volumes of SDS loading 
buffer were added to the samples and to the marker. Samples were heated for 5 minutes 
at 950C on thermal cycle to denature proteins and moved to ice immediately afterwards.   
 
SDS-PAGE Electrophoresis Preparation 
Following denaturing, a 10% Tris-HCl gel was inserted into a gel chamber which was 
placed into an electrophoresis tank ensuring that the chamber is balanced correctly. The 
tank was filled with 1x Running Buffer. The samples were then dispensed into the wells 
and run gel at 100V for 1 hour or until the samples reach the wire at the bottom of the 
gel chamber. 
 
Electroblotting Protein to PVDF Membrane 
A piece of polyvinylidene difluoride membrane (PVDF) (Amersham Biosciences) was 
soaked in methanol for 10 seconds then water for 5 minutes prior to use, to activate. Gel 
and membrane were compressed between blotting paper and sponges soaked in transfer 
buffer and proteins electro-transferred for 45 minutes at 90V.  
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The PVDF membrane was then washed twice in 1x TBS-Tween for 10 minutes. The 
blocking buffer was prepared and 30 mls was added to the membrane for 90 minutes at 
room temperature on a roller to block non specific protein binding sites. Blocking buffer 
was then removed and 5ml blocking buffer with primary antibody at the correct dilution 
added overnight at 4oC (or otherwise specified).  
Following 3 washes of 10 minutes with 15ml 1x TBS-Tween buffer the peroxidase 
conjugated (HRP) secondary antibody was added, at an appropriate dilution in 5ml 
blocking buffer. This was left for a further 90 minutes on a roller and then washed once 
more as above.  
 
Detection of Proteins 
Protein bands were visualised using a chemiluminescence detection system. Two 
different kits where used. 
 
ECL Plus Western Blotting Detection Reagents Kit (Amersham Biosciences) 
This system is based on the enzymatic generation of an acridium ester and numerous 
luminescent intermediates, the emissions of which can be detected on X-ray film. The 
kit was used in accordance with the manufacturer’s recommendations.  
 
In brief, 2ml of ECL Solution A was mixed with 25µl of ECL solution B and added to 
the membrane, the tube was wrapped with foil to shield it from light and it was mixed 
on a roller for 5 minutes to develop. The membrane was then wrapped in Saran Wrap 
and placed in a developing cassette. A sheet of X-OMAT x-ray film was placed over the 
membrane for varying exposure times and developed on a Compact X4 (Xograph 
Imaging Systems). 
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LumiGLO (Cell Signaling Technology 7003) 
This is a luminol-based system. In the presence of hydrogen peroxide, horseradish 
peroxidase converts luminol to an excited intermediate which emits light on its return to 
ground state. 0.5ml of Reagent A and 0.5ml of reagent B were added to 9ml of water. 
This was then added to the membrane for 1 minute and then the membrane was 
prepared for x-ray in the same fashion as above. 
 
Stripping PVDF Membrane and Reprobing  
The membrane can be stripped of antibodies to allow further reprobing with different 
antibodies. This was done by washing twice on a roller with 10-15 ml TBS-Tween for 5 
minutes each. Then 50 ml of Stripping Buffer was added and left for 30 minutes in a 
waterbath set to 500C. A further two washes on a roller with 10-15 ml TBS-Tween for 5 
minutes each was performed and the membrane either stored (in TBS-Tween at 4°C) or 
re-probed. 
 
β-actin 
To confirm equal sample loading, the PVDF membrane was stripped and reprobed with 
a β-actin primary antibody at a dilution of 1:5000 at 4oC overnight following the same 
procedures as above. 
 82 
2.6 Cell proliferation studies  
To assess whether cellular proliferation could be affected by interaction with PPARγ 
agonists, a series of experiments were set up to assess a cell lines proliferation with 
varying concentrations of treatments applied. The PPARγ agonist rosiglitazone 
(GlaxoSmithKline, UK) was chosen as the PPARγ agonist and stock solutions were 
made up by dissolving in dimethylsuphoxide (DMSO) to give a stock concentration of 
10-2M. Subsequent dilutions were done using H2O. Cellular proliferation was assessed 
by thymidine incorporation. An example of the protocol used is detailed below. 
 
2.6.1 Method 
1. Culture cells until confluent according to standard protocol. 
 
2. Harvest cells and centrifuge to give a pellet of cells. Re-suspend in normal culture 
medium of known volume. 
 
3. Count cells using haemocytometer. 
 
4. Pipette out the correct volume of cell suspension to each well to the required density 
e.g. 50,000 cells/well and add normal media up to a volume of 500-1000 µl. 
 
5. Place cells into incubator for 24 hours to allow adhesion. 
 
6. Make up treatment solutions e.g. rosiglitazone at 10-3, 10-4, 10-5, 10-6, 10-8 
concentrations. Note that these will be diluted by a factor of 10 when added to the wells 
containing media giving treatment concentrations of 10-4, 10-5, 10-6, 10-7 and 10-9. 
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7. Remove normal media from wells and replace with 900µl of serum free media (plus 
antibiotics), and add 100µl of the treatment solutions to each well to give final volume 
of 1ml containing the required concentration treatment. 
 
(Note: BON cells did not survive well in serum starved media, instead, DMEM media 
with 2% (charcoal stripped) fetal calf serum was used.) 
 
Example – 24 well plate 
 1 2 3 4 5 6 
1 Media Only Rosiglit (10-4M) Rosiglit (10-5M) Rosiglit (10-6M) Rosiglit (10-7M) Rosiglit (10-9M) 
2 Media Only Rosiglit (10-4M) Rosiglit (10-5M) Rosiglit (10-6M) Rosiglit (10-7M) Rosiglit (10-9M) 
3 Media Only Rosiglit (10-4M) Rosiglit (10-5M) Rosiglit (10-6M) Rosiglit (10-7M) Rosiglit (10-9M) 
4 Media Only Rosiglit (10-4M) Rosiglit (10-5M) Rosiglit (10-6M) Rosiglit (10-7M) Rosiglit (10-9M) 
 
8. Incubate the plate at 37°C in a humidified, 5% CO2 atmosphere for 48 hours.  
 
9. Six hours prior to the end of the experiment, add 2µCi (curie) of [3H]-thymidine 
(Amersham) to each well (i.e. add 50µl [3H]-thymidine to 2.5ml culture media and then 
add 100µl of this to each well).  
 
10. At 24 hours, aspirate the media from the wells and briefly wash with 1ml ice-cold 
PBS.  
 
11. Add 1ml of scintillant (Amersham) to each well and incubate the plate for 5 
minutes.   
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12. Collect the fluid from each well into separate labelled scintillation vials and vortex 
thoroughly.  
 
13. Incorporation of thymidine, in units of counts per minute (CPM), can then be 
measured using a scintillation counter. 
 
Charcoal Stripping 
50mls   fetal calf serum (FCS) 
2g  charcoal 
Left on rollers overnight at 4oC 
 
Optimisation of Treatment Duration 
Experimental plates were set up as described and treatments were left on for variable 
durations i.e. 24, 48 72 and 96 hours. Tritiated thymidine was added to the wells 6 hours 
prior to the completion of the experimental period. Scintillation counting was then 
performed and raw data collated on an excel file. Outcomes for the three cell lines are 
shown the results section. In all three cell lines, it was felt that treatment duration of 48 
hours gave the best results. 
 
2.6.2 Combined proliferation studies 
All cell lines, CM, BON and QGP1, were then subjected to repeated experimentation 
and the results collated to give combined proliferation studies for treatment with 
rosiglitazone at concentrations of 10-4M, 10-5M, 10-6M, 10-7M and 10-9M. Average 
counts for each group were calculated along with the standard error of the mean. 
Statistical significance was assessed by non-parametric Kruskal-Wallis test, followed by 
Conover-Inman if significance was achieved. 
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2.6.3 Proliferation studies with DMSO 
Rosiglitazone was supplied in concentrated form and dissolved in dimethylsuphoxide 
(DMSO). Subsequent dilutions to treatment dose levels in H2O reduced the effective 
concentration of DMSO in the wells during the treatment periods. This means that at 
higher concentrations of rosiglitazone there will also be higher concentrations of DMSO 
present. We felt that a toxic effect of DMSO on the cells should be excluded. 
 
Proliferation studies were set up in exactly the same way except that rosiglitazone was 
not added. Instead equivalent ‘treatments’ containing H2O and DMSO at the same 
concentration was added. This ‘treatment’ was left for 48 hours and subject to 
thymidine incorporation and scintillation counting in exactly the same way as 
previously performed. Again, repeated experiments were performed and results were 
combined prior to statistical analysis and graphical representation. 
 
2.6.4 Rosiglitazone versus DMSO treatments in QGP1 cells 
At the highest concentration of DMSO it appeared that there may be a toxic effect on 
the QGP1 cell line. A single experiment was performed where two plates were set up to 
allow direct comparison of the effects seen by rosiglitazone and DMSO. On one plate 
QGP1 cells were treated with varying rosiglitazone concentrations, as per previous 
experiments. On the second plate cells were treated with equivalent concentrations of 
DMSO. The results were subject to the same analysis and results are shown in the 
results section. 
 
2.6.5 Recovery studies 
As with all treatments, the effects seen may simply be due to a toxic effect which is 
undesirable if it leads ultimately to cell death. Recovery of cells following removal of 
treatment was therefore felt to be important. To assess this, experiments were set up at 
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the same time and date and from the same harvest of cell cultures to minimise error 
between groups. 
• First set was treated with rosiglitazone for 48 hrs and harvested 
• Second set was treated with rosiglitazone for 48 hrs then washed and left in 
normal media for a further 48 hours prior to harvesting. 
• Third set was treated with rosiglitazone for 96 hrs and harvested at the same 
time as set 2. 
 
The first set is essentially a control to make sure that we see the expected effects of 
rosiglitazone treatment. The second set is the experimental group. The third set is 
another control group to identify that there is a continued effect of rosiglitazone 
treatment and that the cells do not spontaneously recover or escape from treatment 
effects. 
 
2.6.6 Antagonist studies  
To complete the PPARγ cell proliferation experiments we decided to try and prevent the 
effect of rosiglitazone by blocking the PPARγ receptors irreversibly, thereby attempting 
to prove that the effects seen are mediated by the PPARγ. 
 
A PPARγ antagonist was purchased from Calbiochem (Calbiochem-Novabiochem 
Corp., La Jolla, CA, USA) identified as T0070907 antagonist (2-Chloro-5-nitro-N-(4-
pyridyl)benzamide)  
 
T0070907 is a potent, specific, irreversible, and high-affinity antagonist of PPARγ  with 
a Ki of 1nM. It also displays >800-fold greater selectivity for PPARγ over PPARα and 
PPARδ (Ki = 0.85µM and 1.8µM, respectively). 
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A second anatagonist was obtained through a colleague (Dr D B Bailey, St 
Bartholomews Hospital) identified as GW9662 antagonist (2-Chloro-5-nitro-N-phenyl-
benzamide) (Sigma, St Louis, Missouri, USA). 
 
GW9662 is an irreversible PPARγ antagonist. GW9662 binds PPARγ with IC50 in 
nanomolar range, and is 10- and 600-fold less potent in binding PPARα and PPARδ, 
respectively. 
 
For both antagonists, a 1µM concentration was used. Plating was performed with a 
control group (no antagonist), antagonist on its own, plus cells treated with rosiglitazone 
at 10-4M, 10-5M and 10-6M concentrations. Cells were pre-treated with the antagonist for 
90 minutes prior to the addition of rosiglitazone. Incorporation of thymidine, harvesting 
and assessment of proliferation were performed as for previous experiments. 
 
2.6.7 Direct comparison studies 
So far all antagonist experiments had been run without a comparative rosiglitazone 
treated group. It was felt that if the antagonist was having any effect then there should 
be a significant difference seen when cells treated with rosiglitazone are compared 
directly with cells treated with antagonist and rosiglitazone. Thus direct comparison 
studies were performed. Cells were plated in two lines. Following cell adhesion, one 
line was treated with rosiglitazone at a concentration of 10-4M, the second line being 
treated with rosiglitazone at a concentration of 10-4M plus 1µM antagonist. This was 
repeated for rosiglitazone concentrations of 10-5M and 10-6M. 
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Repeated experiments were performed for QGP1 and BON cell lines at the above 
concentrations for 48 hours and subject to the same thymidine incorporation, harvesting 
and scintillation counting. 
2.7 Statistical analysis 
Statistical analysis was performed with StatsDirect software package. Data for 
immunohistochemistry and cell culture groups was not normally distributed as assessed 
by Shapiro-Wilk testing. The majority of comparisons were performed using Kruskal-
Wallis analysis of variance test. If P<0.05 subgroup analysis was performed using the 
Conover-Inman test. Alternatively, Mann-Whitney test was performed to compare 2 
groups following subgroup analysis by Ki-67 index. When appropriate, graphs have 
been generated to help present the data.  
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CHAPTER 3  
 
RESULTS I  
 
Human Frozen Tissue Samples 
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3.1 Human tissue Samples  
A selection of pancreatic neuroendocrine tumours was held in the -80oC freezer within 
the Academic Department of Endocrinology at St Bartholomew’s Hospital. Ethical 
consent for collection and experimentation had been gained prior to the commencement 
of this project by Professor A. Grossman through the North East London Research 
Ethics Committee (Ref. P/02/069). Details of the diagnosis and histopathology were 
held on database. 
 
SAMPLE SEX AGE 
DATE OF 
SURGERY 
DIAGNOSIS 
1 F 42 1997 Gastrinoma 
2A F 26 1997 MEN-Insulinoma 1 
2B F 26 1997 MEN-Insulinoma 2 
2C F 26 1997 MEN-Insulinoma 3 
3A M 57 1995 Insulinoma 
3B M 57 1995 Lymph node met 
4 F 44 1994 Gastrinoma 
5 M 51 1998 MEN-Insulinoma 
6A M 34 1998 Normal pancreas 
6B M 34 1998 Insulinoma 
7 F 67 2001 Gastrinoma 
8 F 61 2001 Insulinoma 
 
Table 1 Tumour bank samples and clinical details 
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3.1.1 RNA Extraction. 
Work done on tissue samples: 
Example – Sample 2C 
3 X Homogenisation and RNA extraction (Promega SV Total RNA Isolation System) 
3 X Spectrophotometry 
2 X RNA gels 
GAPDH PCR  4 X SHORT  (repeated at 26 and 35 cycles) 
   1 X LONG 
1 X PPARγ PCR 
SAMPLE         2B   2C   3B    4    8 
 
 
Figure 3.1 Example of a typical RNA gel result 
← 28S 
 
← 18S 
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3.1.2 GAPDH PCR 
 
SAMPLE             H2O  SM    2A  2B   2C    3B     4     8     6A   
 
Figure 3.2 Example of short GAPDH results 
 
SAMPLE               SM     2A   2B    2C    3B      4      8     6A  H2O 
 
Figure 3.3 Example of long GAPDH results 
 
SM = SIZE MARKER PROMEGA φX174 HAE III 
← SHORT GAPDH 
 
 
← PRIMER DIMERS 
 
 
← PRIMER DIMERS 
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SAMPLE 260/280 
RATIO 
RNA GEL SHORT GAPDH LONG  
GAPDH 
1 2.1 No bands Present-weak Absent 
2A 2.1 No bands Present-weak Absent 
2B 2.3 Good bands Present-good Absent 
2C 1.9 No bands Present-weak Absent 
3A 1.6 No bands Present-weak Absent 
3B 1.9 No bands Present-good Absent 
4 2.1 No bands Present-good Absent 
5 3.0 No bands Present-good Absent 
6A 2.0 No bands Absent Absent 
 
6B 2.1 No bands Present-good Present-good 
7 3.1 Good bands Present-good Present-weak 
8 2.3 Good bands Present-good Absent 
 
 
Table 2 Summary of best results obtained for human tissue samples  
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3.1.3 PPARγ EXPRESSION 
We wanted to look at PPARγ expression in fresh tumour samples at the RNA level and 
subjected the extracted RNA to Qiagen PCR, using the primers described. 
 
SAMPLE TUMOUR PPARγ EXPRESSION 
1 Gastrinoma Absent 
2A Insulinoma Absent 
2B Insulinoma Present - good 
2C Insulinoma Absent 
3A Insulinoma Absent 
3B Lymph node met Present – good 
4 Gastrinoma Present – good 
5 Insulinoma Present – weak 
6A Normal pancreas Absent 
6B Insulinoma Absent 
7 Gastrinoma Present – good 
8 Insulinoma Present - good 
 
Table 3 Summary of PPARγ expression in human tumour samples 
 
RNA extraction from previously frozen tissue samples was hampered by issues with the 
quality and quantity of samples available. Despite multiple procedures, reliable high 
quality RNA was not re-producible. PPARγ PCR was performed on all samples of RNA 
extracted. Although few conclusions can be made, given the limitations, PPARγ 
expression was seen in 6 out of the 8 patient samples. PPARγ expression was seen in 4 
out of 5 insulinomas (1 insulinoma LN metastasis), and 2 out of 3 gastrinomas. For 
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those samples that had better RNA quality results, there is a more favourable outcome 
in terms of PPARγ expression. 
 
PPARγ PCR products - examples 
 
SAMPLES         SM   2B  2C  3B   4    8    6A  +VE  H2O 
 
Figure 3.4 DNA gel showing PCR products for PPARγ 
 
SAMPLES          SM   7    6B    1   3A     5   +VE  H2O 
 
Figure 3.5 DNA gel showing PCR products for PPARγ 
  SM = SIZE MARKER PROMEGA φX174 Hinf I 
  +VE = POSITIVE CONTROL (ADRENAL TUMOUR TISSUE) 
← PPARγ 
← PPARγ 
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RESULTS II  
 
Immunohistochemistry 
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3.2.1 Immunohistochemistry 
A trust-wide search for pancreatic neuroendocrine tumours through histopathology 
records, endocrine department records and surgeons logbooks revealed a total of 44 
potential subjects going back over 20 years.  
 
In total 25 cases were identified as having good quality specimens that could be used. In 
several cases there was more than 1 specimen available for the same patient – these 
were annotated A, B or C as seen in table 4. 
 
Of the 25 cases, further information is noted to allow better understanding of the results:  
 
1 patient only had tissue from a lymph node metastasis of a gastrinoma (Case 24). This 
was included as a gastrinoma in the tumour results series. 
 
2 cases were removed from the 25 before final analysis. 
Case 16 - equivocal diagnosis being undecided between an endocrine tumour and 
a papillary and solid epithelial neoplasm (PSEN). 
Case 21 - identified as a lymph node metastasis of the gastrinoma in case 22. 
 
Insufficient islets were available in cases 3, 19, 22 and 24. 
Insufficient exocrine pancreas was seen in cases 4, 22 and 24. 
 
Treated in this way the results could be generated in a standard format for all antibodies 
tested. In total, therefore, there are 20 insulinomas and 3 gastrinomas in the tumour 
series, 19 results for the islet series and 20 results for the exocrine series. These 
numbers are the same for all antibodies. 
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For all immunohistochemistry graphical illustrations therefore:- 
 
Insulinomas  n=20 
Gastrinomas  n=3 
Islets   n=19 
Exocrine  n=20 
 
3.2.2 Cell counting 
As described in the methods section, counting was performed using a grid system 
overlying a magnified field of view viewed on a computer screen. For each case and 
antibody, approximately 500 cells were counted for insulinoma, gastrinoma, islet and 
exocrine pancreas. Each was assessed for both nuclear and cytoplasmic staining. 
Staining was described as strong, moderate, weak or negative.  
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Table 4 Cases identified as suitable for immunohistochemistry 
 
ID SEX AGE DIAGNOSIS 
1 M 24 INSULINOMA 
2A/B M 24 INSULINOMA 
3A/B F 69 INSULINOMA 
4 F 58 GASTRINOMA 
5 F 41 INSULINOMA 
6 M 65 INSULINOMA 
7 M 27 INSULINOMA 
8 M 54 INSULINOMA 
9 F 71 INSULINOMA 
10 F 26 INSULINOMA 
11 M 42 INSULINOMA 
12 M 51 INSULINOMA 
13 F 58 INSULINOMA 
14A/B F 39 INSULINOMA 
15A/B F 51 INSULINOMA 
16 F 29 ENDO/PSEN 
17 F 61 INSULINOMA 
18A/B M 21 INSULINOMA 
19A/B F 61 INSULINOMA 
20 M 78 INSULINOMA 
21 M 35 GASTRINOMA LN 
22A/B/C M 35 GASTRINOMA 
23 F 55 INSULINOMA 
24A/B M 69 GASTRINOMA LN 
25 M 37 INSULINOMA 
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3.2.3 PPARγ Immunohistochemistry 
A mouse monoclonal IgG antibody to PPARγ was obtained from Santa Cruz 
Biotechnology. The antibody is raised against a peptide mapping to the carboxy 
terminus of PPARγ of human origin. Optimisation of the antibody was performed on 
normal skin samples which acted as the positive control. A dilution of 1:50 was 
identified as the optimal dilution. Very good staining of the control was observed 
(Figure 3.6) 
 
 
 
Figure 3.6 PPARγ positive control – skin sample with prominent sebaceous glands. 
The sebaceous glands can be seen staining strongly positive (red/brown colour). 
 
From the results tables in the Appendix, it can be seen that only limited PPARγ staining 
was identified in any of the series for tumour, islet or exocrine, despite good positive 
control staining. All samples underwent repeat immunohistochemistry with similar 
results. Examples of staining seen are shown in the figures. 
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Figure 3.7 Only weak nuclear PPARγ staining can be seen here in sample 2 
 
 
Figure 3.8 Stronger nuclear PPARγ staining can be seen in sample 15 
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It is clear that there is little evidence to suggest the nuclear or cytoplasmic presence of 
PPARγ within insulinoma, gastrinoma, islets or exocrine tissue in our samples.  
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Figure 3.9 Graph showing the location and strength of PPARγ staining in insulinoma 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
 
 103 
NUCLEAR PPARg STAINING
0
20
40
60
80
100
INSULINOMA GASTRINOMA ISLET EXOCRINE
%
 
PO
SI
TI
VE
P=0.81
 
Figure 3.10 Graph representing total positive nuclear PPARγ staining in each group. 
Non parametric Kruskal-Wallis testing revealed no statistical difference. 
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3.2.4 p27 Immunohistochemistry 
 
p27 is an inhibitor of both cyclin E-Cdk2 and cyclin A-Cdk2, two CDK complexes 
involved in the regulation of the G1/S transition. p27 has been found to be expressed at 
high levels in quiescent cells, playing an important role in maintaining cells in G0 
through the inhibition of CDKs.  
 
p27 was stained for using anti-p27 antibody from clone SX53G8 (gift from Dr X Lu, 
Barts and the London). After optimisation the antibody was used at a dilution of 1:300 
with very good staining seen with tonsil sections acting as positive control.  
 
 
 
Figure 3.11 p27 positive control (tonsil) showing strong nuclear positive staining in 
the mantle zone 
 
GERMINAL CENTRE 
→        
MANTLE ZONE → 
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In the human tonsil there are multiple follicles which have both a germinal centre 
(consisting of predominantly proliferating T-lymphocytes) and a mantle zone 
(consisting of predominantly quiescent B-lymphocytes). In this control slide we see a 
predominantly unstained germinal centre (blue/purple) and a heavily stained 
(red/brown) mantle zone. For p27 this is an expected finding as cells with higher 
proliferation rates would be expected to show less nuclear p27. 
 
 
 
 
 
Figure 3.12 A lower powered slide of sample 6 showing islet, exocrine and tumour 
portions and the differences seen in staining 
 
 
At lower magnification, the differences often seen in the staining patterns of tumour, 
exocrine tissue and islets can be seen on the same slide. 
 
←TUMOUR 
 
EXOCRINE→ 
ISLET→ 
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Figure 3.13 p27 staining of the insulinoma portion of sample 6, showing both nuclear 
and cytoplasmic staining  
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3.2.5 p27 Staining in insulinoma, gastrinoma, islet and 
exocrine pancreas 
It can be seen from figures 3.14 – 3.17, that p27 is expressed in all the tissues in both 
the nuclear and cytoplasmic compartments. With the exception of exocrine pancreas, 
p27 expression shows a broad distribution of strong, moderate and weak staining. It also 
appears that p27 is expressed slightly higher in the cytoplasm than the nucleus of all 
three endocrine tissues.  
 
In the insulinoma group no significant difference was seen between the nuclear and 
cytoplasmic localisation of p27 with positive nuclear staining seen in 68.7 +/- 6.81% 
and cytoplasmic staining seen in 74.6 +/- 5.6% (figure 3.18) 
 
 A significant difference is, however, seen in the case of gastrinoma (figure 3.19) and 
islets (figure 3.20). Nuclear staining in gastrinoma is 77.3 +/- 13.2% whereas 
cytoplasmic staining is 94 +/- 0.4% (p<0.05). Similarly, in islets, positive nuclear 
staining is 65.5 +/- 8.3% and cytoplasmic staining is 92.6 +/- 1.8% (p<0.001) 
 
In exocrine tissue there is substantially less p27 expression with a trend towards higher 
nuclear localisation (figure 3.21). Positive nuclear staining was seen in 26.9 +/- 2.1% 
and cytoplasmic staining in 18.7 +/- 4.3% (p=0.07) 
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Figure 3.14 Graph showing the location and strength of p27 staining in insulinoma 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.15 Graph showing the location and strength of p27 staining in gastrinoma 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Nuclear/Cytoplasmic p27 Staining in Islet Cells
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Figure 3.16 Graph showing the location and strength of p27 staining in islet  samples 
(S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.17 Graph showing the location and strength of p27 staining in exocrine 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.18 Graph showing the total positive (S+M+W) p27 nuclear and cytoplasmic 
staining in insulinoma samples. 
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Figure 3.19 Graph showing the total positive (S+M+W) p27 nuclear and cytoplasmic 
staining in gastrinoma samples. 
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Figure 3.20 Graph showing the total positive (S+M+W) p27 nuclear and cytoplasmic 
staining in islet samples. 
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Figure 3.21 Graph showing the total positive (S+M+W) p27 nuclear and cytoplasmic 
staining in exocrine samples. 
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3.2.6 Comparison of p27 Nuclear Staining 
Comparing nuclear p27 reveals the similarities in the pattern of staining in insulinoma, 
gastrinoma and islets. This is in contrast to the pattern of exocrine pancreas staining 
suggesting a significant difference in nuclear p27 expression of exocrine pancreatic 
tissue compared to endocrine tissues. 
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Figure 3.22 Graph comparing the relative strength of p27 nuclear staining for all 
tissue types 
 
Comparing total positive counts confirms that there is no significant difference in the 
nuclear expression of p27 in insulinoma compared to islets, nor compared to 
gastrinoma. All three, however, are significantly different compared to exocrine 
pancreas (figure 3.23). 
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Figure 3.23 Graph comparing total positive p27 nuclear staining for all tissue types 
 
Kruskal-Wallis  P = 0.0005 
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)    
INSULINOMA and EXOCRINE   P < 0.0001 
GASTRINOMA and EXOCRINE   P = 0.0097 
ISLET and EXOCRINE    P = 0.0005 
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3.2.7 Comparison of p27 Cytoplasmic Staining 
Trends in the pattern of cytoplasmic staining are less clear when looking at the strength 
of staining. The small numbers of gastrinomas with varying counts leading to large 
error. 
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Figure 3.24 Graph comparing the relative strength of p27 cytoplasmic staining for all 
tissue types 
 
On comparing the total positive counts (figure 3.25), there is a significant difference 
between insulinoma (74.6 +/- 5.6%) and islets (92.6 +/- 1.8%). Gastrinoma show a very 
similar level of positive staining to islets (94.1 +/- 0.4%), again, with a significant 
difference compared to insulinoma. Exocrine pancreas has significantly less p27 
staining (18.7 +/- 4.3%) compared to insulinoma, gastrinoma or islets.  
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Figure 3.25 Graph comparing total positive p27 cytoplasmic staining for all tissue 
types 
 
Kruskal-Wallis test  P < 0.0001  
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)    
INSULINOMA and GASTRINOMA  P = 0.0054   
INSULINOMA and ISLET    P < 0.0001 
INSULINOMA and EXOCRINE   P < 0.0001 
GASTRINOMA and EXOCRINE   P < 0.0001 
ISLET and EXOCRINE    P < 0.0001 
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These differences are enhanced when weak staining is excluded when calculating a 
value for positive staining. Clearly, the significant difference between insulinoma and 
gastrinoma has disappeared but there is a strengthening of the finding that insulinoma 
and islets are significantly different. 
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Figure 3.26 Graph comparing p27 positive staining (where positive = strong 
+moderate staining) for all tissue types. 
 
Kruskal-Wallis test  P < 0.0001    
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)     
INSULINOMA and ISLET    P < 0.0001 
INSULINOMA and EXOCRINE   P < 0.0001 
GASTRINOMA and ISLET    P = 0.0005 
ISLET and EXOCRINE    P < 0.0001 
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3.2.8 Phospho-p27 immunohistochemistry 
p27 plays an important role in maintaining cells in G0 through the inhibition of CDKs. 
When cells re-enter the cell cycle, p27 protein levels but not mRNA levels decrease, this 
is thought to be due to an increase in p27 ubiquitin-mediated degradation. 
Phosphorylation of p27 on threonine 187 is thought to be an important step for the 
widespread ubiquitination of p27. 
 
Slides were treated with an anti-phospho-p27 antibody obtained from Zymed 
laboratories. It is a polyclonal IgG antibody purified from rabbit antiserum. It detects 
threonine 187-phospholylated p27 peptide derived from the C-terminus of the human 
p27 protein. It does not cross react with non-phosphorylated p27 or related CDK 
inhibitor proteins. Optimisation led to an antibody dilution of 1:250 giving good 
staining as can be seen in the tonsil positive control section below. 
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Figure 3.27 Positive control for phospho-p27 (tonsil). Stronger staining can be 
identified in the central germinal centre compared to the slide for p27 
 
 
 
Figure 3.28 Positive phospho-p27 cytoplasmic staining seen in tumour sample 20 
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Figure 3.29 Positive phospho-p27 cytoplasmic staining seen in islet sample 20 
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3.2.9 Phospho-p27 staining in insulinoma, gastrinoma, islet 
and exocrine pancreas  
Looking at the pattern of staining, the vast majority of phospho-p27 staining is seen in 
the cytoplasm of all tissue types (figures 3.30 – 3.33). 
 
In insulinomas (figure 3.34), positive nuclear phospho-p27 staining was seen in only 1.5 
+/- 0.8% compared to cytoplasmic staining of 78.9 +/- 6.2% (p<0.001). With 
gastrinomas (figure 3.35), nuclear staining was 6.8 +/- 4.3% compared to cytoplasmic 
staining of 86.2 +/- 11.6% (p<0.05). Similarly, islets (figure 3.36) show nuclear staining 
in only 3.6 +/- 2.1% but cytoplasmic staining in 87.4 +/- 4.2% (p<0.001).  
 
Exocrine tissue had the highest positive nuclear count of 7.9 +/- 4.5% and the lowest 
cytoplasmic count of 41.5 +/- 4.5% (figure 3.37), but this is still a significant difference 
(p<0.001) in favour of cytoplasmic localisation of phospho-p27. 
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Figure 3.30 Graph showing the location and strength of phospho-p27 staining in 
insulinoma samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.31 Graph showing the location and strength of phospho-p27 staining in 
gastrinoma samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.32 Graph showing the location and strength of phospho-p27 staining in islet 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.33 Graph showing the location and strength of phospho-p27 staining in 
exocrine samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.34 Graph showing the total positive (S+M+W) phospho-p27 nuclear and 
cytoplasmic staining in insulinoma samples. 
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Figure 3.35 Graph showing the total positive (S+M+W) phospho-p27 nuclear and 
cytoplasmic staining in gastrinoma samples. 
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Figure 3.36 Graph showing the total positive (S+M+W) phospho-p27 nuclear and 
cytoplasmic staining in islet samples. 
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Figure 3.37 Graph showing the total positive (S+M+W) phospho-p27 nuclear and 
cytoplasmic staining in exocrine samples. 
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3.2.10 Comparison of phospho-p27 Nuclear Staining 
 
In all tissues there was little phospho-p27 nuclear staining seen, as indicated by figure 
3.38. Unsurprisingly, there is no significant difference between any of the tissue types. 
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Figure 3.38 Graph comparing the relative strength of phospho-p27 nuclear staining 
for all tissue types 
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3.2.11 Comparison of phospho-p27 Cytoplasmic Staining  
The pattern of phospho-p27 cytoplasmic staining was predominantly moderate to weak 
with only a few staining strongly positive (figure 3.39).  
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Figure 3.39 Graph comparing the relative strength of phospho-p27 cytoplasmic 
staining for all tissue types 
 
On comparison of total counts (figure 3.40), cytoplasmic staining was seen in a high 
proportion of insulinoma (78.9 +/- 6.2%), gastrinoma (86.2 +/- 11.6%) and islets (87.4 
+/- 4.2%). Exocrine pancreas samples, in comparison, had the lowest positive 
cytoplasmic count at 41.5 +/- 6.2%, predominantly due to the reduction in moderate 
staining compared to the other tissues. It is clear that there is no statistical difference in 
the cytoplasmic staining of insulinoma and islets or that of gastrinoma. All three 
endocrine tissues are, however, significantly different from the exocrine pancreas. 
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Figure 3.40 Graph comparing total positive phospho-p27 cytoplasmic staining for all 
tissue types 
 
Kruskal-Wallis test  P < 0.0001 
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)     
INSULINOMA and EXOCRINE   P < 0.0001  
GASTRINOMA and EXOCRINE   P = 0.0028 
ISLET and EXOCRINE    P < 0.0001 
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3.2.12 JAB1 (Jun activation domain-binding protein 1) 
immunohistochemistry 
p27 degradation is related to its export from the nucleus and the protein that appears to 
be responsible is JAB1, which is a coactivator of the c-jun transcription factor. JAB1 
binds to the C-terminal part of p27 in the nucleus and over-expression causes 
translocation of p27 into the cytoplasm. This decreases the amount of p27 in the cell by 
up-regulating its degradation. 
 
Slides were treated with an anti-JAB1 IgG monoclonal antibody purified from mouse 
ascites and supplied from Zymed laboratories. It reacts with a peptide from the N-
terminal region of JAB1. Optimisation was achieved with an antibody dilution of 1:250. 
Tonsil sections were used as positive controls, an example of which is shown below. 
 
 
Figure 3.41 Slide showing a positive control slide (tonsil) for JAB1 with 
predominantly nuclear staining seen. 
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Figure 3.42 Slide showing predominantly cytoplasmic JAB1 staining in tumour 
sample 8 
 
 
Figure 3.43 Slide showing typical strong cytoplasmic staining for JAB1 in islet 
sample 8 
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3.2.13 JAB1 staining in insulinoma, gastrinoma, islet and 
exocrine pancreas  
In our series the pattern of JAB1 staining in all tissues is overwhelmingly cytoplasmic, 
with either no or negligible nuclear staining seen (figures 3.44 – 3.47). 
 
Insulinoma, gastrinoma and islet series had essentially no nuclear staining identified, 
but significant cytoplasmic staining levels at 75.3 +/- 7.6% (p<0.0001), 41.4 +/- 28.3% 
(p<0.05) and 98.4 +/- 0.8% (p<0.0001) respectively (figures 3.48 – 3.50). In the 
exocrine series (figure 3.51), there was 2.1 +/- 0.9% nuclear staining compared to 27.3 
+/- 6.95% cytoplasmic staining (p<0.001).  
 
The pattern of cytoplasmic staining is varied between the tissues with insulinoma 
showing a broadly equal distribution in strength of staining whereas islets show 
increasingly strong staining. In contrast, gastrinoma and exocrine pancreas samples 
show a pattern of decreasing strength of staining.  
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Figure 3.44 Graph showing the location and strength of JAB1 staining in insulinoma 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.45 Graph showing the location and strength of JAB1 staining in gastrinoma 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.46 Graph showing the location and strength of JAB1 staining in islet 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.47 Graph showing the location and strength of JAB1 staining in exocrine 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.48 Graph showing the total positive (S+M+W) JAB 1 nuclear and 
cytoplasmic staining in insulinoma samples. 
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Figure 3.49 Graph showing the total positive (S+M+W) JAB1 nuclear and 
cytoplasmic staining in gastrinoma samples. 
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Figure 3.50 Graph showing the total positive (S+M+W) JAB1 nuclear and 
cytoplasmic staining in islet samples. 
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Figure 3.51 Graph showing the total positive (S+M+W) JAB1 nuclear and 
cytoplasmic staining in exocrine samples. 
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3.2.14 Cytoplasmic JAB1 Staining 
Looking at all tissues together, reveals the varied patterns of JAB1 cytoplasmic staining 
(figure 3.52). 
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Figure 3.52 Graph comparing the relative strength of JAB1 cytoplasmic staining for 
all tissue types 
 
 
Comparing the total positive counts for each tissue simplifies the picture considerably. 
It is seen that there is significantly less cytoplasmic expression of JAB1 in insulinoma 
compared to islets. Also, despite the large SEM in the gastrinoma group, there is still a 
significant difference between it and the islet group. Exocrine tissue is shown to have 
the least cytoplasmic expression of JAB1, and this is significantly lower than that of 
islets or insulinoma. 
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Figure 3.53 Graph comparing total positive JAB1 cytoplasmic staining for all tissue 
types 
 
Kruskal-Wallis test   P < 0.0001     
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)     
INSULINOMA and ISLET    P < 0.0001 
INSULINOMA and EXOCRINE   P < 0.0001  
GASTRINOMA and ISLET    P = 0.0002 
ISLET and EXOCRINE    P < 0.0001 
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As the pattern of staining is varied between groups, the differences are highlighted 
further when weak staining is excluded from total positive counts.  
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Figure 3.54 Graph comparing JAB1 positive staining (where positive = strong 
+moderate staining) for all tissue types. 
 
Kruskal-Wallis test   P < 0.0001 
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)   
INSULINOMA and GASTRINOMA  P = 0.0165 
INSULINOMA and ISLET    P < 0.0001 
INSULINOMA and EXOCRINE   P < 0.0001  
GASTRINOMA and ISLET    P < 0.0001  
ISLET and EXOCRINE    P < 0.0001 
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3.2.15 Phospho-Akt (p-Akt) Immunohistochemistry 
Cells were treated with phospho-Akt (Ser473) antibody from cell Signaling 
Technology. It is a polyclonal antibody isolated from rabbits following immunisation 
with mouse phospho-Akt. It detects Akt1 only when phosphorylated at serine 473. It 
also detects Akt2 and Akt3 when phosphorylated at equivalent sites. Tonsil was used as 
a positive control and optimal staining was achieved with an antibody dilution of 1:100. 
 
Immunohistochemistry with p-Akt proved the most problematic to optimise and 
interpret. Overnight incubation with primary antibody at 4oC gave the best results but 
interpretation could be difficult as cytoplasmic staining may be confused with 
background staining. Extra care and optimisation was required to give the results 
obtained.  
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Figure 3.55 Slide showing p-AKT positive control (tonsil) with nuclear staining 
 
 
Figure 3.56 Slide showing diffuse cytoplasmic staining and minimal background 
staining for p-AKT in tumour sample 5 
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 3.2.16 p-AKT staining in insulinoma, gastrinoma, islet and 
exocrine pancreas 
Widespread nuclear and cytoplasmic staining for p-Akt was seen in all four tissue types 
with cytoplasmic staining being predominant (figures 3.57 – 3.60). 
 
Insulinoma (figure 3.61) showed positive nuclear staining in 58.2 +/- 8.6% compared to 
a substantially higher cytoplasmic staining of 90.3 +/- 3.9% (p<0.001).  
 
Gastrinoma (figure 3.62) nuclear staining was lower at 37.3 +/- 22.2% compared to 
cytoplasmic staining of 92.2 +/- 1.7% (p<0.05).  
 
Islets (figure 3.63) had a higher level of p-Akt nuclear staining than any other tissue at 
82.3 +/- 5.2% but cytoplasmic staining was higher still at 98.1 +/- 0.7% (p<0.001).  
 
Exocrine pancreas (figure 3.64) shows both the lowest nuclear staining and cytoplasmic 
staining but the pattern is still the same with nuclear staining at 35.6 +/- 7.5% and 
cytoplasmic staining at 83.9 +/- 6% (p<0.0001) 
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Figure 3.57 Graph showing the location and strength of p-Akt staining in insulinoma 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.58 Graph showing the location and strength of p-Akt staining in gastrinoma 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.59 Graph showing the location and strength of p-Akt staining in islet 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.60 Graph showing the location and strength of p-Akt staining in exocrine 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.61 Graph showing the total positive (S+M+W) p-Akt nuclear and 
cytoplasmic staining in insulinoma samples. 
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Figure 3.62 Graph showing the total positive (S+M+W) p-Akt nuclear and 
cytoplasmic staining in gastrinoma samples. 
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Figure 3.63 Graph showing the total positive (S+M+W) p-Akt nuclear and 
cytoplasmic staining in islet samples. 
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Figure 3.64 Graph showing the total positive (S+M+W) p-Akt nuclear and 
cytoplasmic staining in exocrine samples. 
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3.2.17 Comparing nuclear p-Akt staining 
Comparing positive nuclear staining (figures 3.65 and 3.66), reveals that there is 
significantly lower expression of p-Akt within the nuclei of insulinomas compared to 
islets. A similar finding is seen with gastrinomas. Furthermore, exocrine pancreas shows 
significantly lower expression than either insulinomas or islets. 
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Figure 3.65 Graph comparing the relative strength of p-Akt nuclear staining for all 
tissue types 
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Figure 3.66 Graph comparing total positive p-Akt nuclear staining for all tissue types 
 
Kruskal-Wallis test   P = 0.0003 
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)  
INSULINOMA and ISLET    P = 0.0216 
INSULINOMA and EXOCRINE   P = 0.0106 
GASTRINOMA and ISLET    P = 0.0335 
ISLET and EXOCRINE    P < 0.0001 
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3.2.18 Comparing cytoplasmic p-Akt staining 
There was widespread cytoplasmic staining in all tissues. Staining was predominantly 
weak to moderate with islets showing the strongest levels of staining. 
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Figure 3.67 Graph comparing the relative strength of p-Akt cytoplasmic staining for 
all tissue types 
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Figure 3.68 Graph comparing total positive p-Akt cytoplasmic staining for all tissue 
types 
 
Kruskal-Wallis test   P = 0.0017 
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)  
INSULINOMA and ISLET    P = 0.0175 
GASTRINOMA and ISLET    P = 0.0092 
ISLET and EXOCRINE    P = 0.0002 
 
 
All tissues have stained highly positive. We noted however, that a pattern becomes 
apparent when positive staining is considered as strong and moderate only.  
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Figure 3.69 Graph comparing cytoplasmic p-Akt positive staining (where positive = 
strong +moderate staining) for all tissue types. 
 
Kruskal-Wallis test   P < 0.0001    
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)    
INSULINOMA and ISLET    P = 0.0263  
INSULINOMA and EXOCRINE   P = 0.0005   
GASTRINOMA and ISLET    P = 0.0026 
ISLET and EXOCRINE    P< 0.0001  
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3.2.19 PTEN immunohistochemistry 
PTEN was stained for using a mouse monoclonal IgG antibody which reacts with a 
protein corresponding to a 200 amino-acid C-terminal region of the PTEN molecule. 
Tonsil sections were used as a control and an antibody dilution of 1:100 was found to 
give best optimisation. 
 
 
Figure 3.70 Slide showing strong nuclear staining for PTEN in the tonsil positive 
control 
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Figure 3.71 Slide showing good nuclear PTEN staining in tumour sample 8 
  
Figure 3.72 Lower powered slide showing the difference in PTEN staining between 
the different tissue types in sample 8 
TUMOUR→ 
        ↑ 
   ISLET 
←EXOCRINE 
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3.2.20 PTEN staining in insulinoma, gastrinoma, islet and 
exocrine pancreas 
The pattern of PTEN staining seen is clearly seen in all tissues (figures 3.73 – 3.76). 
There is very high degree of positive nuclear staining and very little cytoplasmic 
staining. 
 
Insulinoma show positive nuclear staining in 95.6 +/- 2.1% of cells compared to 
cytoplasmic staining of 5.6 +/- 2.9%. Gastrinoma are even more black and white with 
99.6 +/-0.4% positive staining and 0% cytoplasmic staining seen. Islets show 97.8 +/-
0.7% positive nuclear staining compared to10 +/- 6.9% cytoplasmic staining. Exocrine 
showed the lowest nuclear staining at 73.2 +/- 3.2% but clearly showed no cytoplasmic 
staining at all.  
 
There is no significant difference between insulinoma and islets nor gastrinoma. All 
three endocrine tissues show significantly more nuclear PTEN expression than exocrine 
pancreas. 
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Figure 3.73 Graph showing the location and strength of PTEN staining in 
insulinoma samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.74 Graph showing the location and strength of PTEN staining in 
gastrinoma samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.75 Graph showing the location and strength of PTEN staining in islet 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
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Figure 3.76 Graph showing the location and strength of PTEN staining in exocrine 
samples (S=strong, M=moderate, W=weak, -VE=negative) 
 155 
3.2.21 Comparing nuclear PTEN staining 
When comparing the nuclear staining of PTEN across the different tissues it is clear that 
there is a similar staining pattern with heavy strong and moderate staining seen. 
 
Looking at total positive counts for the tissues there is no difference between 
insulinoma, gastrinoma or islets. All three, however, show significantly more staining 
than exocrine tissue. 
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Figure 3.77 Graph comparing the relative strength of PTEN nuclear staining for all 
tissue types 
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Figure 3.78 Graph comparing total positive PTEN nuclear staining for all tissue types 
 
 
Kruskal-Wallis test    P < 0.0001    
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)    
INSULINOMA and EXOCRINE   P < 0.0001 
GASTRINOMA and EXOCRINE   P = 0.0007 
ISLET and EXOCRINE    P < 0.0001 
 
When positive staining is considered as strong plus moderate staining, there is no 
change in the pattern seen. 
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3.2.22 Comparing cytoplasmic PTEN staining 
 
No differences are seen when comparing the cytoplasmic staining of any of the tissues. 
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Figure 3.79 Graph comparing the relative strength of PTEN cytoplasmic staining for 
all tissue types 
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 3.2.23 Ki-67 immunohistochemistry 
 
A rabbit anti-human polyclonal antibody to Ki-67 protein was used (AO47, Dako, 
Cambridgeshire, UK).  This antibody had been previously optimised in the laboratory 
and good staining was seen with standard dilutions of 1:200.  
 
 
Figure 3.80 Slide showing good nuclear Ki-67 staining in tonsil positive control 
 
An estimation of the percentage of positive Ki-67 staining for insulinomas and 
gastrinomas was performed in the laboratory by a consultant histopathologist (Dr E 
Carlsen). 
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Table 5 Ki-67 staining for insulinoma samples 
 Ki-67 STAINING (% POSITIVE) 
ID TUMOUR ISLET EXOCRINE 
1 <1 <1 <1 
2 <1 <1 <1 
3 <1 <1 <1 
5 <1 <1 <1 
6 <1 <1 <1 
7 <1 <1 <1 
8 <1 <1 <1 
9 <1 <1 <1 
10 <5 <1 <1 
11 <5 <1 <1 
12 <1 <1 <1 
13 <5 <1 <1 
14 <1 <1 <1 
15 <5 <1 <1 
17 <1 <1 <1 
18 <1 <1 <1 
19 <1 <1 <1 
20 <1 <1 <1 
23 <1 <1 <1 
25 <1 <1 <1 
 
Table 6 Ki-67 staining for gastrinoma samples 
 Ki-67 STAINING (% POSITIVE) 
ID TUMOUR ISLET EXOCRINE 
4 <1 <1 <1 
22 <5 <1 <1 
24 <1 <1 <1 
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3.2.24 Insulinoma proliferation sub group analysis 
Within the insulinoma group there were 4 tumours that may have been proliferating at a 
higher rate as shown by the Ki-67 Index (ID 10, 11, 13 and 15). To identify whether 
these are acting differently to less proliferative tumours, they were separated out for 
comparison. 
 
Although not statistically significant, probably due to the small sample size, there was a 
trend for the less proliferative tumours to express less nuclear PPARγ (% positive 
staining, 2.6 +/- 1.9% vs 31.1 +/- 20.1%). 
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Figure 3.81 Graph showing total positive nuclear PPARγ in insulinomas split into 
two groups based on their Ki-67 index. 
 
 161 
With p27 staining it was noted that there was a trend for reduced nuclear and 
cytoplasmic p27 expression. On testing this reached statistical significant in the 
cytoplasmic group. 
 
 
Figure 3.82 Graph showing total positive nuclear p27 in insulinomas split into two 
groups based on their Ki-67 index. (% positive = 72.4 +/- 7.7% (for insulinomas <1%) 
vs 53.8 +/- 13.4% (for insulinomas <5%)) 
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Figure 3.83 Graph showing total positive cytoplasmic p27 in insulinomas split into 
two groups based on their Ki-67 index. (% positive = 79.5 +/- 5.9% (for insulinomas 
<1%) vs 54.9 +/- 12.5% (for insulinomas <5%)) 
 
Mann-Whitney test   P = 0.0499 
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With phospho-p27, there was little difference between the nuclear staining but there was 
lower cytoplasmic staining in those tumours with a higher Ki-67 index, (86.9 +/- 5% vs 
46.5 +/- 16.7%). This did not reach statistical significance. 
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Figure 3.84 Graph showing total positive cytoplasmic phospho-p27 in insulinomas 
split into two groups based on their Ki-67 index. 
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Assessing JAB1 staining revealed a significant difference in the cytoplasmic staining. It 
was found that tumours with the higher Ki-67 index showed lower JAB1 expression in 
the cytoplasm, (85.9 +/- 5.8% vs 33.2 +/- 20.6%). 
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Figure 3.85 Graph showing total positive cytoplasmic JAB1 in insulinomas split into 
two groups based on their Ki-67 index. 
 
Mann-Whitney test   P = 0.0293 
  
No obvious differences were noted in the staining patterns with phospho-Akt or PTEN 
series. 
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3.2.25 Summary of immunohistochemistry 
Immunohistochemistry was performed using seven different antibodies: PPARγ, p27, 
phospho-p27, JAB1, phospho-Akt, PTEN and Ki-67. With the exception of Ki-67 (see 
below), we wanted to identify the location of these proteins (nuclear or cytoplasmic) 
and to identify any pattern of differences between the tissue types. 
 
Regarding PPARγ expression in the whole series, we were unable to demonstrate any 
significant nuclear or cytoplasmic expression, despite good staining of positive controls. 
 
In the p27 series, good staining was seen in both the nucleus and cytoplasm. In fact, 
there was significantly more cytoplasmic than nuclear staining seen with gastrinoma 
and islet cells. On comparing the tissues, no difference was found in the nuclear 
expression of p27 between insulinoma, gastrinoma or islets, but there was significantly 
lower expression of p27 in the cytoplasm of insulinomas compared to islets. Nuclear 
and cytoplasmic staining in insulinomas, gastrinomas and islets was significantly higher 
than that seen in exocrine tissue. 
 
In the phospho-p27 series, the expression is overwhelmingly within the cytoplasm of all 
tissue types. Very little nuclear staining was identified and there were no differences 
between tissue types. Despite the high levels of cytoplasmic staining there was no 
difference in expression between insulinomas, gastrinomas or islets. All three tissues 
showed significantly higher cytoplasmic expression compared to exocrine tissue. 
 
In the series of JAB1 staining, all tissues overwhelmingly showed cytoplasmic 
expression, with either no or negligible nuclear staining seen. Although there is a 
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variation in the pattern of staining, overall there was a significantly lower cytoplasmic 
expression of JAB1 in insulinomas and gastrinomas compared to islets. Both 
insulinomas and islets showed significantly higher expression compared to exocrine 
tissue.  
 
In the phospho-Akt series, widespread nuclear and cytoplasmic staining was seen in all 
four tissue types, with cytoplasmic expression being significantly higher than nuclear in 
all tissues. There was significantly lower nuclear expression of p-Akt in insulinomas 
and gastrinomas compared to islets. Exocrine pancreas shows significantly lower 
nuclear expression than either insulinoma or islets. Despite very high levels of 
cytoplasmic staining there was significantly less expression in insulinomas and 
gastrinomas compared to islets. Again, exocrine expression was lower than either 
insulinoma or islets. 
 
PTEN staining was similar in all tissues. There was very high degree of positive nuclear 
staining and very little cytoplasmic staining. No significant differences were identified 
between insulinoma, gastrinoma and islets. All three show significantly more nuclear 
PTEN expression than exocrine pancreas. 
 
Regarding the Ki-67 subgroup analysis, tumours with a higher Ki-67 index had 
significantly less cytoplasmic p27 and JAB1.  Trends were noted towards higher nuclear 
expression of PPARγ, lower nuclear expression of p27 and lower cytoplasmic phospho-
p27. 
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RESULTS III 
Cell Cultures 
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3.3.1 Cell Culture Work  
Three cell lines were obtained by kind permission of Professor N Lemoine (Institute of 
Cancer, Barts and The London, Queen Mary's School of Medicine and Dentistry). The 
cell lines denoted as CM, BON and QGP1 represent human insulinoma, carcinoid and 
somatostatinoma cell lines respectively. 
 
The three cells lines were successfully transferred and cultured in our laboratory under 
the conditions explained in the methods section. 
 
Work with these cells can be divided into three main sections, RNA/DNA, protein 
expression and proliferation studies 
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3.3.1.1 RNA Extraction 
Cells were harvested, washed in PBS and separated by centrifuging. RNA was then 
extracted using standard Promega extraction protocol as described. RNA was then 
subjected to spectrophotometry and RNA gel electrophoresis with good results. 
 
Example of RNA 1% agarose gel 
         CM       CM      BON     BON      QGP       QGP 
 
Samples were subject to reverse transcription using ABI standard protocols as 
described. To check quality, cDNA were subjected to PCR using standard Promega 
protocols to check for short GAPDH.  
 
SHORT GAPDH 
     SM    H2O +VE   CM  CM  BON BON QGP QGP 
 
Size marker = phix 174 Hinf 1  +VE = positive control 
←GAPDH 
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Samples were considered to be of a reasonable quality to proceed with further 
investigation. 
 
3.3.1.2 Expression of PPARγ  
To check for the expression of PPARγ mRNA in our cell lines, cDNA samples were 
subjected to PCR for PPARγ using Qiagen standard PCR protocols 
PPARγ primers were obtained from Sigma-Genosys as described in the methods 
section. 
 
  SM  H2O +VE   CM  CM   BON  BON  QGP QGP QGP 
 
Size marker phix 174 Hinf 1   +VE = positive control 
Figure 3.86 Gel showing the products of PCR for PPARγ on mRNA extracted from 
cell lines CM, BON and QGP1 
The duplicate samples had been extracted on separate days and therefore the negative 
PPARγ results with CM cell line were thought to be a true finding. 
 
3.3.1.3 Repeat PPARγ PCR 
In view of the unusual finding that the cell line CM did not express PPARγ mRNA but 
PPARγ protein was apparently being detected in my Westerns blots, it was felt that the 
cell lines should be subjected to further RNA extraction, RT and repeated PPARγ PCR. 
←PPARγ 
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       CM       BON      QGP1 
RNA 1% agarose gel of repeated extractions of cell lines CM BON and QGP1 
REPEATED PPARγ PCR 
           SM   H2O  +VE    A      B       C      D      E       F      G 
 
Size marker phix 174 Hinf 1   +VE = POSITIVE CONTROL 
Figure 3.87 Gel showing the products of repeat PCR for PPARγ on mRNA extracted 
from cell lines CM, BON and QGP1 
 
SAMPLES A BON  (previous sample with positive result) 
  B QGP1  (previous sample with positive result) 
  C CM  (1st previous sample with negative result) 
  D CM  (2nd previous sample with negative result) 
  E CM  (Newly prepared sample as above on RNA gel) 
  F BON (Newly prepared sample as above on RNA gel) 
  G QGP1 (Newly prepared sample as above on RNA gel) 
 
←PPARγ 
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From the gel it can be confirmed that the previous samples give the same results with 
this new PCR i.e. both previous CM samples do not express PPARγ mRNA whereas 
both BON and QGP1 do. This has been confirmed again with the newly extracted 
samples represented by E, F and G. 
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3.3.2 Somatostatin Receptor PCR 
It is widely accepted that a large proportion of neuroendocrine tumours express 
somatostatin receptors and clinical therapy often utilises somatostatin analogues. It was 
felt worthwhile to identify whether these cell line expressed these somatostatin 
receptors (SSTR’s). Somatostatin is thought to act through five membrane receptors 
which are expressed variably in tissues and tumours. The somatostatin analogue 
octreotide for example activates SSTR receptor subtype 2 (SSTR2), and to a lesser 
extent receptor subtype 5 (SSTR5). The inhibition of cellular proliferation attributed to 
somatostatin analogues may involve several signal transduction pathways including the 
MAP Kinase pathway and stimulation of the cyclin dependent kinase inhibitor p27 
 
Previously extracted RNA from all 3 cell lines was subjected to PCR for receptors 1-5 
using Promega PCR standard protocols, previously optimised in our laboratory. 
 
3.3.2.1 PCR FOR SSTR 1 
 
  SM  H2O   +VE    X     CM   CM  BON  BON  QGP  QGP  QGP 
Figure 3.88 Gel showing the products of PCR for SSTR1 on mRNA extracted from 
cell lines CM, BON and QGP1 
 
←SSTR1 
 
 174 
SM = phix 174 Hinf 1   SSTR 1 product 401 bp 
X = pituitary tumour tested to see if it could be used in the future as a positive control 
Repeat labels represent samples extracted on different days 
 
3.3.2.2 PCR FOR SSTR 2 AND 3 
 
              SSTR2                  SSTR3   
 SM     H2O  +VE     X    CM    BON  QGP  +VE   X      CM   BON  QGP 
 
SM = phix 174 Hinf 1  SSTR 2 product 459 bp SSTR 3 product 225bp 
Figure 3.89 Gel showing the products of PCR for SSTR2 and 3 on mRNA extracted 
from cell lines CM, BON and QGP1 
 
←SSTR 2 
 
←SSTR 3 
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3.3.2.3 PCR FOR SSTR 4 AND 5 
 
              SSTR4          SSTR5         
 SM  H2O  +VE   X   CM    BON  QGP  +VE   X    CM   BON  QGP 
 
SM= phix 174 Hinf 1  SSTR 4 product 451 bp SSTR 5 product 233 bp 
Figure 3.90 Gel showing the products of PCR for SSTR4 and 5 on mRNA extracted 
from cell lines CM, BON and QGP1 
 
Despite repeated experimentation, we concluded that cell lines CM, BON and QGP1 do 
not express any of the somatostatin receptors 1-5 mRNA.  
 
Regarding the PCR for SSTR4, it is acknowledged that the +ve control sample was 
negative and therefore interpretation of our findings for this receptor could be in doubt. 
Given that the experiment was repeated with the same results and given the lack of 
other SSTR’s within our cell lines. It is probable that these cell lines do not express 
SSTR4 either. It is likely that our positive control actually is inappropriate and does not 
express SSTR4 itself. As a side note, sample X, a pituitary tumour (growth hormone 
secreting) added to see if it could be used as a positive control in the future, was positive 
for receptors 3 and 5 
 
←SSTR 5 
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3.3.3 PPARγ Protein Expression 
Proliferating cells from all three cell lines were harvested using cytobuster protein 
extraction reagent (Novagen) as described in methods and subjected to protein assay to 
determine concentration. Samples were held -800C awaiting experimentation. 
 
3.3.3.1 Western Blotting To Assess PPARγ Protein Presence  
Following protein denaturing, 20µg protein samples were loaded into a 10% Tris-HCL 
gel and subject to electrophoresis. Electroblotting onto a PVDF membrane (Hybond-P, 
Amersham) was then performed and the resultant membrane washed and treated with 
5% non fat milk to prevent non specific binding of the antibody. 
 
A PPARγ mouse monoclonal IgG antibody from Santa Cruz (sc-7273) was obtained and 
optimised in the laboratory. A 1:50 dilution of this 1st antibody diluted in non fat milk 
was applied to the membrane and left on motion rollers overnight at 40C. 
Following washing a 1:10000 dilution of a goat antimouse 2nd antibody was applied for 
90 minutes. 
 
The resultant washed membrane was treated with LumiGLO reagent and peroxidise 
(Cell Signalling Technology) – a chemiluminescent detection system – and light 
emission was recorded by optimising exposure to X-Ray film. 
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3.3.3.2 PPARγ Western Result 
 
1st PPARγ  (Santa Cruz)  1:50  40C overnight 
2nd Goat anti-mouse  1:10000 90 mins 
Lumiglow 5 mins     Exposure 8 mins 
 
        CM      BON     QGP1 
 
 
Kaleidoscope pre stained standards (Bio-Rad) – shown to scale. 
Figure 3.91 Western blot result for PPARγ in the cell lines CM, BON and QGP1 
 
The PPARγ protein is 67 kD in weight. Double bands were unexpected and although the 
top line of bands would most likely be the correct weight, the strength of the lower 
bands made us question which was correct. 
 
To help answer the question, the membrane was stripped and re-probed with a different 
PPARγ antibody (Calbiochem-Novabiochem Corp., La Jolla, CA, USA). 
10 PPARγ  (Calbiochem)  1:2000  room temp 90 mins 
20 Goat anti-rabbit  1:10000 90 mins 
Lumiglow 5 mins     Exposure 2 mins 
←PPARγ ? 
 
 
 
 
←PPARγ ? 
 
82 kD→ 
 
 
 
 
 
 
 
 
 
 
 
32 kD→ 
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        CM      BON     QGP1 
 
 
Figure 3.92 Repeat western blot result for PPARγ in the cell lines CM, BON and 
QGP1 following administration of a different PPARγ antibody. 
 
The figures are both to the same scale. Clearly, the lower line has disappeared with the 
second antibody confirming that with the Santa Cruz antibody the upper band was the 
correct band for PPARγ. 
 
The same membrane was probed for β-actin (43 kD) 
 
 
           CM              BON           QGP1 
 
 
Figure 3.93 Western blot result for β-actin on the same membrane as above 
82 kD→ 
 
 
 
 
 
 
 
 
 
 
 
32 kD→ 
←PPARγ 
 
 
 
 
 
82 kD→ 
 
 
 
 
 
 
 
 
 
 
 
32 kD→ 
←β ACTIN 
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The expression of PPARγ protein in the CM cell line was unexpected, as repeated PCR 
for PPARγ cDNA was negative. I thought it best to repeat the Western experiments 
again using the protein samples from the above experiment (OLD), and newly extracted 
protein from all three cell lines (NEW). 
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3.3.3.3 Repeat Western for PPARγ 
Conditions as above for Santa Cruz PPARγ antibody 
 
         CM     BON     QGP     CM      BON     QGP 
 
                  OLD         NEW   
 
 
Figure 3.94 Repeat western blot for PPARγ in the cell lines CM, BON and QGP1 
following re extraction of proteins 
 
The membrane was stripped and re-probed for β-actin using the same conditions as 
above 
 
 
 
 
         CM       BON     QGP     CM      BON     QGP 
 
Figure 3.95 Western blot result for β-actin on the same membrane as above 
82 kD→ 
 
 
 
 
 
 
 
 
 
 
 
32 kD→ 
←PPARγ 
82 kD→ 
 
 
 
 
 
 
 
 
 
 
 
32 kD→ 
←β ACTIN 
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3.3.4 Proliferation Studies  
Cells were harvested and counted as described to calculate concentration of cells per ml 
of media. The correct volume of cell suspension was then pipetted into plate wells to 
give 50 000 cells per well. Cells were left for 8 hours to allow for cell adhesion prior to 
experimentation 
 
3.3.4.1 Rosiglitazone (PPARγ agonist) studies 
 
Optimising the duration of treatments 
Experimental plates were set up as described in methods. Tritiated thymidine was added 
to the wells 8 hours prior to the completion of the experimental period. Scintillation 
counting on completion of the time period allowed for assessment of the proliferation or 
inhibition of cell lines. Preliminary experiments were set up to assess the most suitable 
time period for treatments. 
 
Rosiglitazone treated QGP1 cells at 24, 48, 72 and 96 hours 
 
Example of results generated and tabulated in Excel. 
QGP1 ROSI 24HOURS
Molar Conc ROW 1 ROW 2 ROW 3 ROW 4 AVERAGE SD
CONTROL 20822.40 62214.40 49836.50 103434.70 59077.00 17142.175
x10--4 1734.90 8867.80 6561.50 11723.70 7221.98 2111.8414
x10--5 58615.50 54805.50 42751.00 50589.80 51690.45 3400.7971
x10--6 58266.50 90781.00 47548.80 46016.20 60653.13 10405.719
x10--7 53239.20 72567.20 68966.90 68694.40 65866.93 4300.7517
x10--9 73149.30 77005.50 60652.60 56186.80 66748.55 4957.1984
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Rosiglitazone Treated QGP1 cells 48 hours
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Rosiglitazone treated QGP1 cells 72 hours
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Rosiglitazone treated QGP1 cells 96 hours
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Figure 3.96 Graphs A-D showing thymidine scintillation counts as a marker of 
cellular proliferation versus molar concentration in QGP1 cells following treatment 
of rosiglitazone for, 24, 48, 72 and 96 hours. 
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Preliminary treatment series were performed for all cell lines and it was felt that 48 
hours was the best time frame for treatments. It appeared that at 72 and 96 hours some 
of the cells were becoming detached or dying. 
 
Example of length of treatment leading to variability of counts 
 
Rosiglitazone treated BON cells at 96 hours
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Figure 3.97 Graph showing variability in thymidine scintillation counts in BON cells 
following treatment of rosiglitazone for 96 hours probably due to cell death.  
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3.3.4.2 Combined results of proliferation studies with Rosiglitazone treated QGP1 
cells 
 
Proliferation of QGP1 After 48Hrs Treatment With 
Rosiglitazone (n=16, * P at least <0.002)
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Figure 3.98 Graph showing a reduction in proliferation of QGP1 cells after 48 hours 
at higher concentrations of rosiglitazone 
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3.3.4.3 Combined results of proliferation studies with Rosiglitazone treated BON 
cells 
 
Proliferation of BON Cells After 48 Hrs Treatment 
With Rosiglitazone (n=12, p<0.001)
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Figure 3.99 Graph showing a reduction in proliferation of BON cells after 48 hours 
at higher concentrations of rosiglitazone 
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3.3.4.4 Combined results of proliferation studies with Rosiglitazone treated CM 
cells 
 
 
Proliferation of CM cells after 48 hrs treatment 
with Rosiglitazone (n=12, p< 0.001)
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Figure 3.100 Graph showing a reduction in proliferation of CM cells after 48 hours 
of treatment at only the highest concentration of rosiglitazone 
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3.3.4.5 Proliferation studies with Dimethyl Sulfoxide (DMSO) 
Dimethyl sulfoxide (DMSO) is a colourless liquid that is an important solvent 
dissolving both polar and non-polar compounds. Use of DMSO in medicine increased 
when it was discovered it could penetrate the skin and other membranes without 
damaging them carrying other compounds into a biological system. It is often used in 
PCR reactions and has been used as a cryoprotectant. It is thought to have a low 
toxicity. 
 
Rosiglitazone was supplied in concentrated form and dissolved in DMSO. Subsequent 
dilutions to treatment dose levels in H2O reduced the effective concentration of DMSO 
in the wells during the treatment periods, but we felt that an effect of the DMSO on the 
cells should be excluded. 
 
Proliferation of QGP1 cells following 48 hrs 
treatment with DMSO (n=16, p<0.01)
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Figure 3.101 Graph showing the proliferation versus increasing DMSO dilutions of 
QGP1 cells after 48 hours of treatment. It can be seen that there is a significant 
reduction in proliferation at the highest concentration. 
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Proliferation of BON cells following 48 hours 
treatment with DMSO (n=8)
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Figure 3.102 Graph showing the proliferation of BON cells after 48 hours of 
treatment with DMSO dilutions. 
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Figure 3.103 Graph showing the proliferation of CM cells after 48 hours of treatment 
with DMSO dilutions. 
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3.3.4.6 Rosiglitazone versus DMSO treatments on QGP1 cells 
As it appeared that there might be an effect by DMSO on the QGP1 cells at the highest 
concentration, I was concerned that the effect seen could be solely due to the DMSO 
rather than the rosiglitazone. An experiment was set up where a comparison could be 
made. From the same harvest of cells two plates of QGP1 cells were set up. To one, 
treatment doses of rosiglitazone were added, to the other, comparative concentrations of 
DMSO. The cells were treated in exactly the same way and subjected to tritiated 
thymidine incorporation prior to the end of the experiment. 
 
Proliferation of QGP1 Cells following treatment of 
Rosiglitazone or DMSO (n=4)
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Figure 3.104 Graph showing direct comparison of the effects of DMSO compared to 
Rosiglitazone treatment 
     Rosiglitazone  DMSO 
Concentrations (M):  A 1x10-4   1x10-2 
    B  1x10-5   1x10-3 
    C 1x10-6   1x10-4  
    D 1x10-7   1x10-5 
    E 1x10-9   1x10-7 
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Kruskal-Wallis test    P =0.0075 
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)  
CONTROL and x10-4M Rosi    P < 0.0001  
CONTROL and x10-4M DMSO    P = 0.0011  
CONTROL and x10-5M Rosi    P = 0.0035 
 
In this experiment the expected pattern of inhibition of proliferation by the addition of 
rosiglitazone is seen in the 10-4M and 10-5M groups, with the 10-6M group just missing 
statistical significance. With the DMSO group it is seen that there is no significant 
effect of DMSO in any of the treatment groups B to E. DMSO, therefore, maybe 
contributing partially to the anti-proliferative effects seen with rosiglitazone at 10-4M 
concentrations in the QGP1 cell line. 
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3.3.5 Recovery studies 
To ensure that the effects seen by rosiglitazone were reversible and not toxic to the 
cells, I decided to show recovery of cellular proliferation following removal of 
rosiglitazone. 
 
Initial experiments were performed on the CM cell line. CM cells were treated with 10-
4M and 10-5M concentration of rosiglitazone and treated for 48hrs as per usual 
protocols. Treatments were then washed off and the cells left in normal media for a 
further 48 hrs. As can be seen in figure 3.105, CM cells at 10-4M concentration did not 
recover. 
 
Proliferation of CM 48hrs After Removal of 
Rosiglitazone Treatment (n=9)
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Figure 3.105 showing no recovery of CM cells following treatment and subsequent 
removal of 10-4 M rosiglitazone 
 
The non recovery of the CM cell line, at the only concentration at which reduction in 
proliferation was seen with rosiglitazone treatment, led to significant concern that the 
anti-proliferative effects being seen were due to toxicity. I therefore set up more robust 
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experiments for BON and QGP1 cell lines to see whether the effects seen in these cell 
lines was due to toxicity of rosiglitazone. 
 
The experiments were set up at the same time and date and from the same harvest of 
cell cultures to minimise error between groups. 
First set was treated with rosiglitazone for 48 hrs and harvested 
Second set was treated with rosiglitazone for 48 hrs then washed and left in 
normal media for a further 48 hours prior to harvesting. 
Third set was treated with rosiglitazone for 96 hrs and harvested at the same time 
as set 2. 
 
The first set is essentially a control to make sure that we see the expected effects of 
rosiglitazone treatment. The second set is the experimental group. The third set is 
another control group to identify that there is a continued effect of rosiglitazone 
treatment and that the cells do not spontaneously recover or escape from treatment 
effects. 
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Figure 3.106 Graph A-C showing the expected pattern of proliferation in BON cells 
after 48 hours of rosiglitazone treatment (A) followed by full recovery following 
removal (B) and the continued reduction in proliferation if the treatment is left on for 
96 hours (C) 
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Proliferation of QGP1 after 96hrs Treatment with 
Rosiglitazone (n=4)
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Figure 3.107 Graph A-C showing the expected pattern of proliferation in QGP1  cells 
after 48 hours of rosiglitazone treatment (A) followed by full recovery following 
removal (B) and the continued reduction in proliferation if the treatment is left on for 
96 hours (C) 
 
From the recovery studies it is seen that there is good recovery of both BON and QGP1 
cells following removal of treatments. However, it appears that a toxic effect of 
rosiglitazone on CM cells cannot be ruled out. CM cells were therefore excluded from 
anatgonist experiments. 
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3.3.6 Antagonist Studies  
We have shown that by adding rosiglitazone to cell lines BON and QGP1 at various 
concentrations, the proliferation of these cells can be reduced. We have also established 
that at the highest concentration of these treatments, the solvent in which the 
rosiglitazone is dissolved may also be having an additive effect. We have shown that by 
removing the treatments, washing and adding normal media to the treated cell lines 
normal cellular proliferation returns after 48 hours. To complete the PPARγ cell 
proliferation experiments I decided to try and prevent the effect of rosiglitazone by 
blocking the PPARγ receptors irreversibly, thereby confirming that the effects seen are 
mediated by PPARγ. 
 
3.3.6.1 Results for QGP1 and BON with Antagonist T0070907 
 
T0070907 antagonist (2-Chloro-5-nitro-N-(4-pyridyl)benzamide)  
(Calbiochem-Novabiochem Corp., La Jolla, CA, USA). 
 
T0070907 is a potent, specific, irreversible, and high-affinity antagonist of PPARγ  with 
a Ki of 1 x10-9M. It also displays >800-fold greater selectivity for PPARγ over PPARα 
and PPARδ (Ki = 0.85 x10-6M and 1.8 x10-6M, respectively). 
 
A 1 x10-6 M concentration of antagonist was used. Following standard plating and 
preparation, cells were pre-treated with the antagonist for 90 minutes prior to the 
addition of rosiglitazone. Incorporation of thymidine, harvesting and assessment of 
proliferation were performed as for previous experiments. 
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With antagonist treatment, there was still a significant effect on proliferation of QGP1 
by the higher concentration of rosiglitazone. Effects of rosiglitazone at concentrations of 
10-5M and 10-6M did however appear to be reduced. 
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Figure 3.108 Graph showing the effects on proliferation of QGP1 cells following 
treatment with T0070907 antagonist and combinations of antagonist and 
rosiglitazone (n=4 for all groups) 
 
Kruskal-Wallis test   P=0.0104 
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)  
CONTROL and ANTAG  P = 0.1454 
CONTROL and A+10-4M  P = 0.002 
CONTROL and A+10-5M  P = 0.1235 
CONTROL and A+10-6M  P = 0.6382 
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Similar findings were seen when BON cells were treated in the same manner with 
possible inhibition at lesser concentrations. A strong anti-proliferative effect was 
however still seen at the higher concentration of rosiglitazone. 
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Figure 3.109 Graph showing the effects on proliferation of BON cells following 
treatment with T0070907 antagonist and combinations of antagonist and 
rosiglitazone (n=4 for all groups) 
 
Kruskal-Wallis test   P=0.0176 
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)  
CONTROL and ANTAG  P > 0.999 
CONTROL and A+10-4M  P = 0.0007 
CONTROL and A+10-5M  P = 0.0535 
CONTROL and A+10-6M  P = 0.3114 
 
It was felt that antagonism by T0070907 had not been fully successful. Further 
investigation was deemed necessary and a different antagonist was sought. 
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3.3.6.2 Results for QGP1 and BON with Antagonist GW9662 
 
GW9662 antagonist (2-Chloro-5-nitro-N-phenyl-benzamide) 
(Sigma, St Louis, Missouri, USA). 
 
GW9662 is an irreversible PPARγ antagonist. GW9662 binds PPARγ with IC50 in 
nanomolar range, and is 10- and 600-fold less potent in binding PPARα and PPARδ, 
respectively. 
 
Exactly the same methods were used as for previous treatments with antagonist 
T0070907. Following pre-treatment of QGP1 cells with GW9662, rosiglitazone was 
added at the concentrations shown. Cells were harvested at 48 hours and proliferation 
assessed by tritiated thymidine uptake. 
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Figure 3.110 Graph showing the effects on proliferation of QGP1 cells following 
treatment with GW9662 antagonist and combinations of antagonist and rosiglitazone 
(n=8 for all groups) 
 
Kruskal-Wallis test   P=0.0018 
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)  
CONTROL and ANTAG  P = 0.5474 
CONTROL and A+10-4M  P < 0.0001 
CONTROL and A+10-5M  P = 0.2114 
CONTROL and A+10-6M  P = 0.4359 
 
 
Again only partial antagonism was seen with the anti-proliferative effect of the highest 
dose of rosiglitazone not being abolished. Experiments were repeated for BON and 
again only partial antagonism was seen. 
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Figure 3.111 Graph showing the effects on proliferation of BON cells following 
treatment with GW9662  antagonist and combinations of antagonist and rosiglitazone 
(n=8 for all groups) 
 
Kruskal-Wallis test   P=0.0005 
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)     
CONTROL and ANTAG  P = 0.0799 
CONTROL and A+10-4M  P = 0.0019 
CONTROL and A+10-5M  P = 0.0521 
CONTROL and A+10-6M  P = 0.6757 
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3.3.6.3 Direct comparison studies 
So far all antagonist experiments had been run without a comparative treated group at 
the same concentration of rosiglitazone. It was felt that if the antagonist was having a 
true effect then there should be significant difference seen when cells treated with 
rosiglitazone are compared directly with cells treated with antagonist and rosiglitazone. 
Thus direct comparison studies were performed at rosiglitazone concentrations of 10-
4M, 10-5M and 10-6M. 
 
For QGP1, there was no significant effect seen when the antagonist was added to the 
treatment group. At concentrations of 10-5M and 10-6M there was a possible trend seen 
towards antagonism with increased proliferation. Proliferation as a percentage of the 
non antagonised group was 109.7 +/- 12.6% in the 10-5M group and 117.7 +/- 9% for 
the 10-6M group. Neither was statistically significant from the treatment only group. 
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C 
Figure 3.112 Graph A-C showing a direct comparison of proliferation of QGP1 cells 
treated with rosiglitazone at 10-4M (A), 10-5M (B) and 10-6M (C) when one group is 
pre treated with the antagonist GW9662 (n=8, all groups) 
 
A similar picture is seen with BON cells treated in the same way. There is a trend for 
increased proliferation on addition of the antagonist but the difference is not statistically 
significant. In the 10-4 M group, proliferation as a percentage of the non antagonised 
group was 127.3 +/- 11.8%. In the 10-5 M group, proliferation was 120.5 +/- 12.7%. 
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Figure 3.113 Graph A-B showing a direct comparison of proliferation of BON cells 
treated with rosiglitazone at 10-4M (A) and 10-5M (B) when one group is pre treated 
with the antagonist GW9662 (n=8, all groups) 
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At 1µM (1x10-6M) concentration of GW9662 full antagonism of PPARγ receptors 
should be occurring. To remove any doubts regarding inadequate antagonist 
concentration the direct comparison experiments were repeated again for both QGP1 
and BON with a concentration of 10µM GW9662 (results not shown). Again, 
proliferation was not significantly increased with addition of the antagonist. 
 
 209 
 
 
CHAPTER 4 
 
DISCUSSION 
 210 
4.1 Human Pancreatic Tumours 
At the outset of the project, there was a selection of pancreatic neuroendocrine tumours 
held in the ‘tumour bank’ within the Academic Department of Endocrinology at St 
Bartholomew’s Hospital. My initial aim was to use these tumour samples for extraction 
of RNA and subsequent PCR work to look at PPARγ expression. Further studies 
planned involved PCR (conventional ± real time) to identify any variations in other cell 
cycle markers. Unfortunately, it was found that there were too few samples that gave 
good quality reliable RNA for any substantial results to be gained. Attempts at gaining 
further fresh tissues samples led to the submission for ethical approval for collection 
and work on fresh tissue samples from two sites, including The Hammersmith Hospital 
(with the help of Professor A Grossman and Mr John Lynn respectively). Although 
agreement was gained in principle the incidence of resection was too low, even across 
two sites, for this to become viable given the time constraints of the project. Further 
work on human tissue samples was therefore halted. 
 
All human tissue samples available to us were subjected to RNA extraction, reverse 
transcription and PCR for GAPDH and PPARγ. Of the eight subjects (5 insulinomas 
and 3 gastrinomas) PPARγ expression was identified variably in the majority. The 
simple interpretation of this finding is that PPARγ is expressed in the majority of 
insulinomas and gastrinomas. This suggests that the majority of insulinomas and 
gastrinomas may be susceptible to the effects of ligands of this receptor such as the 
thiazolidinediones. Ultimately, proliferation could be affected by interaction with this 
receptor. There is good evidence to suggest that the thiazolidinediones, such as 
rosiglitazone, can reduce the proliferation of certain types of cancers of adipose tissue 
(Tontonoz et al, 1997), colon (Sarraf et al, 1998), breast (Mueller et al, 1998), prostate 
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(Mueller et al, 2000), liver (Rumi et al, 2001), lung (Tsubouchi et al, 2000), and 
pancreatic acinar tissue (Elnemr et al, 2000). Most of these models are non-human but 
there is also evidence extending into human tumours such as liposarcoma (Demetri et al, 
1999) and prostate cancer (Mueller et al, 2000).  
 
A further aspect of the tissue collection also has to be considered: as samples were taken 
prior to the start of the project, there is no way that I can guarantee that samples were 
harvested correctly and only contain tumour, i.e. it is possible that samples could 
inadvertently contain normal pancreas along with tumour taken at the time of resection. 
This contamination would weaken the power of the study.   
 
4.2 Immunohistochemistry 
The aims of the immunohistochemistry work were multiple. Firstly, I wanted to confirm 
the presence of PPARγ within the chosen samples, then identify its cellular location, and 
quantify the strength of staining for each tissue type (insulinoma, gastrinoma, islet and 
exocrine pancreas). Subsequently, I wished to compare the different tissues types 
against each other, using total positive counts for both nuclear and cytoplasmic 
compartments. This procedure was then repeated using antibodies for p27, phospho-
p27, JAB 1, phospho-Akt and PTEN, all previously implicated in the development of 
endocrine tumours (Lidhar et al 1999, Kouvaraki et al 2006, Stanger et al 2006, 
Schleiman et al 2003, Altomare et al 2002) and compare the expression of these 
proteins with PPARγ levels. 
 
Regarding PPARγ expression in exocrine tissue and islets, I was unable to demonstrate 
any significant nuclear or cytoplasmic expression. This was confirmed with repeated 
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experiments. Good staining of positive controls suggested that the antibody was 
working correctly and staining had been optimised appropriately. That we could not 
show significant PPARγ expression in the islets is in contradiction to previous reports of 
high expression (Dubois et al 2000). Significant islet cell hyperplasia has been shown in 
mice models in which the expression of the PPARγ gene in β cells has been eliminated 
(Rosen et al 2003) suggesting both presence and a significant anti proliferative effect. 
PPARγ expression has also been shown in human pancreatic cancer cell lines Capan-1, 
AsPC-1, BxPC-3, PANC-1 and MIA PaCa-2. My results, therefore, were unexpected. 
 
My expectation that PPARγ would be widely expressed in these tissues was not 
supported by my findings. In the absence of significant previously published data in this 
area, my preliminary conclusions are that PPARγ is only expressed at very low levels in 
these tissues. 
 
Following Ki-67 analysis of the samples, it was clear that there were several tumours 
that were proliferating at a higher rate. I thought it was of interest to separate these 
tumours out from the lesser proliferating tumours to see if there was any difference in 
the expression of PPARγ. Although statistical significance was not achieved in the 
PPARγ  group, due to the low numbers, there was certainly a trend showing that higher 
proliferating tumours express PPARγ in greater proportion. 
 
The CDK inhibitor p27 is a tumour suppressor protein that acts in the nucleus to enforce 
cell cycle checkpoints. p27 inhibits and binds to many cyclin/CDK complexes, 
including cyclin D/CDK4, cyclin E/CDK2, and cyclin A/CDK2. This inhibition can 
block progression through different phases of the cell cycle. The known actions of p27 
are thus predominantly nuclear with expectation that localisation is similar. It has been 
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documented, however, that translocation of p27 from the nucleus to the cytoplasm and 
loss of p27 through proteasomal degradation can occur in certain cancers, including 
breast, prostate, gastric, lung, ovarian, pancreatic, and hepatocellular carcinomas. The 
status of p27 may be a predictor of patient outcomes in these cancers (Viglietto et al, 
2002 , Nikoleishvili et al, 2008, Claudio et al, 2002, Gamboa-Dominguez et al, 2007, 
Pateras et al, 2006, Qin et al, 2001).  
 
In this p27 series, staining was seen in both the nucleus and cytoplasm. p27 staining was 
predominantly cytoplasmic in all three endocrine tissues (insulinoma, gastrinoma and 
islets - significantly so in gastrinoma and islets). Exocrine pancreas showed slightly 
higher nuclear than cytoplasmic expression, but both at much lower levels than that of 
the endocrine tissues. There are two main points of note with these results. Firstly, it 
appears that there is significantly higher expression of p27 within all three endocrine 
tissues compared to exocrine pancreas, suggesting a more significant role for p27 within 
these tissue types. Secondly, the expected p27 expression is, in general, nuclear and 
although my findings show that there is a high level of nuclear expression of p27 there 
is also a high level of cytoplasmic staining.  
 
As mentioned above, re-localisation of p27 into the cytoplasm has been seen in various 
cancers, with the assumption that the inhibitory effects of p27 on cell cycle progression 
are reduced. Is it possible that we are seeing a re-localisation in our samples? This is 
unlikely for two reasons. Cytoplasmic staining does not appear to be high at the expense 
of nuclear staining – both show high levels. It may also be expected, that on direct 
comparison of the tissues, there would be lower nuclear and higher cytoplasmic 
expression in neoplastic tissues compared to benign tissues. This was not the case, with 
no difference found in the nuclear expression of p27 between insulinoma and islets, and 
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conversely, there was significantly lower expression of p27 in the cytoplasm of 
insulinoma.  
 
It has previously been reported that p27 is inversely related to Ki-67 index in a number 
of endocrine tissues (Lloyd et al 1997). With separation of the insulinoma group by Ki-
67 labelling, lower p27 expression was seen in both the nucleus and cytoplasm of 
samples with a higher Ki-67 index. This finding concurs with the idea that p27 is 
reduced in more highly proliferating tumours.  
 
In a study by Canavese et al (2001), immunohistochemical p27 expression in 109 
endocrine tumours of the pancreas and gastro-intestinal tract (pancreas tumours 
included 17 insulinoma, 10 gastrinoma and 5 glucagonoma) was compared with Ki-67. 
They too concluded that p27 expression was inversely related to Ki-67 labelling. 
Interestingly, however, they also found that the vast majority of pancreatic 
neuroendocrine tumours, both benign and malignant, were highly expressing p27 
(usually between 70-100%) and no difference in p27 expression could be seen between 
normal (islets), hyperplastic and corresponding tumours. Similarly, in a study by Guo et 
al (2001), increased p27 expression was seen in both benign and malignant 
neuroendocrine tumours of the pancreas and four pancreatic islet tumour cell lines as 
assessed by Western analysis. No difference was seen between benign and malignant 
tumours.  
 
Other investigators have reported anomalous over-expression of p27 in human tumour 
tissues. This includes Burkitt’s lymphoma and diffuse large B-cell lymphoma (Sanchez-
Beato et al, 1999), thyroid tumours (Baldassarre et al 1999), oesophageal squamous cell 
carcinoma (Anayama et al, 1998), and node-negative breast carcinoma (Reed et al 
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1999). Some of the possible mechanisms proposed by the authors include inactivation 
of p27 by cyclin D3, abnormal sequestration of p27 in the cytoplasm and dysregulation 
of cyclin D1 expression. 
 
Phosphorylation is a key mechanism which p27 undergoes prior to transport out of the 
nucleus and degradation. If p27 deactivation was a significant feature of pancreatic 
neuroendocrine tumours, enhanced transport out of the cell and increased phospho-p27 
levels in the cytoplasm may be expected. In this study, phospho-p27 expression has 
been shown to be overwhelmingly cytoplasmic in all tissue types. Very little nuclear 
staining was identified and there were no differences between the three endocrine 
tissues. In our JAB1 series, all tissues overwhelmingly showed cytoplasmic expression, 
with negligible nuclear staining seen. Interestingly, normal islets showed the strongest 
positive cytoplasmic staining for JAB1, significantly higher than either insulinoma or 
gastrinoma, quite the opposite to the idea that neoplastic tissues would have enhanced 
p27 transport into the cytoplasm. Interpretation of my results would therefore not 
support enhanced p27 phosphorylation and shuttling out of the nucleus in the aetiology 
of pancreatic neuroendocrine tumours. 
 
The protein kinase Akt, also known as protein kinase B (PKB), plays a pivotal role in 
tumourigenesis (Testa et al, 2001). Akt is activated by phospholipid binding and 
phosphorylation at threonine 308 by PDK1 and phosphphorylation within the C-
terminus at serine 473. Through the phosphorylation and relocalisation of key 
regulatory molecules such as Bad (Datta et al, 1997), caspase-9 (Cardone et al, 1998), 
forkhead transcription factors (Brunet et al, 1999), p21 (Zhou et al, 2001) and p27 (Shin 
et al, 2002), phospho-Akt (p-Akt) functions to promote cell survival by inhibiting 
apoptosis. Cytoplasmic relocalisation of p27 secondary to Akt mediated 
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phosphorylation at threonine 157 has been shown in human primary breast cancer 
(Viglietto et al, 2002, Shin et al 2002). In the pancreas, transgenic mice that express a 
constitutively active Akt/PKB have been shown to have a significant increase in islet 
cell mass, due largely to proliferation of insulin containing β cells (Bernal-Mizrachi et 
al, 2001).  
 
In all four tissue types, both nuclear and cytoplasmic staining was seen for p-Akt. 
Cytoplasmic expression was significantly higher than nuclear expression in all tissues. 
On comparing the tissues, there is significantly lower nuclear and cytoplasmic 
expression of p-Akt in insulinoma and gastrinoma compared to islets. This is contrary to 
the expected finding that neoplastic tissues will have higher levels of the pro-survival p-
Akt, and suggests that the phosphoinositide-3-kinase (PI3K)-Akt pathway is unlikely to 
play a major role in pancreatic neuroendocrine tumours 
 
PTEN is a tumour suppressor gene and is thought to negatively control the PI3K-Akt 
pathway. Over-expression of PTEN with subsequent influence on the expression of p-
Akt would identify this pathway as important in tumourigenesis of pancreatic 
neuroendocrine tumours. Although there is a high degree of nuclear expression seen, no 
significant difference was identified between the neoplastic cells of insulinoma and 
gastrinoma, and that of normal islets. 
 
Regarding exocrine tissue, there appears to be a fundamental difference compared to the 
endocrine tissues. Although, the pattern of staining has been similar, there are 
significantly reduced levels of expression of nearly all the cell cycle markers tested. 
With the exclusion of PPARγ, where no tissue showed significant expression, exocrine 
tissue has consistently shown lower expression of p27, phospho-p27, JAB 1, Phospho-
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Akt and PTEN compared to all three endocrine tissues whether benign or neoplastic. 
Higher levels of expression in the endocrine tissues suggest that these cell cycle 
participants are more important in the cell cycling of the endocrine tissues 
 
Despite the potential of these cell cycle participants in dysregulation, the results have 
not been able to support a significant role for p27, its phosphorylation or mislocalisation 
in the tumourigenesis of these tumours. Cellular p27 effects can be modulated by cell 
cycle pathways involving PTEN and PI3K/Akt, which have been previously implicated 
in tumourigenesis. My evidence again, does not support direct involvement of these 
pathways in our series. The high levels of expression without evidence of direct 
involvement may suggest increased expression secondary to alternate pathways as yet 
unclarified. 
 
During the course of the experimental work, insulinomas have been compared to the 
islets, being considered its control. This has been widely accepted as pancreatic islet cell 
tumours show marked cytological similarity to pancreatic islets and are therefore 
believed to originate from the endocrine pancreas. It is of interest therefore that 
Vortmeyer et al (2004) et al, have suggested that pancreatic islet cell tumours do not 
necessarily originate from islets. In MEN 1 patients with characteristic allelic deletions, 
microdissection of the tumour, surrounding acinar/ductal pancreas and islets revealed 
similar abnormalities present in the acinar/ductal samples but not in the islets, 
concluding therefore that the islets are not the origin. Use of islets as control could 
therefore be called into question. My immunohistochemical findings showed a high 
degree of similarity and behaviour between these two tissue types and comparison is 
still valid, in that, differences noted may be indicative of differences between neoplastic 
and benign behaviour. The importance of this potential embryological difference is, 
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however, noted. Methodological and theoretical difficulties in harvesting nearby 
acinar/ductal tissue and justifying its use as control material, maybe difficult to 
overcome and it is felt that this was beyond the time constraints of this project. 
 
4.3 Cell Proliferation 
Human neuroendocrine tumour cell lines CM (insulinoma), BON (carcinoid) and QGP1 
(somatostatinoma) were made available to us due to the kindness of Professor N 
Lemoine. As for the resected tumour and immunohistochemistry series, I initially 
investigated the expression of PPARγ within the cell lines. All cell lines gave good 
quality RNA and underwent conventional PCR for PPARγ. I confirmed that both BON 
and QGP 1 expressed PPARγ mRNA but CM cell line did not. All cell lines were, 
however, subject to Western blotting to confirm protein expression. Interestingly, all 
cells lines showed evidence of PPARγ protein expression including the CM cell line. 
Repeated RNA extraction and PCR, with similarly repeated protein extraction and 
Western blotting failed to clarify this inconsistency. The possibility of the discrepancy 
being due to a splice variant was considered. Splice variants have been identified and 
characterised (Chen Y, Jimenez A, Medh J, 2006). Personal communication with Dr J 
Medh confirms that the discrepancy is unlikely to be due to a splice variant. The primers 
are in the region of exons 1-6 which is common in all splice variants. On balance, it is 
the opinion of the author that CM cell line does not express PPARγ mRNA and 
consequently should not express PPARγ protein. 
 
It is also of interest that the validity of the CM cell line as a true insulinoma cell line has 
recently been called into question (Gragnoli, 2008), as various severe and consistent 
chromosomal aberrations were identified including chromosome 11 tetraploidy and 
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translocation abnormalities. Jonnakuty and Gragnoli (2007) karyotyped the CM celll 
line and confirmed its human origin but also identified 64 chromosomes with structural 
abnormalities. This information may have significant bearing on the reliability of this 
study as it has to be acknowledged that the cell lines are not truly immortalised and 
therefore are subject to potential phenotypic instability over time. 
 
Somatostatin inhibits cell proliferation and growth hormone secretion through 
interaction with SSTRs. Five SSTRs have been cloned in the human, mouse, and rat; 
and many studies have investigated the tissue distribution, expression, binding affinity 
to somatostatin, and downstream signal transduction pathways of these five receptors 
(Benali et al 2000, Fisher et al, 1998). My cell lines were subjected to RNA extraction 
and PCR for all 5 SSTRs to identify expression patterns. The results failed to confirm 
expression of any of the SSTRs in any of the cell lines. Plans for cellular proliferation 
studies following treatment of somatostatin analogues was therefore excluded from the 
project. One possible explanation for lack of expression may be that the cell lines have 
undergone too many passages and they have lost normal expression patterns. 
 
In fact, loss of SSTRs in pancreatic cancers is not unique. Although both in vitro and in 
vivo studies have shown that SSTRs mediate strong growth inhibition in many cancer 
types including pancreatic cancer, previous clinical trials of somatostatin analogues in 
the treatment of advanced pancreatic cancer have failed (Canobbio et al, 1992). A 
review of the current knowledge of somatostatin, its receptors and pancreatic cancer has 
been published by Li et al (2005). They suggested that further detailed studies are 
needed to determine the reason why functional SSTRs are not expressed or not 
sufficient in pancreatic cancer cells. 
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PPARγ agonists have been shown to have anticancer activity against a variety of 
neoplastic cells in vitro. Liposarcoma, colon, breast, prostate, thyroid, myeloid 
leukaemia, lymphoma, lung, oesophageal, gastric, glioblastoma and pancreatic cancer 
cells have all variably been shown to have reduced growth in the presence of PPARγ 
ligands.  In vivo studies are much less common. Originally, the identification that 
ligands of PPARγ could induce terminal differentiation in normal preadipocytes lead to 
attempts to induce differentiation of human liposarcoma cells, both in vitro and in vivo. 
Demitri et al (1999) gave the TZD troglitazone to a series of patients with liposarcoma 
which resulted in a retardation of growth and induction of differentiation in these 
tumours. Additionally, treatment of patients with advanced prostate cancer with 
troglitazone has shown to cause a high incidence of stabilization of prostate- specific 
antigen (Mueller et al. 2000). Sarraf et al (1998) showed that trogligazone decreased the 
growth of colon cells in vitro as well as when growing as xenographs in nude mice.  
 
In contrast to PPARα knockout mice, PPARγ ablation is lethal. Initial attempts to 
generate a PPARγ knockout mouse model showed that null embryos die at about day 10 
from impaired placental development (Barak et al, 1999). Subsequently the 
heterozygous state and tissue specific models have been developed (Review by Gray et 
al 2005). Rosen et al. (2003) generated a tissue specific β-islet cell mouse model in 
which the expression of the PPARγ gene in β-cells was eliminated (βγKO mice). These 
mice were found to have significant islet cell hyperplasia compared to control. 
Interestingly, the islets did not proliferate indefinitely suggesting that other growth 
regulating factors eventually come into play. This may also explain why tumour 
formation in the islet tissue of βγKO mice was not observed.  
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Most research has, of course, been directed at the metabolic consequences of PPARγ 
knockout models but several studies have concentrated on the potential effects on 
tumour formation. Heterozygous germ line deletions of PPARγ (PPARγ+/-) have been 
shown to be more susceptible to the formation of colonic tumours. After the injection of 
the colon specific carcinogen azoxymethane, all of the PPARγ +/- mice but only 50% of 
the wild type were dead from colonic cancer by 36 weeks (Girnun et al. 2001). 
Heterozygous PPARγ+/- mice have also been shown to have a greater susceptibility to 
develop both breast and ovarian cancers after exposure to the carcinogen 7,12 
dimethylbenzanthracene suggesting a potential protective effect of PPARγ. Lu et al 
(2005), utilisised heterozygous PPARγ+/- mice to show a significant increase in 
susceptibility to N-methyl-N-nitrosourea induced gastric cancer compared to the wild 
type at 10 weeks (89.5% vs 55.5%). In the same experiments, simultaneous 
administration of troglitazone showed a significant reduction in incidence of gastric 
cancer in the wild type (55.5% to 9%) with a reduced effect seen in the heterozygous 
PPARγ+/- group (89.5 to 80%). They concluded that PPARγ suppresses gastric 
carcinogenesis, troglitazone is chemopreventative and dependent on the PPARγ 
receptor.  
 
Methods of examining overexpression of PPARγ have been developed. Garcia-Bates et 
al. (2008) used a lentiviral vector for PPARγ gene delivery and transduced multiple 
myeloma cells. Overexpression decreased multiple myeloma cell proliferation and 
induced spontaneous apoptosis even in the absence of an external ligand. The cells were 
also much more sensitive to ligand induced apoptosis. Bren Mattison et al (2008) 
developed transgenic mice after construction and administration of SP-C/PPARγ 
transgene. Mice were then subjected to injection of a standard intraperitoneal dose of 
urethane, a lung carcinoma carcinogen. After 20 weeks there was a 75% reduction in the 
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number of tumours identified in the PPARγ over expressing mice. In contrast to the 
predominantly protective effects seen with PPARγ, a transgenic mouse model has 
shown breast cancer tumours with accelerated kinetics. Saez et al. (2003) generated a 
transgenic mouse model that expressed a constitutionally active form of PPARγ by 
fusing the activation domain of herpes simplex virus Vp16 protein to PPARγ1. The 
effect of mammary specific VpPPARγ expression was evaluated by generating 
transgenic mice expressing it under the control of mouse mammary tumour virus 
(MMTV) promoter. These MMTV-VpPPARγ mice were morphologically identical to 
the wild type. On breeding with a known breast cancer mouse (MMTV-PyV), 
PyV/VpPPARγ females developed tumours with greatly accelerated kinetics and 
reduced survival. 
 
Currently, I am unaware of any reported cellular proliferation studies on human 
neuroendocrine tumour cell lines investigating the effects of PPARγ agonists. Following 
a period of optimisation all three cell lines were treated with varying doses of 
rosiglitazone. Effects on CM cell line were limited to the highest concentration (10-4M) 
of rosiglitazone. Effects on BON were seen at the two highest concentrations (10-4M 
and 10-5M) whereas QGP1 cells are shown to be the most sensitive been affected upto 
concentrations of 10-6M. The potential role of DMSO having a toxic effect on the cell 
lines that would explain the findings was excluded, except at the highest concentration 
of rosiglitazone treated QGP1 cells. BON and QGP1 cell lines (CM not being tested) 
recovered following a period of treatment with rosiglitazone confirming that the effects 
were mediated by the treatment and that treatment effects were not ultimately life 
threatening to the cells. There is no toxicity data published on the antagonists T0070907 
and GW9662 by the manufactures and an internet search has not revealed any evidence 
that the antagonists have a direct toxic effect on cell cultures. 
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PPARγ antagonist studies were performed on BON and QGP1 to identify whether the 
effects of rosiglitazone on these cell lines could effectively be blocked, thus confirming 
that the effects seen are mediated by the PPARγ receptor. Unexpectedly, the effects 
could only be partially blocked. This was then confirmed by treatment with a second 
antagonist and subsequent direct comparison studies. These studies did not show any 
significant increased proliferation in the group pretreated with the PPARγ antagonist. I 
conclude therefore that the PPARγ agonist rosiglitazone has a significant anti-
proliferative effect on both BON and QGP1 cell lines but it appears that this effect may 
not be mediated by the PPARγ receptor. Similar findings have been reported in pituitary 
cell lines treated with rosiglitazone (Emery et al, 2006) and pancreatic adenocarcinoma 
(Galli et al, 2004). Indeed, evidence that the anti-proliferative effects of TZDs are 
independent of PPARγ receptor has been published (Palakurthi et al 2001) where 
tumour bearing mice injected with either PPARγ -/- or PPARγ+/+ embryonic stem cells 
were treated with troglitazone. Tumour suppression was seen similarly in both mouse 
models suggesting an anti-proliferative effect of troglitazone, but one that is 
independent of the PPARγ receptor. 
 
Explanations for this independent action are speculative, Galli et al, identified 
significant inhibition of matrix metallopeptidase 2 (MMP 2) gene expression. Proteins 
of the MMP family are involved in the breakdown of extracellular matrix in normal 
physiological processes, such as embryonic development, reproduction, and tissue 
remodeling, as well as in disease processes such as arthritis and metastasis. The same 
group identified that TZD treatment inhibits fibrinolytic activity in both PPARγ 
expressing and non-expressing cells and that this effect was correlated with 
upregulation of plasminogen activator inhibitor (PAI-1), a major physiological inhibitor 
of fibrinolysis. Another finding of TZD treatment which is independent of the PPARγ 
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receptor is the activation of 5' adenosine monophosphate-activated protein kinase 
(AMPK) (Lebrasseur et al 2006, Boyle et al, 2006). AMPK is mainly involved in 
cellular metabolism and acts as a switch regulating several intracellular systems 
including the cellular uptake of glucose, the β-oxidation of fatty acids and the 
biogenesis of glucose transporter 4 (GLUT 4) and mitochondria. It also has some effects 
on pathways involved in cellular cycling through molecules such as PI3K, Akt and 
mTOR.  
 
Interestingly, Han and Roman (2006) reported that rosiglitazone reduced the 
phosphorylation of Akt and increased PTEN protein expression in non–small cell lung 
carcinoma (NSCLC) cells and this was associated with inhibition of proliferation. These 
effects were blocked or diminished by GW9662 (PPARγ antagonist, as used in this 
thesis). When the cells underwent transfection with a CMX-PPARγ over-expression 
vector, the effects of rosiglitazone on Akt, PTEN, and cell growth were restored even in 
the presence of GW9662. They also noted that rosiglitazone increased the 
phosphorylation of AMP-activated protein kinase (AMPK), whereas it decreased 
phosphorylation of p70 ribosomal protein S6 kinase (p70S6K), a downstream target of 
mTOR. Of note, GW9662 did not affect the phosphorylation of AMPK and p70S6K 
protein and the inhibitory effect of rosiglitazone on NSCLC cell growth was enhanced 
by the mTOR inhibitor rapamycin. Their conclusion was that rosiglitazone can inhibit 
NSCLC growth through PPARγ-dependent signals that inhibit Akt and stimulate PTEN. 
Also, through PPARγ-independent signals, rosiglitazone up-regulates AMPK, thereby 
down-regulating the mTOR/p70S6K pathway, which further contributes to growth 
inhibition. 
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Taken together, it would appear that the PPARγ independent actions maybe modulated 
through AMPK and mTOR pathways. Investigation of these pathways using the cell 
lines pre and post treatment with rosiglitazone would be of considerable interest. 
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4.4 Summary  
The main aim of the project was to identify the expression of PPARγ in various 
pancreatic neuroendocrine tumour tissue types. I conclude that PPARγ is expressed to 
variable degrees in pancreatic neuroendocrine tumours. This is based on the evidence 
presented from the human tissue samples expressing in the majority of samples, despite 
poor quality, and that there was good evidence PPARγ was being expressed in the 
human neuroendocrine tumour cell lines BON and QGP1. These findings unfortunately, 
cannot be substantiated by the immunohistochemical results which failed to show 
widespread PPARγ expression.  
 
Further aspects of the project have identified that it is unlikely that cyclin dependent 
kinase p27 is directly responsible for proliferation of these tumours. Phosphorylation 
and transport by JAB1 do not appear to be playing a vital role. Also, modulators of the 
cell cycle that influence p27 including p-Akt and the PI3K/Akt pathway influenced by 
PTEN do not appear to playing a primary vital role. 
 
The PPARγ agonist rosiglitazone does have an anti-proliferative effect on human 
neuroendocrine cell lines BON and QGP1 at higher concentrations, but the evidence 
suggests that this action may not be mediated by the PPARγ receptor. 
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4.5 Future Work Considerations 
There are various aspects of this project that could be expanded upon to take the work 
done so far further. Firstly, regarding frozen tissue samples, I have found significant 
difficulties utilising previously harvested samples. This may have been due to the 
inherent difficulties in working with pancreatic tissue because of the digestive enzymes 
it produces, the harvesting technique or the conditions of storage. To optimise future 
work, samples must be resected by a surgeon understanding the tissue requirements and 
the samples would have to undergo either RNA extraction or be frozen and held at -
80oC immediately. To obtain enough samples, a multicentre collection strategy would 
have to be employed with ethical consent gained over several areas. If a reasonable 
tumour series could be gained then I would firstly repeat the PPARγ expression studies 
and investigate p27 expression. Further studies would depend on the results but due to 
the clinical importance of somatostatin analogues in neuroendocrine tumours, I would 
also like to study the expression of the somatostatin receptor subtypes. Real time PCR 
would be employed rather than conventional and results would ideally be related to the 
clinical aspects of the tumour. 
 
A surprising aspect of the immunohistochemical work was the low level of expression 
of PPARγ in either exocrine, endocrine or cancerous tissues, despite good positive 
control staining. It would be interesting to repeat this series with alternative PPARγ 
antibodies. 
 
With the cell proliferation studies, there are multiple possibilities for further work as 
very little work has been published in this area. The first set of studies that I would 
perform would be to assess the effects on proliferation of different PPARγ agonists such 
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as pioglitazone. The relative efficacies could then be determined. Further studies would 
be aimed at determining which cell cycle markers are being affected by the reduction in 
proliferation. Given the emphasis of the MD on the expression of p27 and its regulatory 
proteins, we would investigate the effects on p27 following treatment of the cell lines 
with PPARγ agonists. If significant effects were found, further investigation into the 
effect on p27 modulators such as JAB1, p-Akt and PTEN would be performed.  
 
As the findings of the immunohistochemistry, did not suggest a significant role for p27 
involvement in pancreatic neuroendocrine tumour development, it would be of interest 
to investigate alternative cell cycle pathways such as p21 and its related regulatory 
proteins. As discussed earlier, the PPARγ-independent anti-proliferative effects of 
rosiglitazone maybe due to pathways involving AMPK and mTOR, both of which 
would be targets for future work. 
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Immunohistochemistry counting sheet 
 
Immuno grid explanation: 
The grid is split into 5 large squares each representing one high powered field as seen 
on the computer screen. 
 
Each large square is split into columns representing: 
nuclear staining  
cytoplasmic staining  
 
There are 5 rows to each large square. The first four represent strength of staining: 
strong 
moderate 
weak 
negative 
The fifth row contains the total number of cells that has been counted in each field. This 
will be a number out of approximately one hundred 
 
            Nuclear           Cytoplasmic 
strong   
moderate   
weak   
negative   
No. of cells counted   
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Working sheet 
 
ANTIBODY:      DATE: 
SLIDE NUMBER:     TUMOUR/NORM/ISLET: 
 
 
          
          
          
          
     
 
 
 
Total cells counted =  
 
 NEGATIVE WEAK MEDIUM STRONG 
NUCLEAR     
CYTOPLASMIC     
 
Comments: 
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Immunohistochemistry data tables 
PPARγ - TUMOUR SAMPLES - INSULINOMA 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 0 0 100 0 0 0 0 0 100 0 0 
2 0 0 30 70 30 0 0 0 0 100 0 0 
3 0 0 0 100 0 0 0 0 0 100 0 0 
5 0 0 0 100 0 0 0 0 0 100 0 0 
6 0 0 0 100 0 0 0 0 0 100 0 0 
7 0 0 0 100 0 0 0 0 0 100 0 0 
8 0 0 0 100 0 0 0 0 0 100 0 0 
9 0 0 0 100 0 0 0 0 0 100 0 0 
10 0 0 0 100 0 0 0 0 0 100 0 0 
11 0 0 0 100 0 0 0 0 0 100 0 0 
12 0 0 0 100 0 0 0 0 0 100 0 0 
13 0 0 39.7 60.3 39.7 0 0 0 0 100 0 0 
14 0 0 0 100 0 0 0 0 0 100 0 0 
15 12.3 38.6 33.6 15.5 84.5 50.9 0 0 0 100 0 0 
17 0 0 0 100 0 0 0 0 0 100 0 0 
18 0 0 0 100 0 0 0 0 0 100 0 0 
19 0 0 1 99 1 0 0 0 0 100 0 0 
20 0 0 2.4 97.6 2.4 0 0 0 0 100 0 0 
23 0 0 0 100 0 0 0 0 0 100 0 0 
25 0 0 8.3 91.7 8.3 0 0 0 9 94 9 0 
AV 0.62 1.93 5.75 91.71 8.30 2.55 0.00 0.00 0.45 99.70 0.45 0.00 
SEM 0.62 1.93 2.82 4.68 4.68 2.55 0.00 0.00 0.45 0.30 0.45 0.00 
 
GASTRINOMA 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
4 0 0 0 100 0 0 0 0 0 100 0 0 
22 0 0 5.6 94.4 5.6 0 0 0 0 100 0 0 
24 0 0 0 100 0 0 0 0 0 100 0 0 
AV 0 0 1.87 98.13 1.87 0 0 0 0 100 0 0 
SEM 0 0 0.72 0.72 0.72 0 0 0 0 0 0 0 
 248 
PPARγ - ISLET SAMPLES 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 0 0 100 0 0 0 0 0 100 0 0 
2 0 0 6.3 93.7 6.3 0 0 0 0 100 0 0 
4 0 0 0 100 0 0 0 0 0 100 0 0 
5 0 0 0 100 0 0 0 0 0 100 0 0 
6 0 0 0 100 0 0 0 0 0 100 0 0 
7 0 0 0 100 0 0 0 0 0 100 0 0 
8 0 0 0 100 0 0 0 0 0 100 0 0 
9 0 0 0 100 0 0 0 0 0 100 0 0 
10 0 0 0 100 0 0 0 0 0 100 0 0 
11 0 0 0 100 0 0 0 0 0 100 0 0 
12 0 0 0 100 0 0 0 0 0 100 0 0 
13 0 0 0 100 0 0 0 0 0 100 0 0 
14 0 0 0 100 0 0 0 0 0 100 0 0 
15 0 0 8.5 91.5 8.5 0 0 0 0 100 0 0 
17 0 0 0 100 0 0 0 0 0 100 0 0 
18 0 0 0 100 0 0 0 0 0 100 0 0 
20 0 0 7.8 92.2 7.8 0 0 0 0 100 0 0 
23 0 0 0 100 0 0 0 0 0 100 0 0 
25 0 0 7 93 7 0 0 0 0 100 0 0 
AV 0 0 1.56 98.44 1.56 0 0 0 0 100 0 0 
SEM 0 0 0.70 0.70 0.70 0 0 0 0 0 0 0 
 
 249 
PPARγ - EXOCRINE PANCREAS SAMPLES 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 0 0 100 0 0 0 0 0 100 0 0 
2 0 0 3.5 96.5 3.5 0 0 0 0 100 0 0 
3 0 0 0 100 0 0 0 0 0 100 0 0 
5 0 0 0 100 0 0 0 0 0 100 0 0 
6 0 0 0 100 0 0 0 0 0 100 0 0 
7 0 0 0 100 0 0 0 0 0 100 0 0 
8 0 0 0 100 0 0 0 0 0 100 0 0 
9 0 0 0 100 0 0 0 0 0 100 0 0 
10 0 0 0 100 0 0 0 0 0 100 0 0 
11 0 0 0 100 0 0 0 0 0 100 0 0 
12 0 0 0 100 0 0 0 0 0 100 0 0 
13 0 0 0 100 0 0 0 0 0 100 0 0 
14 0 0 0 100 0 0 0 0 0 100 0 0 
15 0 0 7 93 7 0 0 0 0 100 0 0 
17 0 0 0 100 0 0 0 0 0 100 0 0 
18 0 0 0 100 0 0 0 0 0 100 0 0 
19 0 0 3.2 96.8 3.2 0 0 0 0 100 0 0 
20 0 0 0 100 0 0 0 0 0 100 0 0 
23 0 0 0 100 0 0 0 0 0 100 0 0 
25 0 0 0 100 0 0 0 0 0 100 0 0 
AV 0 0 0.69 99.32 0.69 0 0 0 0 100 0 0 
SEM 0 0 0.40 0.40 0.40 0 0 0 0 0 0 0 
 
  
 250 
p27 - TUMOUR SAMPLES 
INSULINOMA 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 0 2.8 97.2 2.8 0 0 34.9 46.6 18.5 81.5 34.9 
2 0 1 33.2 65.8 34.2 1 0.2 3 78.7 18.1 81.9 3.2 
3 0 0 10.3 89.7 10.3 0 15.3 65.5 9.3 9.9 90.1 80.8 
5 10.5 39.5 15.3 34.7 65.3 50 8.2 67.8 7.7 16.3 83.7 76 
6 4.6 20.2 51.1 24.1 75.9 24.8 2.5 22.4 64.6 10.5 89.5 24.9 
7 2.5 14.3 39.7 43.5 56.5 16.8 0.8 6 49.8 43.4 56.6 6.8 
8 7.1 32.2 46.4 14.3 85.7 39.3 0 7.5 61 31.4 68.5 7.5 
9 56.5 30 7.7 5.8 94.2 86.5 0 0 0 100 0 0 
10 2.1 10.3 56.9 30.7 69.3 12.4 0 0.9 53.6 48.6 54.5 0.9 
11 2.9 9.1 19.5 68.5 31.5 12 1.7 6.5 18.9 72.9 27.1 8.2 
12 11.4 35.4 39.5 13.7 86.3 46.8 0.6 8.9 72.3 18.2 81.8 9.5 
13 2.6 9 19.2 69.2 30.8 11.6 2.4 19.8 28.2 49.6 50.4 22.2 
14 16 73.7 7.3 3 97 89.7 0.9 6.6 82.7 9.8 90.2 7.5 
15 16 37 30.4 6.6 83.4 53 4.2 16.6 66.8 12.4 87.6 20.8 
17 44.1 36.6 14.6 4.7 95.3 80.7 6.3 73.7 15.3 4.7 95.3 80 
18 17.4 75.8 4.6 2.2 97.8 93.2 2.8 76.2 16.6 4.4 95.6 79 
19 30.1 41 16.9 12 88 71.1 4.3 39.8 46.7 9.2 90.8 44.1 
20 23.7 42.1 28.1 16.1 93.9 65.8 1.2 27.5 64.9 6.4 93.6 28.7 
23 18.9 22.2 41.1 17.8 82.2 41.1 1.1 9.4 72.8 16.7 83.3 10.5 
25 31.6 42.5 20.2 5.7 94.3 74.1 2.6 46.1 40.4 10.9 89.1 48.7 
AV 14.90 28.60 25.24 31.27 68.74 43.50 2.76 26.96 44.85 25.60 74.56 29.71 
SEM 3.51 4.84 3.64 6.81 6.81 7.22 0.83 5.80 5.86 5.66 5.63 6.41 
 
 
GASTRINOMA 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
4 16.8 39.6 31.1 12.5 87.5 56.4 0 1.1 92.7 6.2 93.8 1.1 
22 9.8 40.2 43.3 6.7 93.3 50 0 73.2 20.3 6.5 93.5 73.2 
24 3.1 10.2 37.8 49 51.1 13.3 0 2 92.9 5.1 94.9 2 
AV 9.90 30.00 37.40 22.73 77.30 39.90 0.00 25.43 68.63 5.93 94.07 25.43 
SEM 3.96 9.90 3.53 13.24 13.21 13.43 0.00 23.88 24.17 0.43 0.43 23.88 
 251 
p27 - ISLET SAMPLES 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 6.7 34.4 58.9 41.1 6.7 9.1 23.4 32 35.5 64.5 32.5 
2 0 0 10.7 89.3 10.7 0 48 38.7 10.7 2.6 97.4 86.7 
4 0 0 4.4 95.6 4.4 0 56.9 24.4 12.1 6.6 93.4 81.3 
5 0 0 5 95 5 0 12.2 82.3 5 0 99.5 94.5 
6 0 0 3.4 96.6 3.4 0 50.7 33.8 13.2 2.3 97.7 84.5 
7 2.5 9.9 15.5 82.1 27.9 12.4 37.7 47 14.4 0.9 99.1 84.7 
8 7.3 25.1 49.8 17.8 82.2 32.4 21.1 51.8 21.6 5.5 94.5 72.9 
9 5.5 16.5 57.7 20.3 79.7 22 20.2 60.3 17.2 2.3 97.7 80.5 
10 7.3 13 60.1 19.6 80.4 20.3 10.3 13 60.1 16.6 83.4 23.3 
11 5.8 33.9 44.5 15.8 84.2 39.7 30.6 45.8 14.5 9.1 90.9 76.4 
12 4.9 28 51.1 16 84 32.9 12.4 37.1 41.4 9.1 90.9 49.5 
13 23.6 40.2 24.7 11.5 88.5 63.8 2.7 32.6 56.2 8.7 91.5 35.3 
14 53.6 24.3 14.5 7.6 92.4 77.9 41.7 35.1 14.9 8.3 91.7 76.8 
15 63.5 25.3 7 4.2 95.8 88.8 17.9 60.7 14.2 7.2 92.8 78.6 
17 27.6 36.2 29.1 7.1 92.9 63.8 15.1 58.1 22.2 4.6 95.4 73.2 
18 33.1 41.2 22.1 3.6 96.4 74.3 17.8 60.2 18.9 3.1 96.9 78 
20 44.7 42.4 8.3 4.6 95.4 87.1 9.4 64.3 20.7 5.6 94.4 73.7 
23 29.8 37.6 22.9 9.7 90.3 67.4 9.4 59.6 24.5 6.5 93.5 69 
25 12.2 20.4 57.6 9.8 90.2 32.6 17.6 51 25 6.4 93.6 68.6 
AV 16.92 21.09 27.52 35.01 65.52 38.01 23.20 46.27 23.09 7.42 92.57 69.47 
SEM 4.56 3.50 4.63 8.46 8.32 7.29 3.70 3.94 3.40 1.79 1.78 4.53 
 
 252 
p27 - EXOCRINE PANCREAS SAMPLES 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 8 16.8 75.2 24.8 8 0 0 0 100 0 0 
2 0 5.6 18.4 76 24 5.6 0 3.3 11.9 84.8 15.2 3.3 
3 0 1 6 93 7 1 0 0 4.8 95.2 4.8 0 
5 0 0 11.3 88.7 11.3 0 0 0 5.6 94.4 5.6 0 
6 0 5.8 17.2 77 23 5.8 0 1.3 6 92.7 7.3 1.3 
7 6.6 10.5 13.5 69.4 30.6 17.1 0 0 0 100 0 0 
8 2.4 6.4 19.8 71.4 28.6 8.8 0 0 0 100 0 0 
9 6.8 14.3 19.3 59.6 40.4 21.1 0 0 0 100 0 0 
10 0.3 7.4 20.3 72 28 7.7 0 0 0 100 0 0 
11 1.5 10.6 31.5 56.4 43.6 12.1 0 0.2 29 70.8 29.2 0.2 
12 0.8 4.2 20.2 74.8 25.2 5 0.6 4 31.4 64 36 4.6 
13 3 4 19 74 26 7 0.4 4 64.1 31.5 68.5 4.4 
14 4.1 8.6 13.1 74.2 25.8 12.7 0 2.5 33.8 63.7 36.3 2.5 
15 1.9 3.9 8.2 86 14 5.8 0.2 4.5 23.3 72 28 4.7 
17 2.4 5.7 23.6 68.3 31.7 8.1 0.4 3.9 41.9 53.8 46.2 4.3 
18 4.4 9.4 21.2 65 35 13.8 1.4 4.4 32.4 61.8 38.2 5.8 
19 5.2 8.2 14.7 71.9 28.1 13.4 1 4 21.9 73.1 26.9 5 
20 0 3.6 15 81.4 18.6 3.6 0 0 8.4 91.6 8.4 0 
23 4.4 14.4 18.4 59.2 37.2 18.8 0 1.6 14.8 83.6 16.4 1.6 
25 3.7 12.1 18.7 65.5 34.5 15.8 0 0 6.5 93.5 6.5 0 
AV 2.38 7.19 17.31 72.95 26.87 9.56 0.20 1.69 16.79 81.33 18.68 1.89 
SEM 0.51 0.89 1.24 2.13 2.08 1.30 0.09 0.42 3.92 4.29 4.29 0.49 
 
 253 
Phospho-p27 - TUMOUR SAMPLES 
INSULINOMA 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 0 6.7 93.3 6.7 0 0 27.7 60.7 11.6 88.4 27.7 
2 0 0 0 100 0 0 4.1 69.6 25.6 0.7 99.3 73.7 
3 0 0 0 100 0 0 6.1 57.9 26.3 9.7 90.3 64 
5 0 0 6.7 93.3 6.7 0 1.1 28.9 63.2 6.8 93.2 30 
6 0 0 0 100 0 0 4.3 24.8 58.9 12 88 29.1 
7 0 0 0 100 0 0 0 56.4 29.4 14.2 85.8 56.4 
8 0 0 0 100 0 0 5.6 54.1 39.1 1.2 98.8 59.7 
9 0 0 0 100 0 0 5 84.6 4.6 5.8 94.2 89.6 
10 0 0 0 100 0 0 1.2 4.8 33.4 60.6 39.4 6 
11 0 0 0 100 0 0 6.7 37.9 50.3 5.1 94.9 44.6 
12 0 0 0 100 0 0 18.4 76.4 5.2 0 100 94.8 
13 0 0.1 5 94.9 5.1 0.1 0 3.2 16.1 80.7 19.3 3.2 
14 0 0 0 100 0 0 3.4 82.4 13.4 0.8 99.2 85.8 
15 0 0 12 88 12 0 0 2.3 30 67.7 32.3 2.3 
17 0 0 0 100 0 0 0 11.4 76.4 12.2 87.8 11.4 
18 0 0 0 100 0 0 1.5 12.5 61.9 24.1 75.9 14 
19 0 0 0 100 0 0 0 2.4 14.2 83.4 16.6 2.4 
20 0 0 0 100 0 0 0 8.9 75.2 15.9 84.1 8.9 
23 0 0 0 100 0 0 1.2 75.2 15.2 8.4 91.6 76.4 
25 0 0 0 100 0 0 2.3 74.2 21.4 2.1 97.9 76.5 
AV 0 0.01 1.52 98.48 1.53 0.01 3.05 39.78 36.03 21.15 78.85 42.83 
SEM 0 0.01 0.75 0.75 0.75 0.01 0.96 6.82 5.18 6.18 6.18 7.37 
 
 
GASTRINOMA 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
4 0 0 0 100 0 0 5.1 85.4 9.5 0 100 90.5 
22 0 2.3 12 85.7 14.3 2.3 2.1 42 19.1 36.8 63.2 44.1 
24 0 0 6.1 93.9 6.1 0 3.4 52.4 39.5 4.7 95.3 55.8 
AV 0 0.77 6.03 93.20 6.80 0.77 3.53 59.93 22.70 13.83 86.17 63.47 
SEM 0 0.77 3.46 4.14 4.14 0.77 0.87 13.08 8.85 11.56 11.56 13.93 
 254 
Phospho-p27 - ISLET SAMPLES 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 0 6.7 93.3 6.7 0 0 31.4 45.7 22.9 77.1 31.4 
2 0 0 5.3 94.7 5.3 0 0 4.2 71.2 24.6 75.4 4.2 
4 0 0 0 100 0 0 44.9 35.2 14.2 5.7 94.3 80.1 
5 0 0 0 100 0 0 0 28.7 61.2 10.9 89.9 28.7 
6 0 0 0 100 0 0 0 17.5 72.3 11.2 89.8 17.5 
7 0 0 0 100 0 0 0 8.4 80.4 11.2 88.8 8.4 
8 0 0 0 100 0 0 0 7.1 84.3 8.6 91.4 7.1 
9 0 0 0 100 0 0 0.4 11.2 83.5 4.9 95.1 11.6 
10 0 0 0 100 0 0 27.2 51.4 15.2 6.2 93.8 78.6 
11 0 0 5.4 94.6 5.4 0 3.8 56.4 35.4 4.4 95.6 60.2 
12 0 0 0 100 0 0 11.5 40.5 37.4 10.1 89.4 52 
13 0 9.7 30.1 60.2 39.8 9.7 4.4 76.4 14.1 5.1 94.9 80.8 
14 0 0 0 100 0 0 4.5 73.4 16.4 5.7 94.3 77.9 
15 0 0 6.4 93.6 6.4 0 0 28.4 61.4 10.2 89.8 28.4 
17 0 0 0 100 0 0 0 0 15.5 84.5 15.5 0 
18 0 0 0 100 0 0 2.8 70.8 24.8 1.6 98.4 73.6 
20 0 0 0 100 0 0 2.3 18.4 72.5 6.8 93.2 20.7 
23 0 0 4.3 95.7 4.3 0 0 11.4 85.1 3.5 96.5 11.4 
25 0 0 0 100 0 0 5.3 80.1 12.3 2.3 97.7 85.4 
AV 0 0.51 3.06 96.43 3.57 0.51 5.64 34.26 47.52 12.65 87.42 39.89 
SEM 0 0.51 1.61 2.10 2.10 0.51 2.64 6.10 6.53 4.23 4.23 7.20 
 
 255 
Phospho-p27 - EXOCRINE PANCREAS SAMPLES 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 34.1 44.6 21.3 78.7 34.1 0 15.7 35.1 49.2 50.8 15.7 
2 0 0 5.2 94.8 5.2 0 0 4.6 35.2 60.2 39.8 4.6 
3 0 0 0 100 0 0 0 17.4 25.7 56.9 43.1 17.4 
5 0 0 0 100 0 0 0 15.2 75.2 9.6 90.4 15.2 
6 0 0 0 100 0 0 24.5 55.4 15.4 4.7 95.3 79.9 
7 0 0 0 100 0 0 0 0 10.2 89.8 10.2 0 
8 0 0 0 100 0 0 0 2.3 14.3 83.4 16.6 2.3 
9 0 0 0 100 0 0 0 1.2 33.4 65.4 34.6 1.2 
10 0 0 0 100 0 0 1.2 16.4 17.4 65 35 17.6 
11 0 0 9.4 90.6 9.4 0 0 10.4 33.4 56.2 43.8 10.4 
12 0 0 0 100 0 0 0 0.5 21.5 78 22 0.5 
13 0 24.2 26.7 49.1 50.9 24.2 0 0 11.5 88.5 11.5 0 
14 0 0 0 100 0 0 0 1.3 16.7 82 18 1.3 
15 0 0 9.4 90.6 9.4 0 1.2 19.7 32.4 46.7 53.3 20.9 
17 0 0 0 100 0 0 0 0 11.2 88.8 11.2 0 
18 0 0 0 100 0 0 0 20.2 42.6 37.2 62.8 20.2 
19 0 0 0 100 0 0 0.4 5.3 81.2 13.1 86.9 5.7 
20 0 0 0 100 0 0 0 0 2.5 97.5 2.5 0 
23 0 0 4.2 95.8 4.2 0 0 6.4 61.4 32.2 67.8 6.4 
25 0 0 0 100 0 0 2.1 11.3 20.1 66.5 33.5 13.4 
AV 0 2.92 4.98 92.11 7.89 2.92 1.47 10.17 29.82 58.55 41.46 11.64 
SEM 0 2.04 2.53 4.52 4.52 2.04 1.22 2.89 4.79 6.23 6.23 3.97 
 
 256 
JAB1 - TUMOUR SAMPLES 
INSULINOMA 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 0 0 100 0 0 0 8.4 61.3 30.3 69.7 8.4 
2 0 0 3.7 96.3 3.7 0 4.1 21.4 32.8 41.7 58.3 25.5 
3 0 0 0 100 0 0 17.85 73.45 7.9 0.8 99.2 91.3 
5 0 0 0 100 0 0 78.2 8.5 7.4 5.9 94.1 86.7 
6 0 0 0 100 0 0 53.2 30.6 11.1 5.1 94.9 83.8 
7 0 0 0 100 0 0 13.5 24.6 39.7 22.2 77.8 38.1 
8 0 0 0 100 0 0 0 14.7 81.2 4.1 95.9 14.7 
9 0 0 0 100 0 0 10.4 11.5 69.9 8.2 91.8 21.9 
10 0 0 0 100 0 0 0 0 15.4 84.6 15.4 0 
11 0 0 0 100 0 0 7.3 6.2 3.1 83.4 16.6 13.5 
12 0 0 0 100 0 0 84.3 14.2 1.5 0 100 98.5 
13 0 0 0 100 0 0 0 0 6.2 93.9 6.2 0 
14 0 0 0 100 0 0 1.2 19.7 76.4 2.7 97.3 20.9 
15 0 0 0 100 0 0 42.3 34.9 17.3 5.6 94.5 77.2 
17 0 0 0 100 0 0 5.6 82.9 10.2 1.3 98.7 88.5 
18 0 0 0 100 0 0 12.9 61.8 22.2 3.3 96.8 74.7 
19 0 0 0 100 0 0 19.3 42.3 25.7 2.7 87.3 61.6 
20 0 0 0 100 0 0 0 14.8 85.2 0 100 14.8 
23 0 0 0 100 0 0 7.1 86.4 6.5 0 100 93.5 
25 0 0 0 100 0 0 0 0 12.4 87.6 12.4 0 
AV 0 0 0.19 99.82 0.19 0 17.86 27.81 29.67 24.17 75.34 45.68 
SEM 0 0 0.19 0.18 0.19 0 5.79 6.16 6.42 7.66 7.60 8.34 
 
 
GASTRINOMA 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
4 0 0 0 100 0 0 0 15.2 81.2 3.6 96.4 15.2 
22 0 0 0 100 0 0 0 0 25.3 74.7 25.3 0 
24 0 0 0 100 0 0 0 0 2.4 97.6 2.4 0 
AV 0 0 0 100 0 0 0 5.07 36.30 58.63 41.37 5.07 
SEM 0 0 0 0 0 0 0 5.07 23.40 28.30 28.30 5.07 
 257 
JAB1 - ISLET SAMPLES 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 0 0 100 0 0 87.3 9.4 3.3 0 100 96.7 
2 0 0 0 100 0 0 77.55 15.55 6.9 0 100 93.1 
4 0 0 0 100 0 0 85.4 11.3 3.3 0 100 96.7 
5 0 0 0 100 0 0 86.4 6.4 3.2 4 96 92.8 
6 0 0 0 100 0 0 65 20.4 11.7 2.9 97.1 85.4 
7 0 0 0 100 0 0 71.4 24.6 4 0 100 96 
8 0 0 0 100 0 0 81.2 8.4 6.5 3.9 96.1 89.6 
9 0 0 0 100 0 0 76.4 15.4 7.4 0.8 99.2 91.8 
10 0 0 0 100 0 0 63.7 29.5 4.7 2.1 97.9 93.2 
11 0 0 0 100 0 0 83.8 12.3 3.9 0 100 96.1 
12 0 0 0 100 0 0 91.4 8.4 0.2 0 100 99.8 
13 0 0 0 100 0 0 53.9 46.1 0 0 100 100 
14 0 0 0 100 0 0 42.6 24.4 18.1 14.9 85.1 67 
15 0 0 0 100 0 0 15 81.3 3.7 0 100 96.3 
17 0 0 0 100 0 0 10.5 73.4 16.1 0 100 83.9 
18 0 0 0 100 0 0 34.3 50.8 13.1 1.9 98.2 85.1 
20 0 0 0 100 0 0 81.1 13.5 5.4 0 100 94.6 
23 0 0 0 100 0 0 11.2 82.4 6.4 0 100 93.6 
25 0 0 0 100 0 0 0 72.4 26.7 0.9 99.1 72.4 
AV 0 0 0 100 0 0 58.85 31.89 7.61 1.65 98.35 90.74 
SEM 0 0 0 0 0 0 6.99 6.19 1.55 0.80 0.80 2.00 
 
 258 
JAB1 - EXOCRINE PANCREAS SAMPLES 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 0 0 100 0 0 0 0 12.9 87.1 12.9 0 
2 0 0 5.3 94.7 5.3 0 0 11.7 44.4 43.9 56.1 11.7 
3 0 0 0 100 0 0 0 0 5.6 94.4 5.6 0 
5 0 0 0 100 0 0 0 0 2.3 97.7 2.3 0 
6 0 0 0 100 0 0 0 0 6.7 93.3 6.7 0 
7 0 0 0 100 0 0 0 0 2.4 97.6 2.4 0 
8 0 0 0 100 0 0 0 0 0 100 0 0 
9 0 0 0 100 0 0 0 32.1 35.4 32.5 67.5 32.1 
10 0 0 0 100 0 0 0 0 0 100 0 0 
11 0 0 0 100 0 0 0 0 53.4 46.6 53.4 0 
12 0 0 0 100 0 0 0 0 2.3 97.7 2.3 0 
13 0 0 13.6 86.4 13.6 0 0 0 17.6 82.4 17.6 0 
14 0 0 0 100 0 0 0 0 0 100 0 0 
15 0 0 0 100 0 0 0 7.2 30.0 62.9 37.1 7.2 
17 0 0 0 100 0 0 0 36.4 51.1 12.5 87.5 36.4 
18 0 0 0 100 0 0 0 23.0 69.1 8.0 92.0 23.0 
19 0 0 0 100 0 0 0 0 30.7 69.3 30.7 0 
20 0 0 12.4 87.6 12.4 0 0 0 8.1 91.9 8.1 0 
23 0 0 4.2 95.8 4.2 0 0 24.3 35.7 40 60 24.3 
25 0 0 6.4 93.6 6.4 0 0 0 3.6 96.4 3.6 0 
AV 0 0 2.10 97.91 2.10 0 0 6.73 20.56 72.71 27.29 6.73 
SEM 0 0 0.94 0.94 0.94 0 0 2.69 4.80 6.95 6.95 2.69 
 
 259 
p-AKT - TUMOUR SAMPLES 
INSULINOMA 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 0 0 100 0 0 3.1 78.2 18.7 0 100 81.3 
2 0 6.75 66.55 26.7 73.3 6.75 0 20.75 72.9 6.35 93.65 20.75 
3 0 6.0 80.9 13.2 86.9 6.0 0.0 44.5 47.4 8.2 91.9 44.5 
5 0 20.3 74.8 4.9 95.1 20.3 8.4 81.2 7.5 2.9 97.1 89.6 
6 5.3 39.6 46.2 8.9 91.1 44.9 8.9 76.4 12.8 1.9 98.1 85.3 
7 0.8 58.2 35.6 5.4 94.6 59 0 44.3 52.1 3.6 96.4 44.3 
8 0 0 21.5 78.5 21.5 0 0 16.2 75.4 8.4 91.6 16.2 
9 0 9.7 86.4 3.9 96.1 9.7 2.3 86.2 11.5 0 100 88.5 
10 3.2 47.2 24.4 21.2 74.8 50.4 4.3 83.7 10.2 1.8 98.2 88 
11 0 0 19.7 80.3 19.7 0 13.2 78.5 8.3 0 100 91.7 
12 0 46.4 50.1 3.5 96.5 46.4 5.4 86.4 8.2 0 100 91.8 
13 0 26.1 23.5 50.5 49.5 26.1 0.0 2.1 31.7 66.3 33.8 2.1 
14 0 0 6.8 93.2 6.8 0 0 9.2 86.1 4.7 95.3 9.2 
15 7.4 73.5 12.7 6.4 93.6 80.9 24.3 63.4 11.2 1.1 98.9 87.7 
17 0 0 3.2 96.8 3.2 0 0 4.2 92.5 3.3 96.7 4.2 
18 0 0 14 86 14 0 0 13.9 77.9 8.3 91.7 13.9 
19 9.6 18.3 31.2 41 59 27.8 0 10.7 37.7 1.7 48.4 10.7 
20 0 0 7.6 92.4 7.6 0 0 5.4 85.4 9.2 90.8 5.4 
23 0 35.3 45.8 18.9 81.1 35.3 2.4 36.3 45.2 16.1 83.9 38.7 
25 3.1 64.7 31.7 0.5 99.5 67.8 34.2 36.2 29.6 0 100 70.4 
AV 1.47 22.60 34.13 41.61 58.19 24.06 5.33 43.88 41.11 7.19 90.32 49.21 
SEM 0.63 5.52 5.89 8.60 8.58 5.86 2.04 7.22 6.86 3.25 3.92 8.13 
 
 
GASTRINOMA 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
4 0 12.4 68.9 18.7 81.3 12.4 0 24.9 64.2 10.9 89.1 24.9 
22 0 0 10.15 89.85 10.15 0 0 6.55 88.3 5.15 94.85 6.55 
24 0 0 20.3 79.7 20.3 0 0 5 87.5 7.5 92.5 5 
AV 0 4.13 33.12 62.75 37.25 4.13 0 12.15 80 7.85 92.15 12.15 
SEM 0 4.13 18.13 22.22 22.22 4.13 0 6.39 7.90 1.67 1.67 6.39 
 260 
p-AKT - ISLET SAMPLES 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 20.4 53.4 26.2 73.8 20.4 12.6 73.4 13.1 0.9 99.1 86 
2 0 6.8 52.4 40.9 59.2 6.8 0.0 8.5 81.6 10.0 90.1 8.5 
4 6.1 31.7 38.4 23.8 76.2 37.8 10.4 73.8 13.7 2.1 97.9 84.2 
5 0 38.3 53.2 8.5 91.5 38.3 0 85.2 10.6 4.2 95.8 85.2 
6 25.4 50.4 16.2 8 92 75.8 43.6 36.2 19.3 1.9 99.1 79.8 
7 45.3 45.2 9.5 0 100 90.5 82.8 12.7 4.5 0 100 95.5 
8 0 29.4 69.4 1.2 98.8 29.4 6.1 86.2 7.7 0 100 92.3 
9 0 8.9 83.4 7.7 92.3 8.9 42.7 54.1 3.2 0 100 96.8 
10 0 3.2 15.4 81.4 18.6 3.2 0 9.1 82.3 8.6 91.4 9.1 
11 46.8 40.7 12.5 0 100 87.5 51.2 46.7 2.1 0 100 97.9 
12 0 9.9 21.3 68.8 31.2 9.9 8.6 75.1 16.3 0 100 83.7 
13 0 10 75.4 14.6 85.4 10 2.1 89.4 8.5 0 100 91.5 
14 4.6 64.5 24.1 6.8 93.2 69.1 4.8 83.7 11.1 0.4 99.6 88.5 
15 19.4 38.9 41.2 0.5 99.5 58.3 11 68.4 18.4 2.2 97.8 79.4 
17 0 11.3 75.2 13.5 86.5 11.3 13.2 82.3 4.5 0 100 95.5 
18 0 17.4 67.7 14.9 85.1 17.4 3.7 83.9 9.4 3 97 87.6 
20 8.6 45.3 40 6.1 93.9 53.9 0 11.2 87.6 1.2 98.8 11.2 
23 4.3 59.3 35 1.4 98.6 63.6 0 78.3 20.4 1.3 98.7 78.3 
25 0 13.7 74.8 14.5 88.5 13.7 6.3 70.7 22.5 0.5 99.5 77 
AV 8.45 28.70 45.18 17.83 82.33 37.14 15.74 59.41 22.99 1.91 98.14 75.16 
SEM 3.45 4.37 5.59 5.23 5.24 6.76 5.20 6.75 6.36 0.66 0.66 6.85 
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p-AKT - EXOCRINE PANCREAS SAMPLES 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 0 61.2 24.3 14.5 85.5 61.2 0 9.9 85.1 5 95 9.9 
2 0 0 0 100 0 0 0 3.7 28.7 67.6 32.4 3.7 
3 0 7.2 24.7 68.1 31.9 7.2 0 7.5 85.4 7.1 92.9 7.5 
5 0 0 6.3 93.7 6.3 0 0 3.2 93.2 3.6 96.4 3.2 
6 0 19.4 53.1 27.5 72.5 19.4 0 28.1 69.3 2.6 97.4 28.1 
7 0 19.2 51.2 29.6 70.4 19.2 24.1 54.3 20.2 1.4 98.6 78.4 
8 0 0 5.6 94.4 5.6 0 0 4.2 87.9 7.9 92.1 4.2 
9 0 0 13.2 86.8 13.2 0 1.9 68.5 29.6 0  100 70.4 
10 0 0 3.2 96.8 3.2 0 0 0 5.7 94.3 5.7 0 
11 0 5.3 32.5 62.2 37.8 5.3 0 0 31 69 31 0 
12 0 0 4.3 95.7 4.3 0 0 6.4 91.2 2.4 97.6 6.4 
13 0 4.4 74.2 21.4 78.6 4.4 0 10.2 82.1 7.7 92.3 10.2 
14 0 11.4 59.7 28.9 71.1 11.4 0 14.2 82.4 3.4 96.6 14.2 
15 0 6.7 23.7 69.6 30.4 6.7 0 26.8 66.1 7.1 92.9 26.8 
17 0 0 7.4 92.6 7.4 0 0 12.8 83.2 4 96 12.8 
18 0 5.2 67.3 27.5 72.5 5.2 0 16.1 76.7 7.2 92.8 16.1 
19 0 0 6.7 93.3 6.7 0 0 8.1 83.4 8.5 91.5 8.1 
20 0 0 5 95 5 0 0 8.7 78.4 12.9 87.1 8.7 
23 0 5.1 87.4 7.5 92.5 5.1 0 4.9 91.5 3.6 96.4 4.9 
25 0 0 16.3 83.7 16.3 0 0 10.3 83.7 6 94 10.3 
AV 0 7.26 28.31 64.44 35.56 7.26 1.30 14.90 67.74 16.91 83.94 16.20 
SEM 0 3.15 6.10 7.49 7.49 3.15 1.20 3.96 6.19 6.11 6.01 4.76 
 
 262 
PTEN - TUMOUR SAMPLES 
INSULINOMA 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 17.3 21.2 24.2 37.8 62.7 38.5 0 2.1 11.4 86.5 13.5 2.1 
2 9.4 65.8 24.1 0.7 99.3 75.2 0 0 15.7 84.3 15.7 0 
3 33.6 54.3 12.2 0.0 100.0 87.9 0.0 0.0 8.5 91.6 8.5 0 
5 48.6 20.9 9.9 20.6 79.4 69.5 0 0 14.3 85.7 14.3 0 
6 73.4 16.5 10.1 0 100 89.9 0 0 0 100 0 0 
7 69.4 11.3 6.2 13.1 86.9 80.7 0 0 3.4 96.6 3.4 0 
8 83.2 6.4 4.9 5.5 94.5 89.6 0 0 0 100 0 0 
9 21.6 53.8 16.4 8.2 91.8 75.4 0 0 0 100 0 0 
10 13.4 79.6 7 0 100 93 0 0 0 100 0 0 
11 23.1 67.5 9.4 0 100 90.6 0 0 0 100 0 0 
12 76.8 18.6 4.6 0 100 95.4 0 0 0 100 0 0 
13 0 40.0 58.5 1.6 98.4 40.0 0 0 0 100 0 0 
14 61.3 35.4 3.3 0 100 96.7 0 0 0 100 0 0 
15 38.3 51.4 10.3 0 100 89.7 0 0 56.2 43.8 56.2 0 
17 93.4 6.6 0 0 100 100 0 0 0 100 0 0 
18 29.4 63.1 7.5 0 100 92.5 0 0 0 100 0 0 
19 16.4 72.4 10.8 0.4 99.6 88.8 0 0 0 100 0 0 
20 15.4 81.4 3.2 0 100 96.8 0 0 0 100 0 0 
23 72.7 15.6 11.7 0 100 88.3 0 0 0 100 0 0 
25 51.2 45.6 3.2 0 100 96.8 0 0 0 100 0 0 
AV 42.40 41.37 11.87 4.40 95.63 83.76 0 0.11 5.47 94.42 5.58 0.11 
SEM 6.36 5.67 2.83 2.14 2.12 3.84 0 0.11 2.91 2.93 2.93 0.11 
 
GASTRINOMA 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
4 46.3 41.6 11 1.1 98.9 87.9 0 0 0 100 0 0 
22 21.9 70.2 8.0 0.0 100.0 92.1 0 0 0 100 0 0 
24 24.1 42.4 33.5 0 100 66.5 0 0 0 100 0 0 
AV 30.77 51.38 17.48 0.37 99.63 82.15 0 0 0 100 0 0 
SEM 7.79 9.39 8.06 0.37 0.37 7.92 0 0 0 0 0 0 
 263 
PTEN - ISLET SAMPLES 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 18.7 64.8 16.5 0 100 83.5 0 0 0 100 0 0 
2 6.4 84.7 9.9 0 101 91.1 0 0 0 100 0 0 
4 65.6 21.7 10.7 2 98 87.3 0 47.4 50.2 2.4 97.6 47.4 
5 75.5 14.3 5.7 4.5 95.5 89.8 0 10.7 81.6 7.7 92.3 10.7 
6 79.9 9.6 6.1 4.4 95.6 89.5 0 0 0 100 0 0 
7 12.3 70.2 8.7 9.8 91.2 82.5 0 0 0 100 0 0 
8 55.3 32.5 4.8 7.4 92.6 87.8 0 0 0 100 0 0 
9 24.9 53.8 16.5 4.8 95.2 78.7 0 0 0 100 0 0 
10 19.8 61.7 13.2 5.3 94.7 81.5 0 0 0 100 0 0 
11 71.8 26.4 1.8 0 100 98.2 0 0 0 100 0 0 
12 81.6 16.9 1.5 0 100 98.5 0 0 0 100 0 0 
13 79.2 20.8 0 0 100 100 0 0 0 100 0 0 
14 31.5 39.2 28.6 0.7 99.3 70.7 0 0 0 100 0 0 
15 75.3 14.3 10.4 0 100 89.6 0 0 0 100 0 0 
17 78.4 20.4 1.2 0 100 98.8 0 0 0 100 0 0 
18 42.2 29.8 23.4 4.6 95.4 72 0 0 0 100 0 0 
20 51.4 46.1 2.5 0 100 97.5 0 0 0 100 0 0 
23 85.4 14.6 0 0 100 100 0 0 0 100 0 0 
25 82.1 17.4 0.5 0 100 99.5 0 0 0 100 0 0 
AV 54.59 34.69 8.53 2.29 97.82 89.29 0.00 3.06 6.94 90.01 9.99 3.06 
SEM 6.33 5.15 1.88 0.70 0.68 2.14 0.00 2.53 4.92 6.87 6.87 2.53 
 
 264 
PTEN - EXOCRINE PANCREAS SAMPLES 
 
 NUCLEAR CYTOPLASMIC 
ID S M W -VE +VE S+M S M W -VE +VE S+M 
1 3.3 35.1 31.2 30.4 69.6 38.4 0 0 0 100 0 0 
2 7.7 38.7 24.3 29.3 70.7 46.4 0 0 0 100 0 0 
3 18.3 48.6 12.4 20.4 79.3 66.9 0 0 0 100 0 0 
5 45.7 5.9 8.3 40.1 59.9 51.6 0 0 0 100 0 0 
6 11.7 24.6 28.3 35.4 64.6 36.3 0 0 0 100 0 0 
7 0 32.4 16.4 51.2 48.8 32.4 0 0 0 100 0 0 
8 9.6 39.1 11.7 39.6 60.4 48.7 0 0 0 100 0 0 
9 26.7 21.5 10.7 41.1 58.9 48.2 0 0 0 100 0 0 
10 0 50 21.4 28.6 71.4 50 0 0 0 100 0 0 
11 0 35.5 24.5 40 60 35.5 0 0 0 100 0 0 
12 10.8 30.1 25.7 33.4 66.6 40.9 0 0 0 100 0 0 
13 9.7 50.9 15.4 24 76 60.6 0 0 0 100 0 0 
14 15.4 25.3 26.4 32.9 67.1 40.7 0 0 0 100 0 0 
15 34.5 36.1 25.7 3.7 96.3 70.6 0 0 0 100 0 0 
17 65.3 17.4 14.1 3.2 96.8 82.7 0 0 0 100 0 0 
18 37.6 34.2 21.4 6.8 93.2 71.8 0 0 0 100 0 0 
19 18.6 64.7 16.7 0 100 83.3 0 0 0 100 0 0 
20 7.4 43.2 27.4 22 78 50.6 0 0 0 100 0 0 
23 21.3 29.4 18.4 30.9 69.1 50.7 0 0 0 100 0 0 
25 28.7 29.7 18.4 23.2 76.8 58.4 0 0 0 100 0 0 
AV 18.62 34.62 19.94 26.81 73.18 53.24 0 0 0 100 0 0 
SEM 3.80 2.93 1.48 3.16 3.16 3.39 0 0 0 0 0 0 
 
  
 
